 
           Official Title:   
An Open-label Phase 2 Study of ISIS 703802 (AKCEA -ANGPTL3 -LRx) 
Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy  
Study ID: [REMOVED] 
Document Dates:  
Original Protocol: 09-November -2017  
Protocol Amendment  Version 1: 16-February -2018 
 
 
 
Clinical Study Report   CONFIDENTIAL  Study Number: ISIS 703802- CS5 Akcea Therapeutics, Inc. 
14 Feb 2020  
16.1.1 Protocol and Protocol Amendments 
Document included: 
•Original Protocol, dated 09 Nov 2017
•Protocol Amendment No. 1, dated 16 Feb  2018
•Admi
nistrative Clarification Letter 1, dated 11 Sep 2018
•Administrative Clarification Letter 2, dated [ADDRESS_1233303] 2018
•Administrative Clarification Letter 3, dated 02 Jul 2019
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
1               
 
Sponsor : 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_1233304] Carlsbad, CA  [ZIP_CODE]   Collaborator : 
Akcea Therapeutics 
[ADDRESS_1233305] 
Cambridge, MA  [ZIP_CODE] 
 
 
 
 
ISIS 703802-CS5 
 
An open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-L Rx) 
Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy 
 
Original Protocol – 09 November 2017 
 

ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
2   
 
 ISIS 703802-CS05  
 
 
An open-label Phase 2 Study of ISIS 703802 (AKCEA-
ANGPTL3-L Rx) Administered Subcutaneously to Subjects 
with Familial Partial Lipodystrophy 
Original Protocol – [ADDRESS_1233306] Cambridge, MA  [ZIP_CODE] 
Telephone: ([PHONE_18249] 
 
  

ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
3   
ISIS 703802  
Ionis Protocol Number ISIS  703802- CS05 
Original Protocol  
 
Clinical Phase:  2 
An open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-
LRx) Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy 
Trial Sponsor: Ionis Pharmaceuticals, Inc. [ADDRESS_1233307]:   
 - Akcea Therapeutics, I nc. 
[ADDRESS_1233308] 
Cambridge, MA [ZIP_CODE] Phone:  
E-mail:  
 Sponsor Medical Monitor: , MD 
- Akcea Therapeutics, Inc. 
[ADDRESS_1233309] 
Cambridge, MA  [ZIP_CODE] 
Phone:  
Mobile:  
E-mail:  
 
Date:  [ADDRESS_1233310] of the clinical investigation without the prior written consent of Ionis 
Pharmaceuticals, Inc. and Akcea Therapeutics, Inc . 

ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 703802- CS05 
Protocol Title: An open-label Phase 2 Study of ISIS 703802 (AKCEA-A NGPTL3 -
LRx) Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy 
 Amendment:  Original Protocol 
Date:    [ADDRESS_1233311] read and understand the attached clinical protocol, entitled “An 
open-label Phase 2 Study of ISIS 703802 (AKCEA- ANGPTL3 -LRx) Administered 
Subcutaneously to Subjects with Familial Partial Lipodystrophy” dated [ADDRESS_1233312] the study as described herein. 
I agree to comply with the International Conference on Harmonization Tripartite Guideline on 
Good Clinical Practice (E6). 
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. 
 
   
Investigator’s Signature 
   
[CONTACT_10670]’s Name (please print)   Date (DD Month YYYY) 
  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
5  TABLE OF CONTENTS 
 Page 
PROTOCOL SYNOPSIS ............................................................................................................. 9  
STUDY DESIGN AND TREATMENT SCHEMA .................................................................. 15  
STUDY GLOSSARY .................................................................................................................. 16  
1. OBJECTIVES ................................................................................................................. 21  
1.1 Primary Objective ..........................................................................................................21  
1.2 Secondary Objective(s) ..................................................................................................21  
2. BACKGROUND AND RATIO NALE  .......................................................................... 21  
2.1 Overview of Disease ......................................................................................................21  
2.2 Therapeutic Rationale ....................................................................................................24  
2.3 ISIS 703802 ...................................................................................................................25  
2.3.1  Mechanism of Action .............................................................................................25  
2.3.2  Chemistry ...............................................................................................................25  
2.3.3  Preclinical Experience ............................................................................................26  
[IP_ADDRESS]  Preclinical Pharmacology ................................................................................26  
[IP_ADDRESS]  Preclinical Toxicology .....................................................................................27  
2.3.4  Clinical Experience ................................................................................................28  
[IP_ADDRESS]  ISIS 563580-CS1 Phase 1 SAD/MAD ............................................................29  
2.4 Rationale for Dose and Schedule of Administration .....................................................30  
2.5 Benefit-Risk Assessment ...............................................................................................30  
2.5.2  Risk Assessment .....................................................................................................30  
2.5.3  Overall Assessment of Benefit: Risk ......................................................................31  
3. EXPERIMENTAL PLAN  .............................................................................................. 32  
3.1 Study Design ..................................................................................................................32  
3.2 Number of Study Centers ..............................................................................................33  
3.3 Number of Subjects .......................................................................................................33  
3.4 Overall Study Duration and Follow-up .........................................................................33  
3.4.1  Screening/Qualification ..........................................................................................[ADDRESS_1233313] ELIGIBILITY .............................................................................................. 34  
5.1 Inclusion Criteria ...........................................................................................................34  
5.2 Exclusion Criteria ..........................................................................................................36  
6. STUDY PROCEDURES ................................................................................................ 38  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
6  6.1 Study Schedule ..............................................................................................................38  
6.1.1  Screening/Qualification ..........................................................................................[ADDRESS_1233314]-Treatment Period ............................................................................................39  
6.2 Study/Laboratory Assessments ......................................................................................[ADDRESS_1233315] Results / Temporary Stoppi[INVESTIGATOR_881976] ...................................................................................50  
8.6.3  Stoppi[INVESTIGATOR_10424] ...............................................................51  
8.7 Adjustment of Dose and/or Treatment Schedule ...........................................................53  
8.8 Discontinuation of Study Drug/Treatment ....................................................................[ADDRESS_1233316]-Treatment Follow-up Period ..........................................................................54
 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
7  8.9 Withdrawal of Subjects from the Study .........................................................................55  
8.10  Concomitant Therapy and Procedures ...........................................................................55  
8.10.1  Concomitant Therapy .............................................................................................55  
8.10.2  Concomitant Procedur es .........................................................................................56  
8.11  Treatment Compliance ...................................................................................................56  
9. SERIOUS AND NON-SERIOUS ADVERSE EVENT REPORTING ...................... 56  
9.1 Sponsor Review of Safety Information .........................................................................56  
9.2 Regulatory Requirements ..............................................................................................57  
9.3 Definitions .....................................................................................................................57  
9.3.1  Adverse Event ........................................................................................................57  
9.3.2  Adverse Reaction and Suspected Adverse Reaction ..............................................57  
9.3.3  Serious Adverse Event (SAE) ................................................................................57  
[IP_ADDRESS]  Adverse Events of Special Interest ..................................................................58  
9.4 Monitoring and Recording Adverse Events ...................................................................58  
9.4.1  Serious Adverse Events ..........................................................................................58  
9.4.2  Non-Serious Adverse Events ..................................................................................59  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................59  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................59  
[IP_ADDRESS]  Severity ............................................................................................................59  
[IP_ADDRESS]  Action Taken with Study Drug ........................................................................60  
[IP_ADDRESS]  Treatment Given for Adverse Event ................................................................60  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................60  
9.5 Procedures for Handling Special Situations ..................................................................60  
9.5.1  Abnormalities of Laboratory Tests .........................................................................60  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments ............61  
9.5.3  Dosing Errors .........................................................................................................61  
9.5.4  Contraception and Pregnancy .................................................................................62  
10. STATISTICAL CONSIDERATIONS .......................................................................... 62  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................62  
10.1.1  Primary Endpoint ...................................................................................................62  
10.1.2  Secondary Endpoints ..............................................................................................62  
10.2  Sample Size Considerations ...........................................................................................63  
10.3  Populations .....................................................................................................................63  
10.4  Definition of Baseline ....................................................................................................63  
10.5  Interim Analysis and Early Stoppi[INVESTIGATOR_130] ..........................................................63  
10.6  Planned Methods of Analysis ........................................................................................63  
10.6.1  Demographic and Baseline Characteristics ............................................................64  
10.6.2  Safety Analysis .......................................................................................................64  
[IP_ADDRESS]  Adverse Events ................................................................................................64  
[IP_ADDRESS]  Clinical Laboratory Data..................................................................................64  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
8  [IP_ADDRESS]  Vital Signs and Examinations ..........................................................................64  
10.6.3  Efficacy Analysis ...................................................................................................64  
10.6.4  Pharmacokinetic Analysis ......................................................................................65  
10.6.5  Pharmacodynamic Analysis ...................................................................................65  
10.6.6  Additional Analyses ...............................................................................................65  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS ............................................. [ADDRESS_1233317] of the Study .........................................................................................66  
11.3  Independent  Ethics Committee/Institutional Review Board .........................................[ADDRESS_1233318] ..............................................................................................86  
 
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics ....................................................................................42  
Table 2  Study Drug Dosing Information ............................................................................43  
Table 3  Actions in Patients with Low Platelet Count .........................................................53  
 
TABLE OF FIGURES 
Page 
Figure 1  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  (MOE-
Gapmer).  The sequence of ISIS 703802 is shown. ...............................................26  
  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
9  PROTOCOL SYNOPSIS 
Protocol Title An O pen-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-L Rx) 
Administered Subcutaneously to Subjects with Familial Partial Lipodystrophy 
Study Phase 2 
Indication Familial Partial Lipodystrophy (FPL) 
Primary Objective To assess the effect of ISIS 703802 on reduction in fasting triglycerides (TG). 
Secondary Objective s To evaluate the safety and tolerability of ISIS [ADDRESS_1233319] of ISIS 703802 on changes from Baseline to end of  
treatment on : 
• Plasma glucose, serum insulin, serum C-peptide and free fatty acid 
(FFA) in responses to a mixed meal test (MMT) 
• L ipi[INVESTIGATOR_805], lipoproteins and lipid metabolism  
• Glycosylated hemoglobin (HbA1c) 
• L iver fat and body fat distribution 
• Quality of life and pain score  
 
To evaluate pharmacokinetics (PK) of ISIS 703802   
Study Design This is a single -center, open -label study.  
The study will comprise the following periods: 
Screening period : Up to 6 week s (including an up to  4 week run-in diet 
period) 
Treatment Period : [ADDRESS_1233320]-treatment Follow-up Period : [ADDRESS_1233321] give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]    
2. Age ≥ 18 years at the time of informed consent   
3. Clinical diagnosis of familial partial lipodystrophy plus diagnosis of type 
2 diabetes mellitus and hypertriglyceridemia.  
Diagnosis of lipodystrophy is based on deficiency of subcutaneous 
body fat in a partial fashion assessed by [CONTACT_882019]: men (≤ 10 mm) and women (≤ 22 mm), and at least 1 of the following:  
- Genetic diagnosis of familial PL (e.g., mutations in LMNA, PPAR-γ, 
AKT2, CIDEC, PLIN1 genes)  
OR 
- Family history of FPL or family history of abnormal and similar fat distribution plus 1 Minor Criteria  
OR 
- 2 Minor Criteria (In the absence of FPL-associated genetic variant or family history) and BMI< 35 kg/m
2  
 
MINOR Criteria  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
10  a. Requirement for high doses of insulin, e.g., requiring ≥ 200 
U/day, ≥ 2 U/kg/day, or currently taking U-500 insulin  
b. Presence of acanthosis nigricans on physical examin ation  
c. Evidence/history of polycystic ovary syndrome (PCOS) or 
PCOS-like symptoms (hirsutism, oligomenorrhea, and/or 
polycystic ovaries)  
d. History of pancreatitis associated with hypertriglyceridemia  
e. Evidence of non-alcoholic fatty liver disease  
- Hepatomegaly and/or elevated transaminases in the 
absence of a known cause of liver disease or radiographic evidence of hepatic steatosis (e.g., on ultrasound or CT)   
4. A diagnosis of diabetes mellitus, made at least 6 months prior to the 
Screening, and:  
• A HbA1c ≥ 7% to ≤ 12% at Screening,  
• On anti -diabetic therapy consisting of:  
a. Metformin ≥ 1500 mg/day, or  
b. If the dose of metformin is < 1500 mg/day, or metformin is 
not tolerated, then the patient should be on other oral anti-
diabetic drugs (OAD) or an in jectable glucagon -like peptide -1 
(GLP-1) receptor agonist, or  
c. Insulin therapy alone or in combination with other anti-
diabetic drugs 
5. Hypertriglyceridemia as defined by [CONTACT_882020] ≥ 500 mg/dL (≥ 
5.7 mmol/L) at both Screening and Qualification visits. Patients with the 
clinical diagnosis of FPL and with Fasting TG levels ≥ 200 (≥ 2.26 
mmol/L) to < 500 mg/dL (≥ 5.7 mmol/L) at both Screening and 
Qualification Visits who meet the genetic or family history criteria for 
study inclusion may be further screened and enrolled in the study 
 
6. Presence of hepatosteatosis (fatty liver), as evidenced by a Screening 
MRI indicating a hepatic fat fraction (HFF) ≥ 6.4%  
 
7. Willing to maintain their customary physical activity level and to follow a 
diet moderate in carbohydrates and fats with a focus on complex 
carbohydrates and replacing saturated for unsaturated fats  
 
8. Satisfy 1 of the following:  
a. Females:  Non -pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post- menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and follicle -stimulating 
hormone (FSH) levels in the postmenopausal range for the 
laboratory involved), abstinent*, or if engaged in sexual relations 
of child -bearing pot ential, patient is using an acceptable 
contraceptive method (refer to  Section 6.3.1) from time of 
signing the informed consent form until at least [ADDRESS_1233322] dose of Study Drug administratio n. 
b. Males:  Surgically sterile, abstinent, or if engaged in sexual 
relations with a female of child -bearing potential, patient is 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
11  utilizing an acceptable contraceptive method (refer to  Section  
6.3.1) f rom the time of signing the informed consent form until at 
least [ADDRESS_1233323] dose of Study Drug administration.   
*Abstinence is only acceptable as true abstinence, i.e., when this is in line 
with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), 
declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception). 
Exclusion Criteria 
1. A diagnosis of generalized lipodystrophy 
2. A diagnosis of acquired partial lipodystrophy (APL) 
3. Acute pancreatitis within 4 weeks of Screening 
4. History within 6 months of Screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack, or unstable congestive heart failure requiring a change in medication 
5. Major surgery within 3 months of Screening   
6. History of heart failure with [LOCATION_001] Heart Association functional 
classification (NYHA) greater than Class II or unstable congestive cardiac failure requiring a change in medication 
7. Uncontrolled hypertension (blood pressure [BP] > 160 mm Hg systolic 
and/or 100 mm Hg diastolic) 
8. Clinically -
significant abnormalities in screening laboratory values that 
would render a subject  unsuitable for inclusion, including the following: 
a. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg.  In the event 
of a UPCR above this threshold, eligibility may be confirmed by a 
quantitative total urine protein measurement of ˂ 1 g/24-hr  
b. Estimated GFR ˂ 60 mL/min (as determined by [CONTACT_517495]-Epi[INVESTIGATOR_368010] (CKD- EPI) 
Equation for creatinine clearance 
c. Alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) > [ADDRESS_1233324]  
d. Bilirubin > ULN, unless prior diagnosis and documentation of 
Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
e. Alkaline phosphatase (ALP) > 1.[ADDRESS_1233325] 
f. Platelet count ˂ LLN 
9. Uncontrolled hyper - or hypothyroidism.   Subjects on dose stable 
replacement therapy for at least [ADDRESS_1233326] for human immunodeficiency virus 
(HIV), hepatitis C or chronic hepatitis B 
14. Malignancy within 5 years, except for basal or squamous cell 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
12  carcinoma of the skin or carcinoma in situ  of the cervix that has been 
successfully treated 
15. Treatmen t with another investigational drug, biological agent, or device 
within 1 -month of Screening, or 5 half-lives of investigational agent, 
whichever is longer 
16. Unwilling to comply with lifestyle requirements (se e Section  6.3) 
17. Use of any of the following:  
a. Metreleptin within the last [ADDRESS_1233327] 3 months prior to Screening .  
For lipid lowering medications (e.g., omega-3 fatty acids) dose, 
brand and regimen are expected to remain the same from Day 1 
throughout Week 13.  Patients not receiving these drugs within 4 
weeks prior to Screening are also eligible 
c. Insulin unless on a stable daily basal insulin dose r egimen (± 20 
%) for at least [ADDRESS_1233328] 4 weeks 
prior to dosing and regular clinical monitoring is performed 
j. Anti-obesity drugs [e.g., the combination of phentermine and 
extended-release topi[INVESTIGATOR_052] (Qsymia), orlistat (Xenical), and 
lorcaserin (Belviq), phentermine, amphetamines, herbal 
preparations] within 12 weeks prior to Screening (except 
liraglutide [rDNA origin] injection (Saxenda) if on st able therapy 
for more than 6 weeks prior to Screening). 
k. Any other medication unless stable at least 4 weeks prior to 
dosing (occasional or intermittent use of over-the -counter 
medications will be allowed at Investigator’s discretion) 
18. Blood donation of 50 to 499 mL within 30 days of Screening or of          
> [ADDRESS_1233329] any other conditions, which, in the opi[INVESTIGATOR_37593], or could interfere with the patient participating in or completing the study 
Treatment Groups  Single Group, open-label treatment with 20 mg of ISIS 703802 SC weekly  
Study D rug Dosage and 
Administration The Sponsor will provide ISIS 703802 in a single vial with a concentration of 
100 mg/mL 20 mg every week of ISIS 703802 (0.2 mL).  
The study dose of 20 mg (0.2 mL) of ISIS [ADDRESS_1233330] and/or caregiver.  
Rationale for Dose and Schedule 
Selection  A [ADDRESS_1233331] dose that provided 
maximum TG lowering of approximately 60%, based on the TG lowering 
effect of ISIS 703802 observed in healthy volunteers with elevated TGs. 
Adjustment of Dose or Treatment 
Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose 
and dose  frequency may be allowed for safety or tolerability after consultation 
with the Sponsor Medical Monitor.    
Study Visit Schedule and 
Procedures Detailed information regarding the study  procedures are outlined in  Section [ADDRESS_1233332] of the following 
periods:  
• A n up to 6- week Screening period , including a 4 -week diet 
stabilization phase  for subjects not already on a stable diet 
• A 26-week treatment period during which Study Drug will be 
administered weekly by [CONTACT_10530]  
• A 13-week post -treatment follow -up period 
During the Screening period , subject will be advised to maintain diet and 
exercise routines, and remain on a stable regimen of diabetes and lipid medications (if they are already taking any).  As part of the Screening period , 
subjects may have [ADDRESS_1233333] 6.4 % liver fat assessed by [CONTACT_9268]-PDFF (via central 
reviewer) will return to the clinic on Day 1.   In addition, TG will be measured 
at qualification and results of TG and MRI must be available prior to 
registration and administration of the first dose of study drug . 
Blood and urine samples will be collected regularly throughout the study for safety, efficacy, and PK analysis.  Appendix B  shows a list of analytes 
required for the study and  Appendix C  details the PK sample schedules.  
The Mixed Meal Test (MMT) will be done at Baseline
, at week [ADDRESS_1233334] , fasting plasma glucose, free fatty acids ( FFA), C-peptide, 
insulin, serum ghrelin, GIP, GLP-[ADDRESS_1233335] meal (such as 
Optifast®) and the same metabolic parameters are measured again over the 
course of 300 minutes  at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 
minutes .  In addition, a validated visual analogue scale (VAS) will be used to 
measure the subject’s perception of hunger . 
Safety and Tolerability 
Evaluations Safety and tolerability assessments include: AEs, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs, use of concomitant 
medications .   
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
14  Efficacy Evaluations Primary Endpoint:  
• The effect of ISIS  703802 on the percent change from Baseline in 
fasting triglyceride levels  (TG) at week 27 
Secondary Endpoints: 
• Change from Baseline in AUC plasma glucose, serum insulin, serum 
C-peptide, free fatty acid, serum ghrelin, GIP, GLP-1, and PYY in 
response to a mixed meal test (MMT)  
• Change from Baseline in l ipi[INVESTIGATOR_881977]-
density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), total cholesterol (TC), very low-density lipoprotein cholesterol (VLDL-C), non-HDL -C, apolipoprotein B 
(apoB), apolipoprotein B-48 (apoB-48), apolipoprotein B-100 (apoB-
100), apolipoprotein A-1 (apoA-1), apolipoprotein C-III (apoC- III: 
total, chylomicron, VLDL, LDL and HDL), Lipoprotein a [Lp(a)], free 
fatty acids (FFA), and glycerol levels,  lipoprotein particle 
size/number  
• Change from Baseline in glycosylated hemoglobin (HbA1c)  
• Change  from Baseline in homeostasis model assessment -estimated 
insulin resistance (HOMA-IR)  
• Change  from Baseline in adiponectin and leptin  
• Change from Baseline in hepatic fat fraction (as assessed by 
[CONTACT_9252] [MRI]) 
• Changes  from Baseline in body fat distribution for various areas in 
the body as measured by [CONTACT_882021]-energy X-ray 
absorptiometry (DEXA); visce ral adipose tissue ( VAT) and 
subcutaneous adipose tissue ( SAT) as measured by [CONTACT_9268]; body 
weight , waist circumference and waist/hip ratio 
• Change s from Baseline in quality of life and pain score 
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of 
ISIS [ADDRESS_1233336]-
treatment Follow-up period.  Plasma sample collection time points are 
detailed in Append ix A and Appendix C.  
Pharmacodynamic Evaluations Plasma angiopoietin-like 3 (ANGPTL3), HDL-C, LDL -C, TC, VLDL-C, non -
HDL-C, apoB, apoB-48, apoB -100, apoA -1, apoC -III, Lp(a), FFA, glycerol 
levels, lipoprotein particle size/number 
Statistical Considerations There is no statistical rationale for the selected sample size.   
Sponsor /Collaborator Ionis Pharmaceuticals, Inc./  Akcea Therapeutics , Inc.  
  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol  09 November  2017  
15  STUDY DESIGN AND TREATMENT SCHEMA 
TREATMENT PERIOD
Weeks 1 to 26 
All Subjects will be receive 20 mg of ISIS 
703802 administered weekly by [CONTACT_882022], routine safety assessments, PK and 
PD/efficacy assessment at specified  time 
points  
POST -TREATMENT 
EVALUATIONS
Week 4, [ADDRESS_1233337] dose of 
Study Drug
EARLY 
TERMINATION
(ET) 
Follow ET visit in 
Schedule of 
Procedures 
Patient strongly 
encouraged to visit 
clinic for post -
treatment 
SCREEN PERIOD  / DIET RUN -IN 
Weeks -6 to -1 
(Period may be reduced if the patient is 
following a stable low fat diet for a minimum of 4 
weeks)  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
16  STUDY GLOSSARY 
Abbreviation Definition 
2′-MOE  2′-O-(2-methoxyethyl) 
AE adverse event 
ALP  alkaline phosphatase 
ALT  alanine aminotransferase (SGPT) 
ANA  antinuclear antibody 
ANGPTL3  Angiopoietin-like [ADDRESS_1233338]  aspartate aminotransferase (SGOT) 
AUC  area under the curve 
AUC t area under the plasma concentration-time curve from time 
zero to time t 
Bb complement factor Bb (activated complement split product) 
βhCG beta-subunit of human chorionic gonadotropin (pregnancy test) 
BP blood pressure 
BUN  blood urea nitrogen 
C centigrade 
C5a complement factor C5a (activated complement split product) 
C
max maximum concentration 
CBC complete blood count 
CKD -EPI [INVESTIGATOR_881978]-relevant Non-major Bleeding 
CRO  Clinical Research Organization 
CRP  C-reactive protein 
ISIS [ADDRESS_1233339] 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
18  HIV human immunodeficiency virus 
HOMA- IR Homeostasis Model Assessment-estimated Insulin Resistance 
HR heart rate 
hr, hrs hour(s) 
hsCRP CRP measured by [CONTACT_882023]-γ interferon- gamma  
IgM immunoglobulin M 
IL-1β interleukin-[ADDRESS_1233340] 
ISIS 703802 antisense inhibitor of ANGPTL3 
IV Intravenous(ly) 
kg kilogram 
L liter 
LDL-C Low Density Lipoprotein Cholesterol 
LPL Lipoprotein Lipase 
m2 square meter 
MAD  multiple ascending dose 
MB Major Bleeding 
MCH  mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration 
MCV  mean corpuscular volume 
MedDRATM Medical Dictionary for Regulatory Activities  
mg milligram 
min minute 
mL milliliter  
mm millimeter  
MRI  magnetic resonance imaging 
mRNA  messenger ribonucleic acid 
ISIS [ADDRESS_1233341] Level 
NCS  not clinically significant 
NSAID  non-steroidal anti-inflammatory drug 
NYHA  [LOCATION_001] Heart Association 
on study The insert  [subject] or [patient] is ‘on study’ from signing of 
the informed consent until their last study visit 
OAD  Oral Antidiabetic Drugs 
OTC  Over the Counter 
PCOS  Polycystic OvarySyndrome 
pH measure of the acidity or basicity of a solution 
PK pharmacokinetic(s) 
PLT Platelet  
pRBC packed red blood cells 
PT prothrombin time 
PYY  Peptide Tyrosine Tyrosine 
RBC Red Blood Cells 
REMS  Risk Evaluation ad Mitigation Strategy 
RNase H1 an ubiquitous endonuclease that specifically hydrolyzes the 
RNA strand in RNA/DNA hybrids 
SAD  single ascending dose 
SAE  serious adverse event 
SAP Statistical Analysis Plan 
SAT  Subcutaneous Adipose Tissue 
siRNA  small interfering ribonucleic acid 
SC subcutaneous(ly) 
SMBG  Self Monitored Blood Glucose 
Study Day [ADDRESS_1233342] upper limit of normal 
UACR  Urine albumin/creatinine ratio 
UPCR  Urine Protein Creatinine Ratio 
VAT  Visceral Adipose Tissue 
VLDL  Very Low Density Lipoprotein 
WBC  white blood cell 
WMA  World Medical Association 
 
  
ISIS [ADDRESS_1233343] of ISIS 703802 on reduction in fasting 
triglycerides (TG) . 
1.2 Secondary Objective (s) 
The secondary objectives are: 
• To evaluate the safety and tolerability of ISIS 703802  
• To evaluate the effect of ISIS 703802 on changes from Baseline to  end of treatment on: 
o Plasma glucose, serum insulin, serum C-peptide and free fatty acid (FFA) in 
responses to a mixed meal test (MMT) 
o Lipi[INVESTIGATOR_805], lipoproteins and lipid metabolism 
o Glycosylated hemoglobin (HbA1c) 
o Liver fat and body fat distribution 
o Quality of life and pain score 
• To evaluate pharmacokinetics (PK) of ISIS 703802. 
2. BACKGROUND AND RATIONALE 
2.1 Overview of Disease 
Lipodystrophy syndromes are a group of rare metabolic diseases characterized by [CONTACT_882024], diabetes, dyslipi[INVESTIGATOR_881979] (Garg 2004; Chan and Oral 
2010; Garg et al. 2011; Shulman et al. 2014) . 
These syndromes are categorized according to the distribution of fat loss into generalized or partial and according to the underlying etiology as inherited or acquired (Garg 2004; Chan and 
Oral 2010; Garg et al. 2011) . 
These syndromes constitute a significant medical unmet need as these patients are refractory to current therapi[INVESTIGATOR_014], mainly used to treat diabetes and elevated TG levels, in an attempt to reduce the risk of serious associated complications (coronary artery disease, diabetic nephropathy, 
cirrhosis and pancreatitis). 
As such, in February 2014, the FDA approved Myalept (metreleptin) as replacement therapy to 
treat the complications of leptin deficiency in addition to diet in patients with congenital or acquired generalized lipodystrophy.  The safety and effectiveness of Myalept was evaluated in 2 open-label studies conducted at the NIH, which included 72 patients (48 with generalized lipodystrophy and 24 with partial lipodystrophy [PL]) with diabetes, high TG, and elevated levels of fasting insulin.  The best results were achieved in patients with generalized lipodystrophy who had low leptin levels (mean [SD]: 1.3 [1.1] ng/mL), while patients with 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
22  partial lipodystrophy who had a wider range of baseline leptin values (mean [SD]: 4.9 
[3.1] ng/mL) had a more varied and attenuated response.  Because of the risks associated with the development of neutralizing antibodies and lymphoma, Myalept is available only through a risk evaluation and mitigation strategy (REMS) program, which requires prescriber and 
pharmacy certification and special documentation ( Chan et al. 2011; Myalept PI ). 
At the present time, the Sponsor does not intend to study the generalized forms for which a 
specific therapy exists (metreleptin) nor the acquired forms of the partial lipodystrophy disorders because of the heterogeneity of etiologies, some iatrogenic, and the high incidence of associated immune disorders in these populations.  Therefore, this study will focus only on patients with the congenital form of the partial lipodystrophy disorders and, among those, on the most severe 
subtype, patients with familial partial lipodystrophy, or FPL.  
Familial Partial Lipodystrophy (FPL) is an orphan disease for which no specific pharmacologic 
treatment currently exists.  FPL was described in the 1970s independently by Köbberling and Dunnigan (Dunnigan et al. 1974; Köbberling et al. 1975) , and is the most common subtype of 
inherited PL (National Organization for Rare Disorders [NORD] 2012) .  It has been estimated 
that FPL affects approximately 0.2 in 10,000 people in the European Union, which is equivalent to a total of around 10,000 people (Committee for Orphan Medicinal Products 2012) .  FPL 
encompasses several subtypes differentiated by [CONTACT_882025] ([ADDRESS_1233344] been identified).  FPL type 1, Köbberling variety has been reported in a handful of individuals and its molecular basis is unknown.  FPL type 2, Dunnigan variety is the most common form and the most well characterized disorder and is due to missense mutations in the A and C LMNA gene.  FPL type [ADDRESS_1233345] mutations in any of these genes, suggesting that additional, as yet unidentified genes can cause the disorder ( Hegele  et al. 2007; Garg et al. 
2011; National Organization for Rare Disorders [NORD] 2012) . 
The diagnosis of FPL is mainly clinical and needs to be considered in patients presenting with the triad of insulin resistance (with or without overt diabetes), significant dyslipi[INVESTIGATOR_881980], and fatty liver  (Huang-Doran et al. 2010) .  Patients often present 
with diabetes and severe insulin resistance requiring high doses of insulin.  Other evidence of severe insulin resistance is provided by [CONTACT_882026] (PCOS) (with symptoms like hyperandrogenism and oligomenorrhea).  Some patients develop severe hypertriglyceridemia resulting in epi[INVESTIGATOR_81719].  In many patients, the 
TG levels remain persistently elevated despi[INVESTIGATOR_81720].  
Radiographic evidence of hepatic steatosis or steatohepatitis with hepatomegaly and/or elevated transaminases is common (Handelsman et al. 2013) .  Patients with the Dunnigan variety have a 
higher risk of coronary artery disease (Hegele 2001) .  Although very rare, patients with a specific 
mutation in the LMNA gene are at an increased risk of cardiomyopathy and its associated 
complications, congestive heart failure and conduction defects. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
23  There is limited natural history data, mostly cross-sectional and derived from publication of 
baseline characteristics of patients entering a clinical trial (Diker-Cohen CE et al. 2015;  Ajluni N 
et al. 2016;  Akinci B et al. 2017; Ahmed Z et al. 2013; Bidault G. et al. 2013) .  The evidence that 
FPL progresses over time comes from a prospective, open-label NIH study with ongoing enrollment since 2000 (N = 87).  Data analyzed in 2014 showed that metabolic manifestations of the cohort of 32 partial lipodystrophy patients (including [ADDRESS_1233346]) were as severe as those of the cohort of generalized lipodystrophy (N = 55), which is recognized as a more severe form of 
lipodystrophy (Diker-Cohen CE et al. 2015) .  
Patients with FPL have both a partial loss and maldistribution of adipose tissue leading to their 
distinct phenotype.  In many of these patients mutations in proteins involved in adipocyte differentiation, fatty acid uptake by [CONTACT_575771], triglyceride synthesis, or lipid droplet formation have been identified (Garg et al. 2011, Handelsman et al. 2013) .  Due to this severe dysfunction 
of adipose tissue FPL patients have much lower TG storage capacity than patients with hypertriglyceridemia without FPL, highlighting the importance of TGs in the pathophysiology of FPL.  Plasma TG levels in FPL patients varied across studies from mean (25-75 percentile) 483 
mg/dL (232, 856) (Diker-Cohen CE et al. 2015) , median (25-75 percentile) 342 mg/dL (279, 
801) (Akinci B et al. 2017) , mean 383 mg/dL (Bidault G et al. 2013) , median 389 mg/dL (155-
3455) (Ahmed Z et al. 2013)  and mean 1058 mg/dL (Ajluni N et al. 2016).  It is estimated that 
1/4 to 1/[ADDRESS_1233347] TG levels > 500 m g/dL.  
Due to inability of adipose tissue to accommodate excess TGs, TGs are deposited in higher amounts in organs other than adipose tissue that are less well adapted to excess lipid storage (“ectopic fat”) (Garg et al. 2011, Handelsman et al. 2013; Robbins et al. 2015; Nolis 2014;  
Huang-Doram et al. 2010) . This ectopic fat accumulation has been found in and around many 
organs and is most clearly associated with metabolic abnormalities in the liver, pancreas and skeletal muscle contributing to severe insulin resistance, hepatic steatosis, diabetes and hypertriglyceridemia and increased risk of pancreatitis, non-alcoholic steatohepatitis and cirrhosis (Robbins et al. 2015; Nolis 2014; Huang-Doram et al. 2010; Vatier et al. 2013; Sleigh 
A et al. 2012) . 
Careful clinical assessment of fat distribution through visual and physical examination can confirm the diagnosis.  Patients with FPL have reduced subcutaneous fat in the limbs and truncal regions and may have excess subcutaneous fat deposition in neck, face and intra-abdominal regions.  Patients with the Dunnigan variety have normal body fat distribution in childhood and gradually lose subcutaneous fat from the extremities and trunk around the time of puberty.  In women, the loss of fat may be most striking in the buttocks and hips.  At the same time these patients accumulate fat on the face (“double chin”), neck and upper back (“Cushingoid appearance with buffalo hump”).  The extent of adipose tissue loss usually determines the severity of the metabolic abnormalities.  Patients display prominent muscularity and phlebomegaly (enlarged veins) in the extremities and complain of disproportionate hyperphagia.  The condition in females is more easily recognized than in men, and so is reported more often.  
Patients may also have a family history of similar physical appearance and/or fat loss. 
Genetic testing, when available, is confirmatory. (Hegele et al. 2007; Huang-Doram et al. 2010;  
Garg et al. 2011) . 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
24  Current treatment includes lifestyle modification such as reducing caloric intake and increasing 
energy expenditure via exercise.  Conventional therapi[INVESTIGATOR_881981] (metformin, thiazolidinediones, Glucagon-like peptide 1s [ GLP -1], insulin), and/or high TGs 
(dietary fat restriction, fibrates, fish oils) are not very efficacious in these patients (Chan and 
Oral 2010) . 
Familial Partial Lipodystrophy is an ultra-orphan indication for which there is a significant 
unmet medical need.  Diabetes, hepatic steatosis, and hypertriglyceridemia associated with this 
condition can lead to serious complications (Handelsman et al. 2013) such as: 
• Acute pancreatitis, especially when triglyceride levels are > 1,000 mg/dL 
• Accelerated microvascular complications from uncontrolled diabetes 
• Accelerated cardiovascular disease from lipid abnormalities and insulin resistance 
• Steatohepatitis that can progress to cirrhosis and an increased risk of hepatocellular 
carcinoma 
• Proteinuric nephropathies which can progress to end stage renal disease 
In patients with Generalized Lipodystrophy the metabolic complications are partially related to leptin deficiency, and can be ameliorated in part by [CONTACT_81777].  However, leptin deficiency alone cannot explain the severity of metabolic disease in patients with PL who have 
variable leptin levels.   
By [CONTACT_882027]3  and TG levels, ISIS [ADDRESS_1233348] and reduce their risk of acute pancreatitis.  In addition, reductions in TG could 
improve hepatic steatosis and reduce cirrhosis risk. Furthermore, this mechanism may also improve insulin sensitivity in these patients and potentially lead to a reduction in the 
complications associated with diabetes.   
2.2 Therapeutic Rationale 
In humans, loss of function mutations within the ANGPTL3 gene give rise to familial combined 
hypolipi[INVESTIGATOR_035] (FHBL2), characterized by [CONTACT_671580], total cholesterol, 
LDL-C, and HDL- C (Minicocci et al. 2012) .  Homozygous individuals with complete 
ANGPTL3 deficiency showed the full combined hypolipi[INVESTIGATOR_881982]3 deficiency showed a more attenuated phenotype.  Of note, FHBL2 homozygous were not affected by [CONTACT_37110], showed lower plasma levels of insulin and lower 
degree of insulin resistance as estimated by [CONTACT_14785]-IR (Robciuc et al. 2013).   
ANGPTL3 protein is produced exclusively in liver, where its expression is downregulated by 
[CONTACT_525646] (Inukai et al. 2004) .  Hepatic specific knock-down of ANGPTL3 mRNA is 
associated with reduction in plasma triglycerides due to increased lipoprotein lipase activity as well as decreased hepatic VLDL triglyceride secretion.  Because ANGPTL3 is produced by [CONTACT_882028], which does not express LPL, it is thought to function as an endocrine rather than paracrine factor with insulin sensitizing effects that go beyond the liver.  In fact, insulin sensitization has been shown in patients with ANGPTL3 gene mutations as well as in ANGPTL3 -deficient mice, in which increased uptake of fatty acids into oxidative tissues such as 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
25  muscle and brown adipose tissue led to decreased uptake of fatty acids and increased uptake of 
glucose in white adipose tissue (Wang et al. 2015) .  Suppression of hepatic ANGPTL3 protein 
production in mice resulted in significant reductions in levels of triglycerides, LDL cholesterol, non-HDL cholesterol, and VLDL cholesterol and these favorable effects were associated with decreased liver triglyceride content, increases in insulin sensitivity, and a reduction in 
atherosclerosis progression (Graham et al. 2017) .    
Treatment with ISIS 703802 would be expected to lower the hepatic expression of ANGPTL3 
protein and result in lowering of the levels of triglyceride-rich lipoproteins and LDL-C, increased HDL -C, improved glycemic control and ameliorated insulin resistance in T2DM patients, 
leading to decreased liver fat content in NAFLD and ultimately, reduced overall risk of coronary 
artery disease.  
2.3 ISIS  703802 
2.3.1 Mechanism of Action 
ISIS 703802 is a second-generation ASO drug targeted to ANGPTL3 that has been covalently 
bonded to triantennary N-acetyl galactosamine (GalNAc), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR) to form an ASO-GalNAc conjugate.  This GalNAc-conjugate approach results in enhanced ASO delivery to hepatocytes versus 
non-parenchymal cells and has increased ASO potency by [CONTACT_3450] 10-fold in mice 
(Prakash et al. 2014) .  The ASO portion of ISIS 703802 is complementary to a region within the 
ANGPTL3 messenger ribonucleic acid (RNA) (mRNA) coding sequence, and binds to the mRNA via Watson and Crick base pairing.  The hybridization (binding) of ISIS 703802 to the cognate mRNA results in the Ribonuclease H1 (RNase H1)-mediated degradation of the ANGPTL3 mRNA, thus preventing production of the ANGPTL3 protein.  Maximal antisense-mediated reduction of target mRNA levels is typi[INVESTIGATOR_37497] 90% of control levels in sensitive tissues ( Crooke and Bennett 1996;  Zhang et al. 2010) .  Furthermore, reduction 
in target mRNA levels using this approach correlates directly with a subsequent reduction in 
target protein levels. 
2.3.2 Chemistry  
Chemically, ISIS 703802
 is a synthetic oligomer of 20 nucleotides (i.e., a 20-mer) that are 
connected sequentially by [CONTACT_19966] (mixed backbone 
design).  The mixed backbone design reduces the total number of phosphorothioate linkages in the MOE-modified regions, which reduces non-specific interactions with proteins and further enhances potency of GalNAc conjugated ASOs.  The nucleotide sequence of ISIS 703802
 
(Figure 1)  is complementary to a 20-nucleotide stretch within Exon 6 of the ANGPTL3 mRNA 
coding sequence at position 1169-1188 bp. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2′- O-(2-methoxyethyl) ( 2′-MOE) -modified 
ribonucleotides.  These MOE-modified nucleotides confer (1) increased affinity for the target mRNA (Altmann et al. 1996; McKay et al. 1999) , (2) increased resistance to exonucleases and 
endonucleases (thereby [CONTACT_37759]) (Geary et al. 2003) , and (3) amelioration of 
some of the high dose toxicities thereby [CONTACT_882029] 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
26  generation antisense drugs containing phosphorothioate modified oligodeoxynucleotides (DNA) 
(Henry et al. 2000) .  The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE-Gapmer, and ISIS 703802 employs this chimeric structure to enable use of the RNase H1 mechanism for antisense activity.  This is because while the 2′-MOE modification confers increased stability and affinity, it does not support RNase H1 catalyzed cleavage of RNA hybridized to 2′- MOE -modified nucleotides 
(McKay et al. 1999) .  This is caused by [CONTACT_37802] 
2′-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H enzymes (Inoue et al. 1987; Monia 
et al. 1993) .  By [CONTACT_37761] 2′-MOE modification to nucleotides flanking the phosphorothioate 
oligodeoxynucleotide core, the beneficial attributes of the 2′-MOE chemistry are preserved while also retaining RNase H1 recognition.  The fourth region is comprised of a triantennary cluster of N-acetyl galactosamine (GalNAc) sugars which is linked to the 5ʹ end of ISIS 703802 via a 
phosphodiester linkage.  The GalNAc cluster is a high affinity ligand for the asialoglycoprotein receptor (ASGPR), a receptor expressed primarily on the surface of liver hepatocytes (Stockert 1995) .  The GalNAc cluster enhances delivery of ISIS 703802 to liver hepatocytes over other 
cell types and enhances potency.  After internalization into cells, the GalNAc cluster is 
metabolized to release ‘free ASO’ inside the cell (Prakash et al. 2014) . 
 
Figure 1 Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of ISIS 703802 is shown. 
2.3.3 Preclinical Experience 
Detailed information concerning the preclinical studies conducted with ANGPTL3 ASOs can be 
found in the Investigator’s Brochure.  A summary is included below. 
[IP_ADDRESS] Preclinical Pharmacology 
The pharmacology of ANGPTL3 ASOs has been examined in multiple in vitro cell lines where 
specific and dose-dependent reduction of ANGPTL3 mRNA and protein was clearly demonstrated, resulting in reductions in apoB secreted protein.  The pharmacology of ISIS 563580, an unconjugated 2′-MOE modified ASO that has the same base sequence as ISIS 
703802, at doses higher than planned for ISIS 703802. 
2ʹ-MOE  
 2ʹ-MOE  
 2ʹ-Deoxy 
GalNAc = THA -GalNAc cluster  
2ʹ-MOE = 2ʹ -methoxylethyl 
RNA  
2ʹ-Deoxy = DNA  
s = phosphorothioate linkage  
o = phosphodiester linkage  
(RNase H1 sensitive)  
GalNAc  
 GsGoAoCoAo 
TsTsGsCsCsAsGsTsAsAs 
ToCoGsCsA 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
27  ISIS 563580 has been explored in human ANGPTL3 transgenic mice, wherein liver mRNA and 
plasma ANGPTL3 protein levels were reduced upon treatment with ISIS 563580. 
Reductions in murine ANGPTL3 mRNA and protein were routinely observed in all mouse 
models treated with a murine-specific ANGPTL3 ASO.  Pharmacology studies were done with Ldlr
-/- mice fed a hypercholesterolemic diet known to develop elevated LDL-C, TG, and 
atherosclerosis, as well as features of metabolic syndrome (hyperglycemia and hyperinsulinemia) (Huszar et al. 2000; Schreyer et al. 2002; Tsuchiya et al. 2012) .  Treatment of mice with a 
murine-specific ANGPTL3 ASO resulted in improvement in all of the aforementioned lipid and metabolic endpoints compared to controls.  In all mouse models tested, total plasma cholesterol, LDL-C, TG, and non-esterified fatty acids (NEFA) have been shown to be consistently reduced upon treatment with ANGPTL3 ASOs, while HDL-C is modestly decreased in wild type mice (- 22%), and either stable or increased in others.  While a clear mechanistic understanding of HDL -C reductions has not been elucidated, results from in vitro reverse cholesterol transport 
assays suggest that HDL function is maintained. 
Administration of ISIS 703802, a human specific, GalNAc conjugated, ANGPTL3 ASO, to 
human AN GPTL3  transgenic mice led to significant, dose-dependent reductions in hepatic 
ANGPTL3 mRNA.  In diet challenged mice, administration of ISIS 731875, a mouse-specific and GalNAc-modified ASO targeting ANGPTL3, led to dose-dependent reductions in both hepatic ANGPTL3 mRNA and plasma ANGPTL3 with concomitant reductions in plasma TG and cholesterol.  Importantly, the potency and the lipid-lowering effects of the ANGPTL3 ASO 
were independent of diet. 
Finally, administration of a mouse-specific ANGPTL3 ASO to western diet fed Ldlr
-/-, a mouse 
model of FH, also led to significant reductions in hepatic ANGPTL3 mRNA and plasma 
ANGPTL3 protein with concomitant reductions in plasma TG and LDL-C that were similar to what was observed in wild type western diet fed mice, indicating that the absence of Ldlr does not affect the ASOs potency or lipid-lowering effects.  This suggests that administration of ANGPTL3 ASO administration is a promising target for clinical study in familial 
hypercholesterolemia patients. 
While formal pharmacology studies have not been conducted in the monkey with the human 
ANGPTL3 ASO, hepatic mRNA expression has been shown to be reduced by [CONTACT_726] 60% in 
cynomolgus monkeys, the same model used to conduct the toxicology evaluation. 
[IP_ADDRESS] Preclinical Toxicology 
General toxicology studies for ISIS 703802 consisted of sub-chronic (16-week) and chronic (26- 
or 39-week) toxicity studies CD-1 in mice and cynomolgus monkeys.  Since ISIS 703802 is not fully complementary to the mouse ANGPTL3 transcript, treatment group receiving a mouse-specific inhibitor (ISIS 731875) was also included in the mouse study.  Please refer to the Investigator Brochure for a detailed description of the preclinical toxicology and 
pharmacokinetics with ISIS 703802. 
Pharmacokinetic data confirmed continuous and dose-dependent exposure to ISIS 703802.  An 
estimated liver and plasma terminal elimination half-life values of approximately 1 week and 3-4 weeks for 2 mg/kg and 35 mg/kg, respectively, were observed in monkeys.  The most 
ISIS [ADDRESS_1233349] noteworthy finding in the monkey was the kidney alteration (hypoalbuminemia and 
proteinuria) seen in one early-sacrifice animal from the 16-week study at 35 mg/kg/week, a dose equivalent to at least ~190-fold of the 40 mg weekly clinical doses by [CONTACT_671584].  Non-dose dependent increases in renal protein excretion (up to 2.2-fold in quantitative urine protein, protein/creatinine ratio or urine albumin) were also observed at 8 and/or 35 mg/kg/week (> ~30 to 190-fold of the 40 mg weekly clinical doses by [CONTACT_671584] ) at the 16-week scheduled 
terminal necropsy.  However, Similar kidney alterations were not seen at the 6-week interim at any doses or in the 39-week chronic monkey study up to 12 mg/kg/week (> ~200-fold of the 
20 mg weekly clinical dose by [CONTACT_671584]). 
Additional findings related to ASO liver accumulation included increased alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) at ≥ 8 mg/kg/week in the 16- and 26-week mouse studies, and were correlated with individual hepatocyte necrosis (minimal to mild) in mouse liver.  Those changes were most prominent in the high dose groups (50 and 24 mg/kg/week for the 16- and 26-week studies, respectively).  Conversely, no changes in liver enzymes were observed in monkeys from the 39-week toxicity study up to 12 mg/kg/week.  In the 16-week monkeys study, increase in ALT was only evident in one early-sacrifice animal at 35 mg/kg/week, and non-statistically significant increases in ALT (< 2-fold of the prestudy baseline) were also observed in the interim- and terminal- sacrifice 
animals at ≥ 8 mg/kg/week but showed no microscopic correlates or dose-dependency. 
Given the spectrum and severity of the test article-related clinicopathologic alterations present in 
monkeys at doses ≤ 12mg/kg/week (> ~100-fold of the 40 mg weekly clinical dose by [CONTACT_671584]) during the 39-week treatment phase, none would be regarded to represent an adverse effect (Dorato and Engelhardt 2005; Everds et al. 2013).  Considering the monkey to be the most 
relevant species, these data have characterized the safety profile and established appropriate 
therapeutic margins for the clinical evaluation of ISIS 703802 in humans. 
2.3.4 Clinical Experience 
Detailed information concerning the clinical studies conducted with ISIS 703802 can be found in 
the Investigator’s Brochure.  A summary is included below. 
The study drug, ISIS 703802, is being evaluated in Phase 1 in the clinical setting with single 
doses up to 120 mg and multiple doses up to 60 mg (once per week for 6 weeks).  The parent drug ISIS 563580, an unconjugated 2′-MOE modified ASO that has the same base sequence as 
ISIS 703802, was also evaluated in a blinded, placebo-controlled Phase 1 study. 
An interim analysis of ISIS 703802 Phase 1 SAD/MAD Study (ISIS 703802-CS1) was 
performed in 44 subjects administered single ascending (20, 40 and 80 mg) or multiple ascending doses (10, 20, 40 and 60 mg/week for 6 weeks).  Twelve participants were randomly 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
29  assigned to single-dose groups (9 to active-agent dose groups and 3 to the placebo group) and 32 
were randomly assigned to multiple-dose groups (24 to active-agent dose groups and 8 to the placebo group).  The main endpoints of the study were safety, tolerability, pharmacokinetics, pharmacodynamics and changes in lipi[INVESTIGATOR_6520].  After 6 weeks of treatment, persons in the multiple dose groups treated with ISIS 703802 had dose-dependent reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from Baseline, P < 0.01 for all doses vs. placebo 1.6%) and in levels of triglycerides (reductions of 33.2 to 63.1% vs placebo 11.4%), LDL cholesterol (1.3 to 32.9% vs placebo 13.6%), very-low-density lipoprotein cholesterol (27.9 to 60.0% vs placebo 4.0%), non–high-density lipoprotein cholesterol (10.0 to 36.6% vs placebo 9.1%), apolipoprotein B (3.4 to 25.7% vs placebo 11.0%), and apolipoprotein C-III (18.9 to 58.8% vs placebo 3.1%).  There were no serious adverse events documented during the trial.  No protocol-defined injection-site reactions were reported.  Of those participants who received the multiple-dose regimen, three reported headache (one who received placebo and two who received ISIS 703802) and three reported dizziness (two who received placebo and one who received ISIS 703802).  There was no clinical evidence of prothrombotic effects, bleeding epi[INVESTIGATOR_1841], significant decreases in platelet count or thrombocytopenia, or significant changes in renal function.  One subject in the [ADDRESS_1233350] had an ALT of 88 U/L on Day [ADDRESS_1233351] to follow-up after 5 doses.  There were no other discontinuations during the treatment period (Graham et al. 2017 and data 
on file ).  
The pharmacokinetics of ISIS 703802 evaluated in Study ISIS 703802-CS1 showed rapid 
absorption following SC administration, with median time to maximum plasma concentrations (T
max) ranging from 1 to 6 hours.  Similar T max values were observed at all dose levels.  After 
reaching C max, plasma concentrations of ISIS 703802 declined in a multi-phasic fashion with a 
rapid disposition phase, followed by a slower elimination phase with terminal elimination half-life of 3 to 5 weeks.  The peak (C
max) and total exposure (AUC) after a single SC dose increased 
approximately dose proportionally from 20 to 40 mg, and greater than dose proportionally from 40 to 80 mg, suggesting more efficient tissue uptake at lower doses.  After single and multiple SC doses in the range of 10 to 60 mg, the C
max and AUC increased approximately dose 
proportionally.  No accumulation based on C max or AUC was observed after 6 weekly doses. 
[IP_ADDRESS] ISIS  563580-CS1 Phase 1 SAD/MAD  
In a Phase 1 study, ISIS 563580-CS1, healthy volunteers received subcutaneous administration of ISIS 563580, an unconjugated 2′-MOE modified ASO that has the same base sequence as ISIS 
703802, from 50 to 400 mg as a single dose, or 100 to 400 mg as multiple doses (8 doses in 36 days).  Overall, the safety findings from this study suggest that ISIS 563580 was not associated with any safety concerns.  There were 383 adverse events (AE) reported in the ISIS 563580-treated subjects of which 363 (95%) were mild in severity.  For the multiple-dose subjects, the most common treatment-emergent adverse events were AEs at the injection site.  There was 1 serious adverse event (SAE) in the study of periorbital cellulitis which was considered a medically important event by [CONTACT_671585].  Together, the above suggest that ISIS 563580 was well-tolerated at the doses and regimen given, which exceed the dose levels and cumulative exposures to be tested in 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
30  the current study.  There were no clinically-relevant changes in laboratory assessments and the 
heparin dose of 80 U/kg was well-tolerated in support of the post-heparin procedures.  ISIS 563580 produced dose-dependent reductions in plasma ANGPTL3 (up to 93%; group means up to 84%), TG (up to 63%; group means up to 49%) and TC (up to 46%; group means up to 28%) 
at Day 36 (Brandt et al. 2015) . 
2.4 Rationale for Dose and Schedule of Administration 
The Phase 1 program evaluated ISIS 703802 doses of 10 mg, 20 mg, 40 mg and 60 mg given 
weekly for 6 weeks that were found to be generally well-tolerated and to induce clinically-relevant reductions in lipid biomarkers.  The dose proposed for the present study will provide the equivalent drug exposure of 20 mg  weekly (80 mg monthly) and is predicted (based on 
modelling of PK/PD data obtained in Phase 1 study) to result in mean reductions from Baseline 
in TGs of approximately 63% at steady- state.  
Safety data from the available chronic mouse (26-week) and monkey (39-week) studies support 
once-weekly dosing for chronic administration.  The No Adverse Effect Level (NOAEL) for 
ISIS 703802 in chronic monkey study was determined to be 12 mg/kg/wk.    
In healthy volunteers, 703802 achieved an equivalent reduction in ANGPTL3 plasma 
concentration to that of the unconjugated form, at approximately 1/10
th of the unconjugated ASO 
(ISIS 563580) dose (Brandt et al. 2015) .   
2.[ADDRESS_1233352] beyond the end of 
the study.  
2.5.2 Risk Assessment 
The known potential risks to study participants associated with ISIS 703802 are elaborated on in 
the Guidance to Investigator section of the Investigator’s Brochure.  
• In preclinical mouse studies, there were increases in ALT and AST and were correlated 
with increased incidence and/or severity of necrosis of individual hepatocytes (minimal 
to mild in severity).  Those changes were most prominent in the high dose groups and showed no clear progression over time.  No increases in liver enzymes were observed in monkeys from the 39-week toxicity study up to 12 mg/kg/week (~200-fold of the 20 mg/week  clinical dose by [CONTACT_671584]).  In the 16-week monkey study, increase in ALT 
was only evident in 1 early-sacrifice animal at 35 mg/kg/week, no meaningful increase in ALT was observed in the schedule sacrificed animals. 
• In the Phase 1 study, there was no elevations in ALT at single dose cohorts up to 120 mg.  
In multiple dose cohorts, two out of six subjects in the 60 mg weekly dose cohort had a    
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
31  > [ADDRESS_1233353] increase of ALT, without increase in bilirubin, which was considered a 
treatment related adverse event (AE) for one by [INVESTIGATOR_678] (PI).  There were no other observed clinically significant changes in ALT and liver function in Phase 1 human study (data on file).  However, to evaluate and mitigate the potential for liver enzyme abnormalities, regular liver chemistry monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6.  
• Injection site adverse events, while not considered safety issues, may affect the ability of 
the subject to tolerate dosing.  Injection site adverse events are the most common side 
effects observed following SC administration of unconjugated 2 ¢-MOE ASOs and are 
dose and concentration dependent.  Erythema is the most prevalent characteristic.  
Generally, these events are mild and reversible, resolve spontaneously and do not worsen with time.  The histologic findings are consistent with a local inflammatory response.  Subjects should be informed of the possibility of occurrence of injection site adverse events.  Symptomatic interventions such as icing of the injection site or administration of NSAIDs prior to and/or after the SC dosing have been utilized. 
• Although no changes in platelet (PLT) counts have been observed in healthy volunteers, 
mouse or monkey in both sub-chronic and chronic studies with ISIS 703802, reductions in platelet counts to below the lower limit of normal have been observed after administration of 
other ASOs and some subjects have experienced severe thrombocytopenia following 
administration of unconjugated 2
¢-MOE ASOs.  To evaluate and mitigate the potential for a 
reduction in PLT count, monitoring and stoppi[INVESTIGATOR_881983] 8.5 and 8.6 (Safety Monitoring Rules and Stoppi[INVESTIGATOR_1869]). 
• No significant changes in serum creatinine, electrolytes, BUN, or urinalysis were 
reported from the interim analysis of the ongoing Phase 1 study (data on file).  To 
evaluate and mitigate the potential for a reduction in renal function, since kidneys are an organ of high distribution for the studied ASO, monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6 (Safety Monitoring Rules and 
Stoppi[INVESTIGATOR_1869]). 
While the long term effects of reducing ANGPTL3 as a target with the study drug are not known 
at this time, there is evidence in literature in humans in whom ANGPTL3 is absent from plasma, due to homozygous or compound heterozygous ANGPTL3 mutations, present a pan-hypobetalipoproteinemia phenotype, with generalized and marked decreases (~50% to 70%) in all apoB-100 containing lipoproteins, including VLDL and LDL, as well as HDL.  This clinical phenotype has been termed familial combined hypolipi[INVESTIGATOR_671554]2 (Romeo et al. 2009;  
Musunuru et al. 2010; Martin -Campos et al. 2012; Minicocci et al. 2012; Noto et al. 2012;  
Pi[INVESTIGATOR_671555]. 2012; Wang et al. 2015) .  Clinical studies in FHBL2 suggest a trend toward lower 
glucose and insulin levels and reported decrease in VLDL.  Remarkably, diabetes and cardiovascular disease are reportedly absent from those with homozygous FHBL2 and no 
adverse clinical phenotype has been reported to date. 
2.5.3 Overall Assessment of Benefit: Risk 
ISIS 703802 has demonstrated the ability to reduce ANGPTL3, APOCIII, and TGs by [CONTACT_92149] 60% and LDL-C by [CONTACT_726] 30% in the Phase [ADDRESS_1233354] up to 6 weeks prior to Day 1 (the first day of Study Drug administration).  During the Screening period, subjects will be advised to maintain routine diet and exercise routines, and remain on a stable regimen of diabetes and lipid medications (if they are already taking any).  As part of the Screening period, following [ADDRESS_1233355] dose of ISIS 703802
 by [CONTACT_6567] (SC) injection.  During the treatment period subjects 
will receive ISIS 703802 (20 mg) administered every week for 26 weeks. 
Subjects will return regularly for outpatient visits throughout the treatment period according to 
the Schedule of Procedures (Appendix A) .  The primary safety and efficacy analysis time point is 
at Week 27.  
Subjects will then enter a [ADDRESS_1233356]-Treatment Follow-up Period and will return to the study 
center for outpatient evaluations according to the Schedule of Procedures (Appendix A) . 
Blood and urine samples will be collected regularly throughout the study for safety, efficacy, and 
PK analysis.  Appendix B shows a list of analytes required for the study and Appendix C details 
the PK sample schedule. 
ISIS [ADDRESS_1233357] will be enrolled, but 
enrollment could be increased to 6 subjects, based on safety profile and efficacy observations. 
3.4 Overall Study Duration and Follow- up 
The length of subjects’ participation in the study may be up to 45 weeks.  This includes an up to 
5-week screening period, that includes a 4-week diet stabilization / run-in period, a 1-week qualification period, a 26-week treatment period, and a 13-week post-treatment evaluation 
period.  
Subjects may be required to attend additional visits for monitoring of adverse events or abnormal 
investigation results.  The frequency of additional monitoring will be determined by [CONTACT_882030]. 
3.4.1 Screening /Qualification 
Subject eligibility for the study will be determined within 42 days/[ADDRESS_1233358] a 4-week diet stabilization/run-in period followed by a up to 2-week qualification period.  Subjects on stable diet known to the investigator and followed at the site may go from Screening to qualification without a 4-week diet run-in.  At the qualification visit subjects will have a baseline DEXA scan and MRI will be obtained to assess liver fat content.  MRI results must be available prior to registration and administration of the 
first dose of study drug . 
3.4.[ADDRESS_1233359] ENROLL MENT  
4.1 Screening  
Before subjects may be enrolled into the Study, the Sponsor or designee requires a copy of the 
Study Center’s written independent ethics committee/institutional review board (IEC/IRB) 
ISIS [ADDRESS_1233360] information and/or 
recruitment material.  
Subjects must sign the consent form before any screening tests or assessments are performed.  At 
the time of consent, the subject will be considered enrolled into the Study and will be assigned a unique subject identification number before any study procedures, including screening procedures, are performed.  This number will be used to identify the subject throughout the trial and must be used on all study documentation related to that subject.  The patient identification number must remain constant throughout the entire trial.  Subject identification numbers, once 
assigned, will not be reused. 
4.[ADDRESS_1233361] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371]   
2. Age ≥ 18 years at the time of informed consent   
3. Clinical diagnosis of familial partial lipodystrophy plus diagnosis of type 2 diabetes mellitus and hypertriglyceridemia.  
Diagnosis of lipodystrophy is based on deficiency of subcutaneous body fat in a partial 
fashion assessed by [CONTACT_882031]: men (≤ 10 mm) and women (≤ 22 mm), and at least 1 of the following:  
- Genetic diagnosis of familial PL (e.g., mutations in LMNA, PPAR-γ, AKT2, CIDEC, 
PLIN1 genes)  
OR 
- Family history of FPL or family history of abnormal and similar fat distribution plus 1 
Minor Criteria  
OR 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
35  - 2 Minor Criteria (In the absence of FPL-associated genetic variant or family history) and 
BMI< 35 kg/m2  
 
MINOR Criteria  
f. Requirement for high doses of insulin, e.g., requiring ≥ 200 U/day, ≥ 2 U/kg/day, or 
currently taking U-500 insulin  
g. Presence of acanthosis nigricans on physical examination  
h. Evidence/history of polycystic ovary syndrome (PCOS) or PCOS-like symptoms (hirsutism, oligomenorrhea, and/or polycystic ovaries)  
i. History of pancreatitis associated with hypertriglyceridemia  
j. Evidence of non-alcoholic fatty liver disease  
- Hepatomegaly and/or elevated transaminases in the absence of a known cause of 
liver disease or radiographic evidence of hepatic steatosis (e.g., on ultrasound or 
CT)  
4. A diagnosis of diabetes mellitus, made at least 6 months prior to the Screening, and:  
• A HbA1c ≥ 7% to ≤ 12% at Screening,  
• On anti-diabetic therapy consisting of:  
d. Metformin ≥ 1500 mg/day, or  
e. If the dose of metformin is < 1500 mg/day, or metformin is not tolerated, then the 
patient should be on other oral anti-diabetic drugs (OAD) or an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, or  
f. Insulin therapy alone or in combination with other anti-diabetic drugs 
5. Hypertriglyceridemia as defined by [CONTACT_882020] ≥ 500 mg/dL (≥ 5.7 mmol/L) at both Screening and Qualification visits. Patients with the clinical diagnosis of FPL and with Fasting TG levels ≥ 200 (≥ 2.26 mmol/L) to < 500 mg/dL (≥ 5.7 mmol/L) at both Screening and Qualification Visits who meet the genetic or family history criteria for study inclusion may be further screened and enrolled in the study  
6. Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI indicating a hepatic fat fraction (HFF) ≥ 6.4% 
 
7. Willing to maintain their customary physical activity level and to follow a diet moderate in carbohydrates and fats with a focus on complex carbohydrates and replacing saturated for unsaturated fats 
 
8. Satisfy 1 of the following: 
a. Females:  Non-pregnant and non-lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post-menopausal (defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
36  fema les ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and follicle-stimulating hormone (FSH) levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1)  from time of signing the informed consent form until at least [ADDRESS_1233362] dose of Study Drug administration. 
b. Males:  Surgically sterile, abstinent, or if engaged in sexual relations with a female of 
child-bearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 6.3.1)  from the time of signing the informed consent form until at least [ADDRESS_1233363] dose of Study Drug administration.  
*Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are 
not acceptable methods of contraception). 
 5.2 Exclusion Criteria 
1. A diagnosis of generalized lipodystrophy 
2. A diagnosis of acquired partial lipodystrophy (APL) 
3. Acute pancreatitis within 4 weeks of Screening 
4. History within 6 months of Screening of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack, or unstable congestive heart failure requiring a change in medication 
5. Major surgery within 3 months of Screening  
6. History of heart failure with [LOCATION_001] Heart Association functional classification (NYHA) greater than Class II or unstable congestive cardiac failure requiring a change in medication 
7. Uncontrolled hypertension (blood pressure [BP] > 160 mm Hg systolic and/or 100 mm Hg diastolic) 
8. Clinically-significant abnormalities in screening laboratory values that would render a subject unsuitable for inclusion, including the following: 
a. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg.  In the event of a UPCR above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of ˂ 1 g/24-hr 
b. Estimated GFR ˂ 60 mL/min (as determined by [CONTACT_81105]-Epi[INVESTIGATOR_368010] (CKD-EPI) Equation for creatinine clearance 
c. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x ULN 
d. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
e. Alkaline phosphatase (ALP) > 1.[ADDRESS_1233364] 
f. Platelet count ˂ LLN 
ISIS [ADDRESS_1233365] for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B 
14. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated 
15. Treatment with another investigational drug, biological agent, or device within 1-month of Screening, or 5 half-lives of investigational agent, whichever is longer 
16. Unwilling to comply with lifestyle requirements (see  Section 6.3)  
17. Use of any of the following: 
a. Metreleptin within the last [ADDRESS_1233366] 3 months prior to Screening.  For lipid lowering medications (e.g., omega-3 fatty acids) dose, brand and regimen are expected to remain the same from Day 1 throughout Week 13.  Patients not receiving these drugs within 4 weeks prior to Screening are also eligible 
c. Insulin unless on a stable daily basal insulin dose regimen (± 20 %) for at least [ADDRESS_1233367] 4 weeks prior to dosing and regular clinical monitoring is performed 
j. Anti-obesity drugs [e.g., the combination of phentermine and extended- release 
topi[INVESTIGATOR_052] (Qsymia), orlistat (Xenical), and lorcaserin (Belviq), phentermine, amphetamines, herbal preparations] within 12 weeks prior to Screening (except liraglutide [rDNA origin] injection (Saxenda) if on stable therapy for more than 6 weeks prior to Screening). 
ISIS [ADDRESS_1233368] 4 weeks prior to dosing (occasional or 
intermittent use of over-the-counter medications will be allowed at Investigator’s discretion) 
18. Blood donation of 50 to 499 mL within 30 days of Screening or of > [ADDRESS_1233369]-treatment Follow-up 
period.  These periods are described below.  
All required study procedures are outlined in Appendix A.  
6.1.1 Screening /Qualification 
Written informed consent for the study will be obtained prior to the performance of any 
study-related procedures including screening procedures.  A 5-week period is provided for completing screening assessments and determining subject eligibility for the study.  During the 
screening period, subject will be advised to maintain diet and exercise routines, and remain on a 
stable regimen of diabetes and lipid medications (if they are already taking any).      
Subjects will undergo a medical history and physical examination including vital signs, 12-lead 
ECG , and have blood and urine samples taken for clinical laboratory testing.  Subjects will be 
screened for HIV, hepatitis B, and hepatitis C.  Safety labs may be re-tested for determination of 
subject eligibility after consultation with the Sponsor Medical Monitor. 
As part of the screening period, subjects not already on a stable diet will have [ADDRESS_1233370] dose of study drug. 
6.1.2 Treatment Period 
Subjects will be managed on an outpatient basis.  Safety and clinical laboratory evaluations as 
well as blood sampling for PK analysis will be performed periodically throughout the treatment 
period.  Any AEs and concomitant medications will be recorded.  
Collection and measurement of vital signs, physical examination results, ECGs, clinical 
laboratory parameters (Appendix B) , ISIS 703802 plasma concentrations, immunogenicity, MRI, 
AEs and concomitant medication/procedure information will be performed according to the 
Schedule of Procedures in Appendix A. 
ISIS [ADDRESS_1233371]-treatment evaluation period, subjects will return to the Study Center for outpatient visits for safety and clinical laboratory evaluations.  A ± 3-day excursion from the 
scheduled visit date is permitted for this time period.  
6.2 Study/Laboratory Assessments  
Laboratory analyte samples will be collected throughout the Study.  A list of these analytes is 
contained in Appendix B.   
Blood chemistry and urine samples (excluding 24-hour urine collection) should be taken after 
fasting for at least 10 hours.  During this time subjects can drink water and should ensure that 
they consume sufficient water to not become dehydrated.  
If tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) or 
missing, a repeat blood or urine specimen should be re-drawn as soon as possible (ideally within 
1 week).  
While on treatment hematology samples will be collected every 14 days.  Each time a 
hematology lab is drawn and sent to the central laboratory for analysis, an additional sample should be collected in parallel and analyzed locally.  In the event that both the central and local samples are unreportable (e.g., due to hemolyzed or clumped blood samples), subject dosing cannot continue until another sample is repeated and determined not to have met a platelet 
stoppi[INVESTIGATOR_1877].  
If there is no reportable platelet count within [ADDRESS_1233372] 3 months of the 
study treatment, and monthly thereafter during the Treatment Period per  Section 8.5.2.   
All lab samples sent to the central laboratory are received on the next day and processed.  Lab 
Alerts issued as per protocol safety monitoring requirements or stoppi[INVESTIGATOR_671558], the Sponsor and the CRO Medical Monitors, the Sponsor D rug 
Safety Physician, and the Clinical Trial Manager (CTM), and should be received by [CONTACT_77314] 2 days from sample collection.  Hematology results from the site’s local laboratories are received by [CONTACT_368157], and should be entered as soon as 
possible into the eCRF to inform the Sponsor and CRO study monitoring teams.  
All platelet count results must be reviewed promptly (within 48 hours of receipt) by [CONTACT_3786], or designee, to ensure that the count has not met the stoppi[INVESTIGATOR_881984] 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
40  interruption rule of 75,000/mm3 as specified in Section 8.6.3.  Any case of a platelet count 
reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is considered an adverse event of 
special interest and must be reported in an expedited fashion to the Sponsor as per  Section 9.4.1.  
All liver and renal function tests must also be reviewed promptly (within 48 hours of receipt) by 
[CONTACT_737], or designee, to ensure that the result has not met the stoppi[INVESTIGATOR_1877].  Any event meeting renal stoppi[INVESTIGATOR_368022] 8.6.[ADDRESS_1233373] be reported in an expedited fashion to the Sponsor as per  Section 9.4.1.  
All lab alerts received, including those related to platelet, liver, or renal function 
monitoring/stoppi[INVESTIGATOR_004], are also reviewed promptly by [CONTACT_474277].  Within 24 hours of receiving an actionable lab alert the CRO Medical Monitor will communicate instructions to the Investigator and the study personnel by [CONTACT_368131]/study personnel and promptly returned to the Sponsor and CRO Medical Monitor.  In urgent cases, such as platelets results below 50,000/mm
3, or liver or renal test results reaching 
a critical stoppi[INVESTIGATOR_671560].  
Further information on safety monitoring and actions to be taken by [CONTACT_368159] 8.5.3 and 8.6.3. 
6.2.1 Physical Exams and Vital Signs 
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures 
(Appendix A) .  Vital signs should include weight, blood pressure (BP), pulse rate, respi[INVESTIGATOR_81725].  BP and pulse rate will be recorded after the subject has been in a sitting position for at least 5 minutes.  BP should always be measured on the same arm 
(preferentially on the left arm).  Height will be measured at Screening . 
6.2.2 DEXA Scan 
Dual-energy X-ray Absorptiometry ( DEXA ) scans will be conducted prior to administration of 
the first dose of Study Drug and repeated at Week 27 using standardized procedures and settings. 
6.2.3 Electrocardiography  
Electrocardiography (ECG) will be conducted as indicated in the Schedule of Procedures 
(Appendix A)  at Screening, Day 1 (prior to the first dose of Study Drug), and during the 
treatment period.  
ECGs will be conducted during the post-treatment follow-up period at scheduled visits. ECGs will be recorded after the subject has been resting in a supi[INVESTIGATOR_21683] 
[ADDRESS_1233374] (MMT) (Appendix E)  will be done at baseline, at week [ADDRESS_1233375], fasting plasma glucose, free fatty acids ( FFA), C-peptide, insulin, serum ghrelin, GIP, G LP-[ADDRESS_1233376] meal (such as Optifast
®) and the same metabolic parameters are measured again over the course of 300 minutes 
at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 minutes. In addition, a validated visual 
analogue scale (VAS) will be used to measure the subject’s perception of hunger. 
6.2.[ADDRESS_1233377] refrain from sperm/egg donation 
and either be abstinent
† or practice effective contraception from the time of signing the informed 
consent form until at least a period of [ADDRESS_1233378]’s last dose of study treatment. 
For the purposes of this study, women of childbearing potential are defined as any female who 
has experienced menarche, and who does not meet one of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy 
For the purposes of the study, effective contraception is defined as follows: 
For male subjects: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository 
• Male subjects with partners that are pregnant must use condoms as contraception to 
ensure that the fetus is not exposed to the Study Drug 
For female subjects and female partners of male subjects: 
• Using 2 of the following acceptable methods of contraception:  surgical sterilization (e.g., 
bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
42  2 barrier methods (a combination of male or female condom* with diaphragm, sponge, or 
cervical cap) together with spermicidal foam/gel/film/cream/suppository 
†Note: Abstinence is only acceptable as true abstinence, i.e., when this is in line with the 
preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the 
duration of a trial and withdrawal are not acceptable methods of contraception. 
*Note: A female condom and a male condom should not be used together as friction 
between the two can result in either or both products failing. 
6.3.[ADDRESS_1233379] 10 hours before visits requiring fasted blood 
sampling.   
7. STUDY DRUG 
7.1 ISIS 703802  
Study Drug (ISIS 703802) characteristics are listed in Table 1. 
Study Drug (ISIS 703802) will be provided as 0.[ADDRESS_1233380] be stored between 2 to 8 °Celsius and be protected from light. 
Table 1 Study Drug Characteristics 
Study Drug  ISIS  703802  
Strength  100 mg/ mL  
Volume/Formulation 0.8 mL/vial 
Route of 
Administration SC* 
* SC = subcutaneous 
7.2 Packaging and Labeling 
The Sponsor will provide the Investigator with packaged Study Drug labeled in accordance with 
specific country regulatory requirements. 
7.3 Study Drug Accountability 
The study staff is required to document the receipt, dispensing, and return of Study Drug ( ISIS 
703802) supplies provided by [CONTACT_1034].  The subject must return all used and unused Study 
Drug to the Study Center for accountability. The Study Center must return all used and unused Study Drug to the Sponsor or designee.  All used syringes must be disposed of as per the site’s 
hazardous waste destruction policy. 
ISIS [ADDRESS_1233381] 2 days apart.   
Every effort should be made to ensure the previous dose is given 7 days prior to a scheduled 
clinic visit. 
Volumes to be administered are shown in Table 2.   Please refer to the Study Drug Manual 
provided by [CONTACT_882032]/or administration.  
Table 2 Study Drug Dosing Information 
Volume to Administer* Total Dose* 
0.20 mL  20 mg (open label) 
8.[ADDRESS_1233382]-treatment evaluation period. 
8.3 Other Protocol-Required Treatment Procedures 
There are no other protocol-required treatment procedures other than those outlined in the 
schedule of procedures. 
8.4 Treatment Precautions 
No specific treatment precautions are required. 
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator” section of the Investigator’s Brochure.  
For the purposes of safety monitoring Baseline is defined as the average of the pre-dose test 
closest to Day [ADDRESS_1233383] be 
initiated based on the more critical (lower or higher, as relevant) of the 2 values.  
Confirmation Guidance:  At any time during the Study (Treatment or Post-Treatment Periods), 
the initial clinical laboratory results meeting the safety monitoring criteria presented below must 
be confirmed by [CONTACT_10533] (ideally in the same laboratory that performed the 
initial measurement) on new specimens prior to administering the next dose of Study Drug.  All new specimen collections should take place as soon as possible (ideally within 3 days of the 
initial collection).   
Stoppi[INVESTIGATOR_86556]:  The Investigator may interrupt or permanently discontinue study 
treatment for any safety reason including clinically meaningful changes in clinical laboratory 
results.  
In the event of an initial clinical laboratory result that meets a stoppi[INVESTIGATOR_107160], subjects must 
not be re-dosed until a confirmatory test result has been reviewed by [CONTACT_10542].  If any of the stoppi[INVESTIGATOR_881985], the subject will be permanently discontinued from further treatment with Study Drug (ISIS 703802), evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post-treatment evaluation portion of the study.  In general, subjects who do not meet the stoppi[INVESTIGATOR_10448].  However, the Investigator and the Study Medical Monitor (or appropriately qualified designee) should 
confer as to whether additional close monitoring of the subject is appropriate.  
Additional Guidance:  If possible, a PK sample should be collected as soon as possible after a 
SAE has occurred (preferably within 2 weeks).  In addition, if a subject is asked to return to the 
clinic for additional evaluations due to an AE, then a PK sample should be taken at the time of 
the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests 
The following rules are adapted from the FDA guidance for industry, “Drug-Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S.  Department of Health and Human Services, Food and Drug Administration, July [ADDRESS_1233384] 3-months of the study treatment period, and monthly thereafter.  Upon completion of the study treatment period, liver chemistry tests should be monitored as per visit schedule in 
Appendix A.  
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, abnormal bleeding or bruising, or eosinophilia  > ULN) liver enzymes and bilirubin should be tested as soon as possible.  Testing 
at a lab that is local to the subject is permissible for this purpose. 
In the event of an ALT or AST measurement that is > [ADDRESS_1233385] (or the greater of [ADDRESS_1233386] if the baseline value was > ULN) at any time during the study (treatment or 
post-treatment period), the initial measurement(s) should be confirmed. 
ISIS [ADDRESS_1233387] levels > [ADDRESS_1233388] their liver chemistry tests 
(ALT, AST, ALP, international normalized ratio [INR] and total bilirubin) retested at least 
once-weekly until ALT and AST levels become ≤ 1.[ADDRESS_1233389] be reviewed promptly (within 48 hours of receipt) by [CONTACT_213328][INVESTIGATOR_004]. 
Further Investigation into Liver Chemistry Elevations:  For subjects with confirmed ALT or AST 
levels > [ADDRESS_1233390], the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets 
3. Obtain a history for exposure to environmental chemical agents and travel 
4. Serology for viral hepatitis (hepatitis A virus [HAV] immunoglobulin M [IgM], hepatitis B surface antigen [HBsAg], hepatitis C virus [HCV] antibody, Cytomegalovirus [CMV] IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
subject’s ALT and/or AST levels reach [ADDRESS_1233391] be promptly (within 48 hours of receipt) 
reviewed by [CONTACT_368094]. 
Lab alerts for abnormal liver chemistry tests will be issued for:  1) ALT or AST > [ADDRESS_1233392]; 
2) ALT or AST > 2 x baseline; 3) total bilirubin > ULN; 4) ALP > ULN.  These alert levels are set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the 
FDA Guidance. 
8.5.[ADDRESS_1233393] 3 months of the study treatment period, and monthly thereafter.  Upon completion of the study treatment period, urine renal biomarkers should be monitored as per visit schedule in 
Appendix A.  
In the event of appearance of symptoms or signs consistent with renal dysfunction such as 
hematuria, polyuria, anuria, flank pain, new-onset hypertension, nausea and/or anorexia, renal function should be tested as soon as possible.  Testing at a lab that is local to the subject is 
permissible for this purpose. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
46  While on treatment during the course of the study, urinary surveillance may include urinalysis to 
include urine albumin/creatinine ratio (UACR), urine protein/creatinine ratio (UPCR) and urinary red blood cells (RBCs), as well as serum creatinine and cystatin-C to estimate glomerular filtration rate (eGFR) which will be monitored every [ADDRESS_1233394] 3-months of the study treatment period, and monthly thereafter.  In addition, other biomarkers of acute renal injury may also be measured if a safety signal is seen that warrants further testing.  (Appendix 
B).  
The assessment of serum creatinine, cystatin-C, and urinalysis more frequently than per the 
Schedule of Procedures in Appendix A will be guided by [CONTACT_671593].  Any decision taken by [CONTACT_671594].  In addition, the decision to discontinue Study Drug may also be based on lesser changes in these parameters observed in isolation or in association with 
other renal-related abnormalities.  Any decision taken to restart study medication will be made in 
consultation with the Study Medical Monitor taking into account all available and relevant data.  
All results of renal function tests must be reviewed promptly (within 48 hours of receipt) by [CONTACT_213328][INVESTIGATOR_004]. 
Lab alerts for abnormal renal tests will be issued for:  Creatinine clearance (by [CONTACT_9289]- EPI 
[INVESTIGATOR_14420]) decrease from Baseline > 25%, urine albumin/creatinine ratio (UACR) > 250 mg/g, 
urine protein/creatinine ratio (UPCR) > 0.5 mg/mg, or an increase in serum creatinine from 
Baseline > 0.3 mg/dL). 
These alert levels are set to anticipate and prevent the risk of a medically significant change in 
renal function while receiving Study Drug.  
In the event of a confirmed laboratory result meeting one or more of the above criteria, the following supplemental renal tests should be immediately obtained:  
Serum creatinine, urine culture, 24-hour urine sample for creatinine clearance, urine albumin and urine protein, urine microscopy sample with inspection of sediment. 
The Investigator should also review the subject’s concomitant medications for potentially 
nephrotoxic agents, and, with the results of these evaluations, review any decision to continue or 
discontinue the subject in consultation with the Study Medical Monitor. 
8.5.[ADDRESS_1233395] dose (as per visit schedule).  
All platelet count results must be reviewed promptly (within 48 hours of receipt) by [CONTACT_368167][INVESTIGATOR_881986] 75,000/mm
3.   
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
47  Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered an adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor.  
Lab alerts related to platelet monitoring/stoppi[INVESTIGATOR_368027]:  1) platelet counts are 
< 140,000 mm3; 2) when platelet count is ≥ 30% decreased from Baseline, or 3) when the 
hematology sample is unreportable.  All these lab alerts, are reviewed promptly by [CONTACT_474284] 
24 hours of receiving an actionable lab alert. 
Actions to be taken in the event of reduced platelet count are shown in Table 3. 
In the event of a platelet count ˂ 100,000/mm
3 the laboratory tests outlined in Table 3, should be 
performed as soon as possible.  Additional lab tests will be determined by [CONTACT_37916].  
8.5.4 Safety Monitoring for Bleeding Events 
Subjects will be evaluated for occurrence of bleeding events continuously after the start of Study 
Drug treatment (Day 1).  Patients will be instructed to promptly report any signs or symptoms of bleeding.  Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically-relevant, non-major bleeding events (which are defined in Section 8.6.3) , for example 
excess bruising, petechiae, or gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT), prothrombin time (PT), 
INR, hepatic enzymes, bilirubin and platelet count may be performed. 
8.5.[ADDRESS_1233396] Self Monitored Blood Glucose (SMBG) levels and report back alert values to the site.  Subjects will be instructed to promptly report symptoms of hypoglycemia: headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating and weakness.  If subjects suspect they might be having a 
hypoglycemia reaction, they should check their blood glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then 
obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose result was before or after treatment.  If a subject presents with symptoms of hypoglycemia, the Investigator will need to 
ISIS [ADDRESS_1233397]’s glucose level and treat the subject accordingly.  
Severe hypoglycemia will be qualified as a SAE only if it fulfills SAE criteria. 
Classification of Hypoglycemia 
The alert value for hypoglycemia is ≤ 70 mg/dL (≤ 3.9 mmol/L) plasma concentration. 
Severe Hypoglycemia 
Requires assistance of another person to actively administer carbohydrates, glucagon, or take 
other corrective actions.  Plasma glucose concentrations may not be available during an event.  Neurological recovery following plasma glucose levels returning to normal considered sufficient 
evidence that event was induced by [CONTACT_81816]. 
Documented Symptomatic Hypoglycemia 
Typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 
mmol/L).  
Asymptomatic Hypoglycemia  
Not accompanied by [CONTACT_11017][INVESTIGATOR_81744] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
Probable Symptomatic Hypoglycemia 
Typi[INVESTIGATOR_881987] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
A documented severe hypoglycemic event is defined as one in which the subject requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level ≤ 70 
mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal 
or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place 
subjects at risk for injury to themselves or others. 
8.5.[ADDRESS_1233398] the Investigator and a 
central laboratory FPG measurement will be performed).  
The threshold values are defined as follows, depending on study period: 
From baseline visit to Week 13 (including value at Week 13) of Randomized Treatment period: 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
49  • FPG > 270 mg/dL (15.0 mmol/L) 
From Week 13 to Week 25/27/ET (including value at Week 25/27/ET) of Randomized 
Treatment period: 
• FPG > 240 mg/dL (13.3 mmol/L) or 
• HbA1c > 9% (for subjects with Baseline HbA1c < 8%) and HbA1c increase of more than 
1% from Baseline (for subjects with Baseline HbA1c ≥ 8%) 
In case of FPG/HbA1c above the threshold values, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency such as unplanned hospi[INVESTIGATOR_059] (e.g., surgery, infection), the Investigator 
can take appropriate measures for glycemic control.  If the measure does not exceed 7 days, then it will not be considered a rescue.  If the measure lasts beyond 7 days then it will be treated as a rescue 
• Compliance to treatment is appropriate 
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should undertake appropriate action, i.e.: 
• Investigation and treatment of intercurrent disease (to be reported in AE/concomitant 
medication parts of the eCRF) 
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to diet and lifestyle recommendations 
• Schedule a FPG/HbA1c assessment at the next visit 
If none from the above-mentioned reason can be found, or if appropriate action fails to decrease FPG/H bA1c under the threshold values, rescue medication may be introduced at the Investigator 
discretion and according to local guidelines. 
All assessments for primary and secondary efficacy and safety parameters planned in final 
primary endpoint assessment visit should be performed before adding the rescue medication if possible.  Then the subject continues the study treatment and stays in the study in order to collect safety information.  The planned visits and assessments should occur until the last scheduled 
visit.  (See more details in Appendix A) . 
Note: After Study Drug discontinuation any treatments are permitted, as deemed necessary by [CONTACT_737]. 
ISIS [ADDRESS_1233399] measurement prior to Day 1. 
8.6.1 Stoppi[INVESTIGATOR_881988], dosing of a 
patient with Study Drug will be stopped permanently: 
1. ALT or AST > [ADDRESS_1233400] > [ADDRESS_1233401], which is confirmed and persists for ≥ [ADDRESS_1233402] > [ADDRESS_1233403] (or the greater of [ADDRESS_1233404] if the baseline value was > ULN), which is confirmed and total bilirubin > [ADDRESS_1233405] or INR > 1.[ADDRESS_1233406] > [ADDRESS_1233407] (or the greater of [ADDRESS_1233408] if the baseline value was > ULN), which is confirmed, and the new appearance (i.e., onset coincides with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (> ULN) felt by [CONTACT_368096]. 
Dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency will be allowed for safety.  Any proposed adjustments to treatment schedule must be discussed 
with, and approved by, the Study Medical monitor prior to initiation.  
8.6.[ADDRESS_1233409] Results / Temporary Stoppi[INVESTIGATOR_881989] (by [CONTACT_9289]-EPI [INVESTIGATOR_14420]) meeting any of the 
following criteria, or any change in renal biomarkers deemed by [CONTACT_882033], a serum creatinine and 24-hour urine sample for creatinine clearance and protein should be obtained: 
1. CKD -EPI [CONTACT_57939] > 40% from Baseline 
2. CKD -EPI [CONTACT_10654] < 45 mL/min/1.73 m
2 
Dosing of a patient with Study Drug (ISIS 703802) will be stopped permanently if 24-hour urine testing confirms any of the following values in the absence of an alternative explanation: 
1. Urine protein is > 1.0 g 
2. Creatinine clearance decrease of > 40% from Baseline 
3. Creatinine clearance < 45 mL/min/1.[ADDRESS_1233410] who has been engaged by [CONTACT_368098].  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
51  Dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency 
will be allowed for safety.  Any proposed adjustments to treatment schedule must be discussed 
with, and approved by, the Study Medical monitor prior to initiation.  
8.6.3 Stoppi[INVESTIGATOR_881990] a low platelet count are summarized in Table 3 below. 
In the event of any platelet count less than 50,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the subject is already on reduced dose, dosing of the subject with Study Drug 
will be stopped permanently (Table 3) .  Platelet count will be monitored daily until 2 successive 
values show improvement then monitored every 2-3 days until platelet count is stable. 
Administration of steroids is recommended for subjects whose platelet count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010)  recommend 
Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2-4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count ˂ 75,000/mm
3 and > 50,000/mm3, dosing of a subject with Study 
Drug should be suspended temporarily until the platelet count has recovered to > 100,000/mm3.  
If dosing is continued, it must be at a reduced dose as shown in Table 1.  The suitability of the 
subject for continued dosing will be determined by [CONTACT_882034]’s platelet count, whether any bleeding events were experienced by [CONTACT_423], and the 
speed of recovery of platelet count after interruption of dosing. 
If, after reintroduction of Study Drug, the platelet count again falls below 75,000/mm
3, then 
dosing of the subject with Study Drug will be stopped permanently.  
Once a subject commences weekly monitoring, this frequency of monitoring should continue 
irrespective of whether the platelet count rises into the normal range. 
Any unreportable platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450]. 
Bleeding events that are either major or clinically-relevant non-major bleeding (as defined 
below) will need to be monitored and treated immediately. Subjects with a suspected bleeding 
event will undergo additional testing if deemed appropriate by [CONTACT_474285] (S)AE case report form will be completed. In addition, if bleeding is considered significant, hemoglobin (Hb), hematocrit (HCT), aPTT, PT, INR, and platelet count are to be obtained.  In addition, approximately [ADDRESS_1233411] be stored allowing for a centralized assessment of ISIS 703802
 concentrations.  
In addition, if a minor bleeding event occurs, the Investigator should notify the Sponsor Medical 
Monitor (or designee) and additional testing of coagulation parameters (aPTT, prothrombin time 
[PT], INR), platelet count, and platelet volume may be performed. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
52  Definitions :  
Major bleeding (MB) is defined as one of the following (Büller et al. 2007) :  
1. Fatal bleeding  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarticular if in a major joint, or pericardial, or intramuscular with compartment syndrome  
3. Clinically overt bleeding leading to transfusion of ≥ 2 units of packed red blood cells or whole blood or a fall in hemoglobin of 20 g/L (1.24 mmol/L) or more within 24 hours  
Clinically-relevant non-major bleeding (CRNMB) is defined as overt bleeding not meeting the criteria for major bleeding but that resulted, for example, in medical examination, intervention, or had clinical consequences for a subject (Büller et al. 2007) .  
 Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically-relevant, non-major bleeding events (defined above), for example excess bruising, petechiae, 
gingival bleeding on brushing teeth. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
53  Table 3 Actions in Patients with Low Platelet Count 
Platelet Count on Rx  Drug Dose  Monitoring 
Normal range, > 140K/mm3 No action  Monitor every 2 weeks 
100K -140K/mm3 No action  Closer observation 
Monitor every week* 
75K-100K/mm3 Permanently reduce as follows: 
Reduce to 10 mg every week Closer observation Monitor every week*  
50K-75K/mm3 Pause dosing 
When platelet count returns to > 100K/mm3 restart 
dosing as follows only if approved by [CONTACT_37858] : 
Reduce to 10 mg every week 
or 
Permanently discontinue Study Drug if it occurs 
while on already reduced dose  Closer observation 
Monitor every 2-3 days until 
2 successive values show 
improvement 
Consider discontinuation of 
antiplatelet agents/non-steroidal anti-inflammatory drug (NSAIDS)/ anticoagulant medication  
25K-50K/mm3 Permanently discontinue Study Drug Closer observation : 
Monitor daily until 
2 successive values show 
improvement then monitor every 2-3 days until platelet 
count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant 
medication while platelet 
count ˂ 50K/mm3 if possible 
˂ 25K/mm3 Permanently discontinue Study Drug Closer observation: 
Monitor daily until 
2 successive values show 
improvement then monitor 
every 2-3 days until platelet 
count stable  
Steroids recommended** 
Consider need for 
hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant medication while platelet 
count ˂ 50K/mm
3 if possible 
* Once a patient commences weekly monitoring this frequency of monitoring should continue irrespective of 
whether the platelet count rises into the normal range . 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days ever y 
2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2-4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require continuation with oral steroids after methylprednisolone). 
8.7 Adjustment of Dose and/or Treatment Schedule 
Dose frequency adjustments for platelet count reduction must be made in accordance with 
Section 8.6.3 and Table 3 (above). 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
54  Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed 
for safety or tolerability in consultation with the Sponsor Medical Monitor.   
Subjects may have their dose interrupted in response to AEs in consultation with Study Medical 
Monitor . 
8.8 Discontinuation of Study Drug/Treatment 
A subject must permanently discontinue study treatment for any of the following: 
• The subject becomes pregnant.  Report the pregnancy according to instructions in 
Section 9.5.4 
• The subject withdraws consent 
• The subject experiences an adverse event (AE) that necessitates permanent discontinuation of Study Drug 
• The subject develops laboratory test abnormalities that meet any of the stoppi[INVESTIGATOR_84151] 8.6.1 t o 8.6.3 
• When a platelet count of less than 50,000/mm3, or a platelet count less than 75,000/mm3 
while the patient is on a reduced dose. 
The reason for discontinuation of Study Drug Treatment must be recorded in the electronic Case 
Report Form (eCRF) and source documentation.  
For subjects who discontinue treatment early every effort should be made to complete the early 
termination study procedures and observations at the time of withdrawal (see  Appendix A) .  
Subjects should then be entered into the post-treatment evaluation period.   
If a subject discontinues treatment after only [ADDRESS_1233412] 6 weeks after discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 3 consecutive values that are stable as determined by [CONTACT_37683] > 100,000/mm
3), the next platelet count should be taken within at least [ADDRESS_1233413] is agreeable to: in person, by [CONTACT_648]/mail, through family/friends, in correspondence/communication with other physicians, and/or from review of the medical records.  Wherever possible these subjects should continue to be followed up via the agreed means to collect information on adverse events, concomitant medications and survival status.  At 
ISIS [ADDRESS_1233414], the patient’s status at the end of the protocol defined study period should be 
ascertained and documented. 
8.[ADDRESS_1233415] be withdrawn from the Study for any of the following: 
• Withdrawal of consent 
• The subject is unwilling or unable to comply with the protocol 
• The subject meets any of the Exclusion Criteria (see  Section 5.2)  after enrolling in the 
study that in the opi[INVESTIGATOR_213280] a safety risk to the subject 
Other reasons for withdrawal of subjects from the Study might include: 
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All information, including the reason for withdrawal from Study, mus t 
be recorded in the eCRF.  
Any subject who withdraws consent to participate in the Study will be removed from further 
treatment and study observation immediately upon the date of request.  These subjects should be encouraged to complete the early termination study procedures and observations at the time of withdrawal (Appendix A) . For subjects withdrawn for reasons other than withdrawal of consent 
every effort should be made to complete the early termination study procedures and observations at the time of withdrawal (see  Appendix A) .  The Investigator should clarify what type of follow-
up the subject is agreeable to: in person, by [CONTACT_648]/mail, through family/friends, in correspondence/communication with other physicians, and/or from review of the medical records.  Wherever possible these subjects should continue to be followed up via the agreed means to collect information on adverse events, concomitant medications and survival status.  At the very least, the patient’s status at the end of the protocol defined study period should be 
ascertained and documented. 
8.[ADDRESS_1233416]’s 
eCRF.  Adverse events related to administration of these therapi[INVESTIGATOR_10459]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including 
over-the-counter medications, herbal medications and vitamin supplements) administered between Screening and the end of the post-treatment evaluation period. All concomitant medications/treatments and significant non-drug therapi[INVESTIGATOR_014] (including supplements and assistive devices) received by a subject, including changes in the subject’s current medications, must be 
ISIS [ADDRESS_1233417]’s source documents and CRF.  Subjects taking over the counter (OTC) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Ibuprofen may be used for symptomatic pain relief.  Any other therapy (including OTC 
medications) should be approved by [CONTACT_748929]. Any medications deemed necessary by [CONTACT_37713].  
Disallowed Concomitant Therapy 
The use of prescription and OTC medications including nonsteroidal anti-inflammatory drugs 
(with the exception of occasional ibuprofen) is prohibited during this study unless the occurrence of an AE requires a drug therapy.  In such cases, the Investigator must consult the Sponsor 
Medical Monitor to decide on subject continuation or withdrawal from the study.  
The medications and therapy identified in exclusion criteria, Section 5.2 are also disallowed 
concomitant medications and are prohibited during the course of study, unless there is a safety concern.  In those cases the Medical Monitor needs to be notified and rationale provided by [CONTACT_3786]. 
Concomitant therapy with oral corticosteroids used as replacement therapy for pi[INVESTIGATOR_881991] (e.g., Pulmicort®), or intra-articular, or topi[INVESTIGATOR_881992]; however, the subject must be on a stable regimen for at least [ADDRESS_1233418] should consult with the Site Investigator or designee prior to initiating any new 
medication, including non-prescription or herbal compounds or any other non-drug therapy. 
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
Screening and the end of the post-treatment evaluation period. 
8.11 Treatment Compliance 
Compliance with treatment dosing is to be monitored and recorded by [CONTACT_37714].  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction of study medication.  Subjects that are self-administering study medication at home must record treatment in a dosing diary that will be reviewed periodically by [CONTACT_882035]. 
9. SERIOUS AND NON-SERIOUS ADVERSE EVENT REPORTING   
9.[ADDRESS_1233419] of the clinical trial. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
57  9.2 Regulatory Requirements 
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators of serious adverse events (SAEs) including suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country-specific regulatory requirements will be followed in accordance with local country regulations and guidelines.  Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any SAE according to applicable regulations. In addition to the Investigator’s assessment of relatedness, the Sponsor or designee will evaluate the available information and perform an independent assessment of relatedness.  While the Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R. For the purpose of regulatory reporting of S[LOCATION_003]Rs, there are no “expected” AEs in this study 
population. 
9.3 Defini tions 
9.3.1 Adverse Event 
An adverse event is any unfavorable and unintended sign (including a clinically-significant 
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
Study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction 
An adverse reaction is any AE caused by [CONTACT_81807]. A suspected adverse reaction is any 
AE for which there is a reasonable possibility that the drug caused the adverse event.  A 
suspected adverse reaction implies a lesser degree of certainty about causality than an adverse 
reaction. 
9.3.3 Serious Adverse Event (SAE) 
A serious adverse event is any adverse event that in the view of either the Investigator or 
Sponsor, meets any of the following criteria: 
• Results in death 
• Is life threatening: that is, poses an immediate risk of death at the time of the event 
An AE or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk of death.  It does not include an AE  or suspected adverse reaction that, had it occurred in a 
more severe form, might have caused death 
• Requires inpatient hospi[INVESTIGATOR_881993] 24 hours to a medical facility and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
58  • Results in a congenital anomaly or birth defect in the offspring of the subject (whether 
the subject is male or female) 
• Important medical events that may not result in death, are not life-threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include  allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
[IP_ADDRESS] Adverse Events of Special Interest 
For the purpose of this study severe reductions in platelet count < 50,[ADDRESS_1233420] to expediting reporting to the Sponsor following 
the same requirements as for SAE reporting (Section 9.4.1) . 
9.4 Monitoring and Recording Adverse Events 
Any pre-existing conditions or signs and/or symptoms present in a subject prior to the start of the 
Study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_1233421] safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event.  The collection of SAEs will 
begin after the subject signs the informed consent form and stop at the end of the subject’s 
follow-up period.  When the Investigator is reporting by [CONTACT_756], it is important to speak to someone in person versus leaving a message.  An Initial Serious Adverse Event Form should be 
completed and a copy should be faxed to the Sponsor or designee.   
The contact [CONTACT_144613]: 
Attention:   INC Research, LLC 
Email:   [EMAIL_3091] 
Fax:   [PHONE_3145] 
Detailed information should be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be followed until resolution.  SAEs that remain ongoing past the subject’s last protocol-specified follow-up visit will be evaluated by [CONTACT_10552].  If the Investigator and Sponsor agree the subject’s condition is unlikely to resolve, the Investigator and Sponsor will determine the 
follow-up requirement. 
ISIS [ADDRESS_1233422]’s follow-up period.  The Investigator will monitor each subject closely and record all observed or volunteered AEs on the Adverse Event Case Report 
Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non-Serious) 
The Investigator’s opi[INVESTIGATOR_10463]: 
[IP_ADDRESS] Relationship to the Study  Drug  
The event’s relationship to the Study Drug (ISIS 703802) is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug, e.g., 
confirmation by [CONTACT_38000]-challenge test 
• Possible:   The event cannot be explained by [CONTACT_423]’s medical condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug (ISIS 703802) administration 
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
Study Drug (ISIS 703802) administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_19578]’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug 
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D) .  Any AE 
not listed in Appendix D will be graded as follows:  
 
• Mild:   The event is easily tolerated by [CONTACT_368101]’s usual 
daily activities 
• Moderate:   The event causes the subject more discomfort and interrupts the subject’s 
usual daily activities  
• Severe:  The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities 
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3) . 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
60  [IP_ADDRESS] Action Taken with Study Drug 
Action taken with Study Drug (ISIS 703802) due to the event is characterized by 1 of the 
following:  
• None:  No changes were made to Study Drug (ISIS 703802) administration and dose 
• Permanently Discontinued:   Study drug was discontinued and not restarted 
• Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily 
interrupted or delayed due to the AE  and restarted at the same dose 
• Temporarily Interrupted, Restarted Reduced Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the next lower dose 
[IP_ADDRESS] Treatment Given for Adverse Event 
Any treatment (e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form.  Treatment should also be recorded on the concomitant 
treatment or ancillary procedures eCRF , as appropriate . 
[IP_ADDRESS] Outcome of the Adverse Event 
If the event is a non-serious AE, then the event’s outcome is characterized by 1 of the following: 
AE Persists:   Subject terminates from the trial and the AE continues : 
 
• Recovered:   Subject recovered completely from the AE 
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the corresponding SAE) 
• Change in Severity (if applicable):   AE severity changed 
If the event is an SAE , then the event’s outcome is characterized by 1 of the following: 
Ongoing:   SAE continuing: 
 
• Persists (as non-serious AE):   Subject has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious AE eCRF  (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Subject recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution date) 
• Fatal:   Subject died (the date of death should be ente red as the SAE resolution date) 
9.[ADDRESS_1233423] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE.  Examples of these include abnormal laboratory results that are associated with symptoms, or require treatment (e.g., bleeding due to thrombocytopenia, 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
61  tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia).  Whenever possible, 
the underlying diagnosis should be listed in preference to abnormal laboratory values as AEs.  Clinically-significant abnormalities will be monitored by [CONTACT_38013].  Laboratory abnormalities deemed not clinically-significant (NCS) by [CONTACT_37723].  Similarly, laboratory abnormalities reported as AEs by [CONTACT_37724]. The Investigator is responsible for reviewing and signing all laboratory reports.  The signed clinical laboratory reports will serve as source documents and should include the Investigator’s assessment of clinical significance of out of range/abnormal laboratory values. All platelet count results must be reviewed promptly (within 48 hours of receipt) by [CONTACT_368143][INVESTIGATOR_368046] 75,000/mm
3 as 
specified in Section 8.6.3. Any case of a platelet count reduction to levels below 50,000/mm3 
(Grade 3 or Grade 4) is considered an adverse event of special interest and should be reported in 
an expedited fashion to the Sponsor as per  Sections [IP_ADDRESS] and 9.4.1) . 
All results of liver function tests must be reviewed promptly (within 48 hours of receipt) by [CONTACT_213328][INVESTIGATOR_213272] 8.6.1. 
All results of renal function tests must be reviewed promptly (within 48 hours of receipt) by [CONTACT_213328][INVESTIGATOR_213272] 8.6.2. 
9.5.[ADDRESS_1233424] is hospi[INVESTIGATOR_057]; the Study Center must document all of the following: 
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the subject’s consent to 
participate in the Study 
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_204884]’s consent to participate in the Study and the timing of the procedure or treatment 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors 
Study Drug (ISIS 703802) errors should be documented as Protocol Deviations.  A brief 
description should be provided in the deviation, including whether the subject was symptomatic 
(list symptoms) or asymptomatic, and the event accidental or intentional. Dosing details should 
be captured on the Dosing eCRF .  If the subject  takes a dose of Study Drug that exceeds protocol 
specifications and the subject  is symptomatic, then the symptom(s) should be documented as an 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
62  AE and be reported per  Secti on 9.4.  Should an overdose occur , the Investigator or designee 
should refer to the Guidance to Investigator’s section of the Investigator’s Brochure and contact 
[CONTACT_10557] [ADDRESS_1233425] learning of the 
occurrence of pregnancy.  Follow-up information including delivery or termination is reported by [CONTACT_10558] ‘Follow-up’ on the Pregnancy Forms and reported within [ADDRESS_1233426]’s responsibility.  Female subjects:  If a suspected pregnancy occurs while on the Study (including follow-up), a 
pregnancy test will be performed.  The subject with a confirmed pregnancy will be immediately withdrawn from treatment with Study Drug.  However, the subject will be encouraged to complete the post-treatment follow-up portion of the Study to the extent that study procedures do not interfere with the pregnancy.  Regardless of continued study participation, the study physician will assist the subject in getting obstetrical care and the progress of the pregnancy will be followed until the outcome of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  Follow-up will be performed to the extent permitted by [CONTACT_10559].  Male subjects:  The progress of the pregnancy of a male subject’s 
partner should be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study 
Center and Sponsor may request access to the mother and infant’s medical records for an 
additional 8 weeks after birth.  Follow-up will be performed to the extent permitted by [CONTACT_368107]. 
10. STATISTICAL CONSIDERATIONS 
10.1 Study Endpoints, Subsets, and Covariates 10.1.1 Primary Endpoint 
• The effect of ISIS 703802 on the percent change from Baseline in fasting triglyceride 
levels (TG) at week 27 
10.1.2 Secondary Endpoints 
• Chang e from Baseline in AUC plasma glucose, serum insulin, serum C-peptide, free fatty 
acid, serum ghrelin, GIP, GLP-1, and PYY and incretin hormones in response to a mixed meal test (MMT) 
• Change from Baseline in lipi[INVESTIGATOR_881977]-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low-density lipoprotein cholesterol (VLDL-C), non- HDL -C, apolipoprotein B 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
63  (apoB), apolipoprotein B-48 (apoB-48), apolipoprotein B-100 (apoB-100), apolipoprotein 
A-1 (apoA-1), apolipoprotein C-III (apoC-III :total, chylomicron, VLDL, LDL and HDL), Lipoprotein a [Lp(a)], free fatty acids (FFA), and glycerol levels, lipoprotein particle size/number  
• Change from Baseline in glycosylated hemoglobin (HbA1c)  
• Change from Baseline in homeostasis model assessment-estimated insulin resistance (HOMA -IR) 
• Change from Baseline in adiponectin and leptin  
• Change from Baseline in hepatic fat fraction (as assessed by [CONTACT_9252] 
[MRI]) 
• Changes from Baseline in body fat distribution for various areas in the body as measured 
by [CONTACT_882036]; VAT and SAT as measured by [CONTACT_9268]; body weight, 
waist circumference and waist/hip ratio 
• Change from Baseline in quality of life and pain score 
10.2 Sample Size Considerations 
There is no statistical rationale for the selected sample size.  The sample size is selected based 
upon prior experience with ISIS 703802 to ensure that the safety, tolerability and efficacy of ISIS 
703802 can be explored in an ultra -rare condition before enrolling subjects in a larger study.   
10.3 Populations 
Safety Set:  All subjects who are enrolled and receive at least 1 dose of Study Drug.  PK Set:  All 
subjects who receive at least [ADDRESS_1233427] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to 
summarize most data.   
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
64  10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570].  All patients enrolled will be included in a summary of patient disposition.  
10.6.2 Safety Analysis 
Treatment duration and amount of Study Drug received will be summarized by [CONTACT_259000]. 
Injection Site Reactions (ISRs) will be summarized by [CONTACT_1570], MedDRA preferred term 
and severity. 
[IP_ADDRESS] Adverse Events 
Treatment duration and amount of Study Drug received will be summarized.  Patient incidence 
rates of all AEs will be tabulated by [CONTACT_11189], and by [CONTACT_6213].  Narratives of treatment-emergent deaths, serious and significant AEs, including earl y 
withdrawals due to AEs, will also be provided. 
All treatment-emergent AEs, all treatment-emergent AEs potentially related to Study Drug, all 
treatment-emergent serious AEs, and all treatment-emergent serious AEs potentially related to 
Study Drug will be summarized. 
[IP_ADDRESS] Clinical Laboratory Data 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, complement, etc., will be summarized by [CONTACT_15449].  These safety variables will also be presented as change and percent change from Baseline over time after Study Drug administration, as appropriate.  In addition, the number of subjects who 
experience abnormalities in clinical laboratory evaluations will be listed. 
[IP_ADDRESS] Vital Signs and Examinations 
Vital signs, weight, and ECG measures will be summarized by [CONTACT_15449]. 10.6.3 Efficacy Analysis 
Change at week 27 relative to Baseline will be summarized for: 
• Fasting TG 
• MTT (plasma glucose, serum insulin, serum C-peptide, FFA , serum ghrelin, GIP, GLP-1 
and PYY) 
• Glycosylated hemoglobin  
• HOMA- IR 
• 24-hr glucose 
• Adiponectin and leptin 
• HFF 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
65  • Fat distribution 
10.6.4 Pharmacokinetic Analysis 
The plasma PK of ISIS 703802 (as total full length oligonucleotides, including, fully conjugated, 
partially conjugated, and unconjugated ISIS 703802) will be assessed following multiple-dose SC administration.  The plasma trough levels of ISIS [ADDRESS_1233428] immunogenicity status if applicable.  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- ISIS 703802 antibodies) before, during, and aft er 
treatment with ISIS [ADDRESS_1233429] ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated with the first positive IM status emerged (T
first, i.e., onset of ADA development), the last positive IM status observed 
(Tlast), the last ADA sample collection day, and subject - peak titer if applicable, will be listed 
and study day.  Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by [CONTACT_1570].  Furthermore, onset and titer of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and range.  
10.6.5 Pharmacodynamic Analysis 
The following parameters will be measured throughout the trial and change at week 27 relative 
to Baseline will be summarized: 
• ANGPTL3  
• HDL -C  
• LDL-C 
• TC  
• VLDL -C   
• non-HDL -C  
• apoB  
• apoB-48  
• apoB-100 
• apoA-1  
• apoC- III 
• Lp(a)   
• FFA  
• Glycerol levels 
• Lipoprotein particle size/number 
10.6.6 Additional Analyses 
Additional analyses may be performed not specified in this open label study protocol from the 
data available. 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
66  11. INVESTIGATOR’S REGULATORY OBLIGATIONS 
11.1 Informed Consent 
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by [CONTACT_16015]. 
Before a subject’s participation in the trial, the Investigator is responsible for obtaining written 
informed consent from the subject or legally acceptable representative  after adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol-specific screening procedures or any Study Drug ISIS [ADDRESS_1233430]’s agreement or refusal to notify his/her 
primary care physician should be documented in the subject’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_28246] a legally acceptable representative  and by [CONTACT_28490] (not necessarily 
an Investigator).  The original signed informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed 
consent form should be provided to the subject  or legally acceptable representative . 
If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
representative, the  Investigator must provide an impartial witness to read the informed consent 
form to the subject and must allow for questions.  Thereafter, both the subject or legally acceptable representative and the witness must sign the informed consent form to attest that 
informed consent was freely given and understood. 
11.[ADDRESS_1233431] of the Study 
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October 
2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands of national drug and data protection laws and other applicable regulatory 
requirements will be strictly followed.  
11.3 Independent  Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written subject information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received by [CONTACT_882037].  A copy of the written approval of any other items/materials that must be approved by [CONTACT_84225]/IRB  must also be received by [CONTACT_882038].  The Investigator’s Brochure must be 
submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH 
GCP Section 4.5.2.  The Investigator should also notify the IEC/IRB  of SAEs occurring at the 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
67  Study Center and other AE reports received from the Sponsor or designee, in accordance with 
local procedures. 
The Investigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study.  Copi[INVESTIGATOR_5699]’s reports, all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor or designee. 
11.[ADDRESS_1233432]’s confidentiality is maintained.  On the case report 
forms or other documents submitted to the Sponsor or designee, subjects should be identified by [CONTACT_10573] (if permitted by [CONTACT_1769]) and a subject identification number only.  Documents that are not for submission to the Sponsor or designee ( e.g., signed informed consent forms) should be 
kept in strict confidence by [CONTACT_737]. 
In compliance with Federal and local r egulations/ICH GCP Guidelines , it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the subject’s original medical records for 
verification of study-related procedures and data.  Direct access includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study.  The Investigator is obligated to inform and obtain the consent of the subject  to permit 
named representatives to have access to his/her study-related records without violating the 
confidentiality of the subject. 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS 
12.[ADDRESS_1233433] be obtained for all protocol amendments and amendments to the informed consent document.  The regulatory authority and IEC/IRB must be informed of all amendments and give approval for any amendments likely to affect the safety of the subjects or the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB to the Sponsor  or designee . 
12.[ADDRESS_1233434].  The 
Investigator/Sponsor or designee should notify the IEC/IRB in writing of the trial’s completion 
or early termination and send a copy of the notification to the Sponsor or designee. 
12.3 Study Documentation and Storage 
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all appropriately qualified persons to whom he/she has 
delegated trial duties are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form. 
ISIS [ADDRESS_1233435]’s case report 
form data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and pharmacy records, diaries, imaging, and correspondence .  Case report 
form entries may be considered source data if the case report form is the site of the original 
recording (i.e., there is no other written or electronic record of data).   
The Investigator and Study Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study-related (essential) documentation in accordance with Section 8 of the ICH Guidelines (E6), suitable for inspection at any time by [CONTACT_882039]/or applicable r egulatory authorities.  Elements should include: 
• Subject files containing completed case report forms, informed consents, and supporting 
copi[INVESTIGATOR_10467] 
• Study files containing the protocol with all amendments, Investigator’s Brochure, copi[INVESTIGATOR_10468]-study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor  or designee 
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug Product 
Accountability Record, Return of Study Drug Product for Destruction, final Study Drug 
product reconciliation, and all drug-related correspondence 
In addition, all original source documents supporting entries in the case report forms must be maintained and be readily available. 
No study document should be destroyed without prior written agreement between the Sponsor or 
designee  and the Investigator.  Should the Investigator wish to assign the study records to 
another party or move them to another location, he/she must notify the Sponsor or designee. 
12.[ADDRESS_1233436], inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that 
subject confidentiality is respected. 
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to subject medical records and other study-related records 
needed to verify the entries on the case report forms. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by [CONTACT_10576]’s Clinical Quality Assurance Department (or designees).  Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study-related records will occur to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements. 
ISIS [ADDRESS_1233437] data will be 
checked for consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center notifications will be 
sent to the Study Center for completion and return to Sponsor or designee . 
The Principal Investigator [INVESTIGATOR_10469].  These 
signatures will indicate that the Principal Investigator [INVESTIGATOR_10470], the data queries, and the Study Center notifications, and agrees with the content. 
12.[ADDRESS_1233438] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury 
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws.  Subjects will be treated and/or compensated for any study-related illness/injury in accordance with the information provided in the Compensation for Injury 
section of the Informed Consent document. 
  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
70  13. REFERENCES  
Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams -Huet B, Garg A. . Cholic acid for hepatic steatosis in 
patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013 Apr 15;168(5):771 -8. doi: 
10.1530/EJE -12-0969. Print 2013 May.  
Akinci B, Onay H, Demir T , Savas -Erdeve S, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, 
Ozdemir NK, Atik T, Ozen S, Yurekli BS , Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. 
Clinical presentations, metabolic abnormalities and end -organ complications in patients with familial partial 
lipodystrophy. Metabolism. 2017 Jul;72:109 -119. doi: 10.1016/j.metabol.2017.04.010. Epub 2017 Apr 27.  
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals. Chimia 1996; 50: 168 -176. 
Bidault G,  Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, Moritz S, Capeau J, Vigouroux 
C, Béréziat V.  Lipodystrophy -linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro 
endothelial dysfunction. Arterioscler Thromb Vasc Biol 2013.  
Brandt TA, Lee RG, Digenio A, Graham MG, Crooke RM, Hughes SG, Singleton W, Witztum JL, Tsimikas S . 
ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin -like 3, reduces plasma lipid levels in mouse models and 
in healthy human volunteers. Atherosclerosis 2015; 241: e30 -e31.  
Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pi[INVESTIGATOR_106310] G, Pi [INVESTIGATOR_787784] F, Prins MH, Raskob GE . 
Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine 2007; 357: 1094- 1104.  
Chan JL and Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy.  Endocr Pract 
2010; 16: 310- 323. Crooke ST and Bennett CF. Progress in antisense ol igonucleotide  therapeutics. Annual Review 
of Pharmacology and Toxicology 1996; 36: 107- 129. 
Diker -Cohen Cochran E, GordenT P, Brown RJ. Partial and generalized lipo dystrophy : Comparison of baseline 
characteristics and response to metreleptin. J Clin Endocrinol Metab 2015.  
Diker -Cohen Cochran E, GordenT P, Brown RJ. Partial and generalized lipodystrophy: Comparison of baseline 
characteristics and response to metreleptin. J Cl in Endocrinol Metab 2015. Ajluni N et al. [ADDRESS_1233439] -level in drug safety evaluations: use, issues, and 
definition(s). Regul Toxicol Pharmacol. 2005 ; 42(3):  265-74. 
Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 1974; 43: 33 -48.  
Everds N, Li N, Bailey K, Fort M, Stevenson R, Jawando R, Salyers K, Jawa V, Narayanan P, Stevens E, He C, 
Nguyen MP, Tran S, Doyle N, Poitout -Belissent F, Jolette J, Xu C, Sprugel K . Unexpected thrombocytopenia and 
anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody. Toxicol Pathol. 2013;  
41(7):951- 69. doi: 10.1177/0192623312474727. Epub 2013 Mar 7.  
FDA Guidance for Indus try: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in 
adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration Center for 
Drug Evaluation and Research (CDER), July 2005.  
Garg A. Acquired and inherited lipodystrophies.  N Engl J Med . 2004 Mar 18; 350(12):1220 -34.  
Garg  A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.  J J Clin Endocrinol Metab. 
2011 Nov;96(11):3313- 25. doi: 10.1210/jc.2011- 1159. Epub 2011 Aug 24.  
Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. 
Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ -O-(2-methoxyethyl) modified antisense 
oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419- 1428.  
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham 
NC, Digenio A, Hughes SG , Geary RS, Witztum JL, Crooke RM, Tsimikas S. Cardiovascular and Metabolic Effects 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
71  of ANGPTL3  Antisense Oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222 -232. doi: 
10.1056/NEJMoa1701329. Epub 2017 May 24.  
Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, 
Grunberger G, Henry RR, Lavin N, Tapi[INVESTIGATOR_881994], Weyer C; American Association of Clinical Endocrinologists . 
The clinical approach to the detection of lipodystrophy - An AACE Consensus Statement. Endocr Pr act. 2013 Jan -
Feb;19(1):107 -16  
Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circ 2001; 103: 2225 -2229.  
Hegele RA, Joy TR, Al -Attar SA, Rutt BK. Thematic review series: Adipocyte Biology. Lipodystrophies: Windows 
on adipose biology and metabolism. J Lipid Res 2007; 48: 1433- 1444.  
Henry SP, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit 
decreased immune stimulation in mice. J Pharmacol Exp Ther. 2000 Feb;292(2):[ADDRESS_1233440] JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare 
disorder.  J Endocrinol . 2010  Dec;207(3):245 -55. doi: 10.1677/JOE -10-0272. Epub 2010 Sep 24  
Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild -Huntress V, Donovan MJ, Tall AR . Increased LDL 
cholesterol and atherosclerosis in LDL receptor -deficient mice with attenuated expression of scavenger receptor B1. 
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1068 -73. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E.  Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H. FEBS Letters 1987  May 11 ; 215 (2): 327 -30. 
Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, Oka Y, Katayama S.  ANGPTL3 is 
increased in both  insulin -deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004 May 
14;317(4):1075- 9.  
Köbberling J, Willms B,  Kattermann R, Creutzfeldt W.  Lipodystrophy of the extremities. A dominantly inherited 
syndrome associated with lipatrophic di abetes. Humangenetik . 1975 Sep 10;29(2):111 -20.  
Martin -Campos JM, Roig R, Mayoral C, Martinez S, Martí G, Arroyo JA, Julve J, Blanco- Vaca F.  Identification of 
a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without 
APOB mutation. Clin Chim Acta. 2012 Mar 22;413(5 -6):552- 5. doi: 10.1016/j.cca.2011.11.020. Epub 2011 Nov 29.  
McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM.  Characterization of a potent and specific 
class of antisense oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem. 1999 Jan 
15;274(3):1715- 22.  
Minicocci I, Montali A, Robciuc MR, Quagliar ini F, Censi V, Labbadia G, Gabiati C, Pi[INVESTIGATOR_119203] G, Sepe ML, Pannozzo 
F, Lütjohann D, Fazio S, Jauhiainen M, Ehnholm C, Arca M.  Mutations in the ANGPTL3 gene and familial 
combined hypolipi[INVESTIGATOR_035]: A clinical and biochemical characterization. J Clin Endocrinol Me tab. 2012 
Jul;97(7):E1266 -75. doi: 10.1210/jc.2012- 1298. Epub 2012 Jun 1.  
Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense inhibitors of gene expression. J  Biol Chem 1993; 268: [ZIP_CODE] -[ZIP_CODE].  
Musunuru K, Pi[INVESTIGATOR_19961], Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry 
AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Alt shuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S.  Exome sequencing, 
ANGPTL3 mutations, and familial combined hypolipi[INVESTIGATOR_035]. N Engl J Med. 2010 Dec 2;363(23):2220 -7. doi: 
10.1056/NEJMoa1002926. Epub [ADDRESS_1233441] 13.  
Myalept, Package Insert  
National Organi zation for Rare Disorders [NORD]. The Physician’s Guide to Lipodystrophy Disorders 2012.  
Committee for Orphan Medicinal Products 2012  
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
72  Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J of Human 
Gen 2014; 59:16- 23.  
Noto D, Cefalu AB, Valenti V, Fayer F, Pi[INVESTIGATOR_347294] E, Ditta M, Spi[INVESTIGATOR_28947] R, Vigna G, Yue P, Kathiresan S, Tarugi P, 
Averna MR.  Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipi[INVESTIGATOR_035]. 
Arterioscler Thromb Vasc Biol. 2012 Mar ;32(3):805 -9. doi: 10.1161/ATVBAHA.111.238766. Epub 2012 Jan 12.  
Pi[INVESTIGATOR_20664] L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, Fancello T, Zavaroni I, Ardigò D, Bernini F, Calabresi L, [LOCATION_009]schini G, Tarugi P, Calandra S, Bertolini S.  Characterizati on of three kindreds with familial 
combined hypolipi[INVESTIGATOR_881995] -of-function mutations of ANGPTL3. Circ Cardiovasc Genet. 2012 Feb 
1;5(1):42- 50. doi: 10.1161/CIRCGENETICS.111.960674. Epub 2011 Nov 7.  
Prakash TP, Graham MJ, Yu J, Carty R, Low A, Cha ppell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, 
Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP. Targeted delivery of 
antisense oligonucleotides to hepatocytes using triantennary N- acetyl galactosamine improves potency 10 -fold in 
mice. Nucleic Acids Res. 2014 Jul;42(13):8796 -807. doi: 10.1093/nar/gku531. Epub 2014 Jul 3.  
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton -Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer 
TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino 
M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary 
immune thrombocytopenia.  Blood. 2010 Jan 14;115(2):168 -86. doi: 10.1182/blood -2009- 06-225565. Epub [ADDRESS_1233442]. 2009 
Jan;119(1):70 -9. doi: 10.1172/JCI37118. Epub 2008 Dec 15.  
Robbins AL and Savage DB. The genetics of lipid storage and human lipodystrophies. Trends Mol Med. 2015 Jul;21(7):433 -8. doi: 10.1016/j.molmed.2015.04.004. Epub 2015 May 12.  
Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC.  LDL receptor but not apolipoprotein E deficiency 
increase diet -induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E207 -14. 
Shulman, GI.  Ectopic Fat in Insulin Resi stance, Dyslipi[INVESTIGATOR_035], and Cardiometabolic Disease N Engl J Med 2014; 
371:1131- 1141.  
Sleigh A, Stears A, Thackray K , Watson L, Gambineri A, Nag S, Campi [INVESTIGATOR_227302], Schoenmakers N, Brage S, Carpenter 
TA, Murgatroyd PR, O'Rahilly S, Kemp GJ, Savage DB.  Mitochondrail  oxidative phosphorylation is impaired in 
patients with congenital lipodystrophy. J Clin Endocrinol Metab. 2012 Mar;97(3):E438 -42. doi: 10.1210/jc.2011-
2587. Epub 2012 Jan 11.  
Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 
1995; 75: 591- 609. 
Tsuchiya H, Ikeda Y, Ebata Y, et al. Retinoids ameliorate insulin resistance in a leptin -dependent manner in mice. 
Hepatology 2012: 56(4): 1319 -1330.  
Vatier C, Bidault G, Briand N, et al. What the ge netics of lipodystrophy can teach us about insulin resistance and 
diabetes. Curr Diab Rep 2013; 13 Sep (online).  
Wang Y , McNutt MC, Banfi S , Levin MG , Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH. Hepatic 
ANGPTL3 regulates adipose tissue energy h omeostasis.  Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):[ZIP_CODE] -5. 
doi: 10.1073/pnas.[PHONE_18250]. Epub 2015 Aug 24.  
Wang Y, McNutt MC, Banfi S, et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl 
Acad Sci [LOCATION_003] 2015; 112:[ADDRESS_1233443] Factor XI by [CONTACT_81834]: a novel 
antithrombotic strategy with lowered bleeding risk. Blood. 2010 Nov 25;116(22):4684 -92. doi: 10.1182/blood- 2010-
04-277798. Epub 2010 Aug 31.   
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
73   
 
  
 
  
14. APPENDICES  
.
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   09 November  2017  
 
74   
 
  
 
  
Appendix A Schedule of Procedures 
  
 
 
  
 
   
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   06 November 2017  
 
75  Appendix A  Schedule of Procedures  
 
  Screen ing 
 
Treatment Period Follow -up Period 
Diet Run-
in# Qual† 
Study Week -6 to -1 -1 to 0 1 5 9 13  17 21 25 27/ET 4* 8* 13* 
Study Day -42 to -1 -7 to -1 1 29  57 85 113 141 169 183 *Post Last Dose of Study 
Drug  
Visit and Testing Window +/ - Days  0 0 0 2 2 2 3 3 3 0 3 3 3 
Informed Consent X             
Outpatient Visit X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria X X X           
Medical History  X             
Vital Signs X  X X X X X X X X X X X 
Physical Examination a X  X X  X    X X  X 
Body Weight and Height b X X X X X X X X X X X X X 
Waist and hip circumference X         X    
DEXA Scan Xd    X    X    
12- lead ECG (triplicate) X  X X  X  X  X X X X 
Ultrasound  X             
Mixed Meal Test c  X    X    X    
MRI  Xd    X    X    
24-Hour Urine for Creatinine 
Clearance and Protein X             
Extended Urinalysis e X  EVERY 14 DAYS (+/- 2 days) e, f X X X X X X X 
Serum Creatinine and Cys -C i, j, k X  EVERY 14 DAYS (+/- 2 days) f, i X X X X X X X 
Chemistry Panel j , k X  EVERY 14 DAYS (+/- 2 days) f X X X X X X X 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   06 November 2017  
 
76  Appendix A  Schedule of Procedures Continued 
# Subjects on stable diet known to the investigator and followed at the site may go from Screening to qualification without the diet run-in period. 
† Qual =Qualification  
All procedures and study samples are to be done pre-dose at respective visits, unless specified 
a Full physical exam will be performed at the screening visit and an abbreviated physic al exam will be performed during treatment and follow-up period s. 
b     Height only required at Screening 
c     Mixed Meal Test -refer to Appendix E for fur ther details  
d     MRI and DEXA scan will only be performed after subjects have met initial screening eligibility .  MRI and DEXA scan should be performed as close to 
anticipated Day 1 date as possible and to allow time for result reporting and analysis . Visit and Testing Window +/ - Days  0 0 0 2 2 2 3 3 3 0 3 3 3 
Hematology  X  EVERY 14 DAYS (+/- 2 days) f Xh Xh Xh 
Coagulation  X  X       X    
Hepatitis B, C, HIV X             
Thyroid Panel X             
Inflammatory   X   X    X   X 
Liver Biomarkers   X   X    X   X 
Plasma PK - ISIS 703802 l   X1 X1 X1 X1 X1 X1 X1 X X X X 
Anti-ISIS 703802 Antibodies   X X X X  X  X  X X 
FSH (women only, if applicable) j, m X             
Serum Pregnancy Test m X  X X X X X X X X X X  
Archived Serum & Plasma Samples 
j, n   X  X  X   X   X 
PD Panel j X X X X X X X X X X X X X 
Extended Lipid  Panel j X X X X X X X X X X X X X 
HbA1C j X  X   X    X   X 
Quality of Life Assessment  X    X    X    
Widespread Pain Diary  X TO BE DONE AT OUTPATIENT VISITS  X X X 
Study Drug:  SC Injection   WEEKLY SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 
through Week 26/Day 176)     
Adverse Events TO BE COLLECTED FROM TIME OF INFORMED CONSENT TO END OF FOLLOW-UP PERIOD 
Concomitant Medication  TO BE COLLECTED FROM TIME OF INFORMED CONSENT TO END OF FOLLOW-UP PERIOD 
ISIS [ADDRESS_1233444] be no more than 
4 weeks apart during the treatment period . 
g U rine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow-up period, hematology sampling for platelet values are taken every 14 days (+/- 2 days)  for [ADDRESS_1233445] 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons. 
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) a repeat blood 
specimen should be re-drawn as soon as possible (ideally within 7 days).  All platelet count results will be reviewed promptly (within 48 hours of receipt) by [CONTACT_368118] 6.2.1.   Any ca se of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
l      Refer to  Appendix C for PK Sampling schedule. 
m Women who are not surgically sterile or post-menopausal.  
n Serum and plasma samples will be collected and stored for follow-up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) and will be retained u ntil completion of the final 
study report. 
 
Time (time is in reference to Study Drug administration): 
[ADDRESS_1233446] of Laboratory Analytes 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN  
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) 
bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  
• Creatinine kinase  
• GGT  
• Cys-C 
 
PD Panel  
• ANGPTL3  
• Insulin  
• Proinsulin  
• C-peptide  
• Fructosamine  
• Glycated albumin  
• Delipi[INVESTIGATOR_671575]  
• Fasting Plasma Glucose  
 
Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 Screening Tests  
• Hepatitis B 
surface antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women 
only)  
• Serum βhCG  
• TSH  
• Free T4  
 
 
Extended Lipid  Panel  
• Total Cholesterol 
(TC)  
• LDL cholesterol (LDL -C) 
• HDL cholesterol 
(HDL -C) 
• Triglycerides (TG)  
• VLDL  cholesterol 
(VLDL -C) 
• Non-HDL 
cholesterol (Non -
HDL -C) 
• Lp(a)  
• FFA 
• ApoB  
• ApoB -48 
• ApoB -100 
• Apo A-1 
• ApoCIII  (total, 
chylomicron, LDL, HDL, 
VLDL)  
• Delipi[INVESTIGATOR_881996]  
• Ceramides  
• Sphingolipi[INVESTIGATOR_805]  
• Diacyglycerol  
• Lipoprotein particle analysis  Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and 
absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 703802  levels in 
plasma  
 
Immunogenicity  
• Anti-ISIS 703802  
antibodies  
 
Liver Biomarkers (Biomarkers 
of liver apoptosis and fibrosis ) 
• CK18  
• PI[INVESTIGATOR_671576]  
• hs-CRP  
• IL-6 
• IFN gamma  
• TNF alpha  
• Leptin  
• Adiponectin  
 
Genetic Testing 
• Genetic sequencing of FPL 
causing genes3 
 Extended Urinalysis  
• Routine Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Blood  
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio (UPCR)  
• A/C Ratio (UACR)  
 
24-Hour Urine Test 
• Creatinine clearance  
• Protein  
• Albumin  
 
Mixed Meal Test  
• Plasma glucose  
• FFA 
• C-peptide  
• Insulin  
• Serum ghrelin  
• GIP 
• GLP-1 
• PYY  
• Incretin hormones  
[ADDRESS_1233447] (e.g., mutations in LMNA, PPAR -γ, AKT2, CIDEC, PLIN1 
genes ).  May not be collected if adequate genetic data are available in medical history or if patient does not consent to 
genetic testing 
 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   07 November 2017  
 
80   
  
 
 
Appendix C PK Sampling Schedule  
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Original  
Protocol   07 November 2017  
 
81  Appendix C PK Sampling Schedule  
 Treatment Period Follow -up Period 
Study 
Week  1 5 9 13  17 21 25 27 4* 8* 13* 
Study 
Day D1 D29 D 57 D 85 D 113 D141  D169  D 183 *Post Last Dose of Study Drug 
 
 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime Anytime Anytime Anytime 
Note:  D, Day  
 
ISIS [ADDRESS_1233448] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 
2010. 
 
 

ISIS [ADDRESS_1233449] 
(MTT) as follows: subjects will consume a standardized meal the evening before the test        (750 kcal; 20% of energy from protein, 30% from fat, and 50%
 from carbohydrate) and refrain 
from consuming alcohol for 72 h.  
A cannula will be inserted into a forearm vein, and an overnight fasting venous blood sample 
will be taken between 8:00 AM and 10:00 AM for measurement of plasma glucose, FFA,         C-peptide and insulin concentrations
 and serum ghrelin, GIP, GLP-1, and PYY.  Incretin 
hormones will be measured using a multiplex assay (EMD Millipore, Billerica, MA).  The tubes for the incretin hormones will contain Pefabloc SC (Sigma-Aldrich, St. Louis, MO) and DPP- IV 
inhibitor (EMD Millipore, Billerica, MA) to inhibit DPP-IV and other proteases.  The change in 
ratings from Baseline will be quantified.  
Subjects will then consume a liquid load of Optifast (Optifast; [COMPANY_001], Minneapolis, MN;        
474 ml, 320 kcal, 50% carbohydrate, 35% protein, 15% fa t)
 within a 15-min period.  Additional 
blood samples will be taken at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 min after meal consumption.  VAS  will be completed at 180 minutes and 300 min.  To calculate the insulin 
sensitivity index (S
I), the oral minimal model for glucose will be used; and to calculate the 
hepatic insulin extraction, oral minimal model for insulin and c-peptide will be used [Cobelli et al, 2007; Cobelli et al, 2005]. Subjects will complete a validated visual analogue scale (VAS)
 questionnaire to assess subjective hunger at 0, 180 and 300 minutes [Luscombe-Marsh et 
al, 2005; Moran et al, 2005].  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
1               
 
Sponsor : 
Akcea Therapeutics 
[ADDRESS_1233450]  
Cambridge, MA  [ZIP_CODE] 
 Collaborator:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_1233451]  
Carlsbad, CA  [ZIP_CODE] 
  
 
 
ISIS 703802-CS5 
 
An open -label Phase 2 Study of ISIS 703802 (AKCEA -ANGPTL3 -LRx) 
Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy  
 
Amendment 1  – 16 February  2018 
 

ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
2   
 
 ISIS 703802- CS5  
 
 
An open-label Phase 2 Study of ISIS 703802 (AKCEA -
ANGPTL3 -LRx) Administered Subcutaneously to Subjects 
with Familial Partial Lipodystrophy  
Amendment 1  – [ADDRESS_1233452]  
Cambridge, MA  [ZIP_CODE] 
Telephone: ([PHONE_18249] 
 
  

ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
3  ISIS 703802  
Protocol Number ISIS  703802- CS5 
Amendment 1  
 
Clinical Phase:   2 
An open- label Phase 2 Study of ISIS 703802 (AKCEA- ANGPTL3 -
LRx) Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy 
Trial Sponsor:  Akcea  Therapeutics , Inc.  
[ADDRESS_1233453]:   
 - A kcea Therapeutics, Inc.  
[ADDRESS_1233454]  
Cambridge, MA [ZIP_CODE]  
Phone:  
E-mail:  
 Sponsor Medical Monitor:  , MD  
 - Ak cea Therapeutics, Inc.  
[ADDRESS_1233455]  
Cambridge, MA  [ZIP_CODE] 
Phone:
Mobile:  
E-mail:  
 
Date:  [ADDRESS_1233456] of the clinical 
investigation without the prior written consent of Akcea Therapeutics, Inc. 
 
 
 

ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
4  Protocol Signature [CONTACT_38020]:          ISIS  703802- CS5 
Protocol Title:  An open -label Phase 2 Study  of ISIS 703802 (AKCEA- ANGPTL3 -LRx) 
Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy  
 Amendment:  Amendment 1  
Date:                              [ADDRESS_1233457] read and understand the attached clinical protocol, entitled “ An open -
label Phase 2 Study of ISIS 703802 (AKCEA -ANGPTL3 -LRx) Administered Subcutaneously to Subjects 
with Familial Partial Lipodystrophy ” dated [ADDRESS_1233458] the study  as described 
herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on Good 
Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for any 
purpose other than the evaluation or conduct of the clinical investigation without the prior written consent 
of Akcea Therapeutics, Inc.  
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date (DD Month YYYY)  
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
5  TABLE OF CONTENTS  
PROTOCOL SYNOPSIS  ......................................................................................................................... 21 
STUDY DESIGN AND TRE ATMENT SCHEMA ................................................................................ 27 
STUDY GLOSSARY ................................................................................................................................ 28 
1. OBJECTIVES  .............................................................................................................................. 32 
1.1 Primary Objective  ...................................................................................................................... 32 
1.2 Secondary Objective(s) ............................................................................................................. 32 
2. BACKGROUND AND RATIONALE  ....................................................................................... 32 
2.1 Overview of Disease .................................................................................................................. 32 
2.2 Therapeutic Rationale ................................................................................................................ 35 
2.3 ISIS 703802  ............................................................................................................................... 35 
2.3.1 Mechanism of Action  ........................................................................................................ 35 
2.3.2 Chemistry  .......................................................................................................................... 36 
2.3.3 Preclinical Experience  ....................................................................................................... 37 
[IP_ADDRESS]  Preclinical Pharmacology  ........................................................................................... 37 
[IP_ADDRESS]  Preclinical Toxicology ............................................................................................... 38 
2.3.4 Clinical Experience ........................................................................................................... 39 
[IP_ADDRESS]  ISIS 563580- CS1 Phase 1 SAD/MAD  ....................................................................... 40 
2.4 Rationale for Dose and Schedule of Administration ................................................................. 40 
2.5 Benefit -Risk Assessment  ........................................................................................................... 40 
2.5.2 Risk Assessment  ................................................................................................................ 40 
2.5.3 Overall Assessment of Benefit: Risk  ................................................................................. 42 
3. EXPERIMENTAL PLAN  ........................................................................................................... 42 
3.1 Study Design  ............................................................................................................................. 42 
3.2 Number of Study Centers  .......................................................................................................... 43 
3.3 Number of Subjects  ................................................................................................................... 43 
3.4 Overall Study Duration and Follow-up ..................................................................................... 43 
3.4.1 Screening/Qualification  ..................................................................................................... [ADDRESS_1233459] ELIGIBILITY  ........................................................................................................... 44 
5.1 Inclusion Criteria  ....................................................................................................................... 44 
5.2 Exclusion Criteria ...................................................................................................................... 46 
6. STUDY PROCEDURES  ............................................................................................................. 48 
6.1 Study Schedule .......................................................................................................................... 48 
6.1.1 Screening/Qualification  ..................................................................................................... [ADDRESS_1233460]-Treatment Period  ....................................................................................................... 49 
6.2 Study/Laboratory Assessments  ................................................................................................. [ADDRESS_1233461] Results / Temporary Stoppi[INVESTIGATOR_881997]  ........................................................................................................ 60 
8.6.3 Stoppi[INVESTIGATOR_10424]  .......................................................................... 61 
8.7 Adjustment of Dos e and/or Treatment Schedule ....................................................................... 63 
8.8 Discontinuation of Study Drug/Treatment  ................................................................................ [ADDRESS_1233462] -Treatment 
Follow -up Period  ............................................................................................................... 63 
8.9 Withdrawal of Subjects from the Study .................................................................................... 64 
8.10 Concomitant Therapy and Procedures  ....................................................................................... 64 
8.10.1  Concomitant Therapy  ........................................................................................................ 64 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
7  8.10.2  Concomitant Procedures .................................................................................................... 65 
8.11 Treatment Compliance  .............................................................................................................. 65 
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  .................................... 65 
9.1 Sponsor Review of Safety Information ..................................................................................... 65 
9.2 Regulatory Requirements .......................................................................................................... 65 
9.3 Definitions  ................................................................................................................................. 66 
9.3.1 Adverse Event  ................................................................................................................... 66 
9.3.2 Adverse Reaction and Suspected Adverse Reaction ......................................................... 66 
9.3.3 Serious Adverse Event (SAE) ........................................................................................... 66 
[IP_ADDRESS]  Adverse Events of Special Interest  ............................................................................. 67 
9.4 Monito ring and Recording Adverse Events  .............................................................................. 67 
9.4.1 Serious Adverse Events  ..................................................................................................... 67 
9.4.2 Non-Serious Adverse Events  ............................................................................................. 67 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  ................................................ 67 
[IP_ADDRESS]  Relationship to the Study Drug  .................................................................................. 68 
[IP_ADDRESS]  Severity ....................................................................................................................... 68 
[IP_ADDRESS]  Action Taken with Study Drug .................................................................................. 68 
[IP_ADDRESS]  Treatment G iven for Adverse Event........................................................................... 69 
[IP_ADDRESS]  Outcome of the Adverse Event  .................................................................................. 69 
9.5 Procedures for Handling Special Situations  .............................................................................. 69 
9.5.1 Abnorma lities of Laboratory Tests  .................................................................................... 69 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ....................... 70 
9.5.3 Dosing Errors  .................................................................................................................... 70 
9.5.4 Contraception and Pregnancy  ............................................................................................ 70 
10. STATISTICAL CONSIDERATIONS  ....................................................................................... 71 
10.1 Study Endpoints, Subsets, and Covariates ................................................................................. 71 
10.1.1  Primary Endpoint .............................................................................................................. 71 
10.1.2  Secondary Endpoints ......................................................................................................... 71 
10.2 Sample Size Considerations ...................................................................................................... 71 
10.3 Populations ................................................................................................................................ 71 
10.4 Defini tio
n of Baseline ................................................................................................................ 72 
10.5 Interim Analysis and  Early Stoppi[INVESTIGATOR_130]  ...................................................................... 72 
10.6 Planned Methods of Analysis  .................................................................................................... 72 
10.6.1  Demographic and Baseline Characteristics  ....................................................................... 72 
10.6.2  Safety Analysis .................................................................................................................. 72 
[IP_ADDRESS]  Adverse Events  ........................................................................................................... 72 
[IP_ADDRESS]  Clinical Laboratory Data  ............................................................................................ 72 
[IP_ADDRESS]  Vital Signs and Examinations  .................................................................................... 73 
10.6.3  Efficacy Analysis  .............................................................................................................. 73 
10.6.4  Pharmacokinetic Analysis ................................................................................................. 73 
10.6.5  Pharmacodynamic Analysis .............................................................................................. 74 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
8  10.6.6  Additional Analyses  .......................................................................................................... 74 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .......................................................... [ADDRESS_1233463] of the Study  ..................................................................................................... 75 
11.3 Independent  Ethics Committee/Institutional Review Board ..................................................... [ADDRESS_1233464]  ....................................................................................................... 95 
Appendix F   Laboratory Tests to Be Performed in the Event of a Plate let Count ˂ 100,000/mm3 97 
 
TABLE OF TABLES 
Page  
Table 1  Study Drug Characteristics ............................................................................................... 52 
Table 2  Study Drug Dosing Information ....................................................................................... 53 
Table 3  Actions in Subjects with Low Platelet Count  ................................................................... 62 
 
TABLE OF FIGURES 
Page  
Figure 1  Design of Chimeric 2ʹ -MOE Phosphorothioate Oligonucleotides  (MOE -
Gapmer).  The sequence of ISIS 703802 is shown.  .......................................................... 37 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
9   
PROTOCOL AMENDMENT  
Protocol Number:          ISIS 703802- CS5 
Protocol Title:  An open-label Phase 2 Study of ISIS 703802 (AKCEA- ANGPTL3 -
LRx) Administered Subcutaneously to Subjects with Familial Partial 
Lipodystrophy 
Amendment Number:   Protocol Amendment 1 
Amendment Date:         [ADDRESS_1233465] been made: 
Akcea Therapeutics, Inc. now appears as the Sponsor and Ionis Pharmaceuticals, Inc. now appears as the 
Collaborator; ISIS 703802- CS05 is being updated to ISIS 703802- CS5.  In addition, the reference list has 
been upda ted. The tables being updated are not shown in this summary of changes.  Finally, minor updates 
noted as inconsistencies have been made throughout the document. Note that language in the Was  section 
that is being deleted appears as strikethrough and new lan guage in the Update  section appears as bold:  
1. Synopsis and Section 5.2 Exclusion Criteria number 6  
Was:  
6. History of heart failure with [LOCATION_001] Heart Association functional classification (NYHA) 
greater than Class II or unstable congestive cardiac failure requiring a change in medication 
Update:  
6. History of heart failure with [LOCATION_001] Heart Association functional classification (NYHA) 
greater than Class II  
Rationale:  
The portion of exclusion criterion 6 that is being deleted is covered in exclusion criterion 4: History 
within 6 months of Screening of acute or unstable cardiac ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack, or unstable congestive heart failure requiring a change in medication 
2. The following changes have been made to several sections with respect to MRI and DEXA 
scan  
Synopsis sections Study Visit Schedule and Procedures  
Was:  
Subjects on stable diet known to the investigator and followed at the site may go from Screening to qualification without a 4- week diet run- in. TGs will be measured and. MRI will be obtained to assess 
ISIS [ADDRESS_1233466] can mo ve directly to qualification.  
Update: 
Subjects on stable diet known to the investigator and followed at the site may go from Screening to 
qualification without a 4- week diet run-in. At the qualification visit  TGs will be measured . MRI and 
DEXA scan  will be  obtained during screening once all other eligibility criteria are met  to assess 
liver fat content.   
Section 3.1 Study Design end of paragraph two 
Was:  
At the qualification visit TGs will be measured to qualify and MRI will be obtained to assess liver fat 
content.  MRI results must be available prior to registration and administration of the first dose of 
study drug.  
Update: 
At the qualification visit TGs will be measured.  MRI and DEXA scan will be obtained during 
screening once all other eligibility criteria are met  to assess liver fat content.  MRI results must be 
available prior to registration and administration of the first dose of study drug.  
Section 3.4.1 Screening/Qualification end of paragraph  one 
Was:  
At the qualification visit subjects will have  a baseline DEXA scan and MRI will be obtained to assess 
liver fat content.  MRI results must be available prior to registration and administration of the first 
dose of study drug. 
Update: 
At the qualification visit TGs will be measured .  A baseline DEXA scan and MRI will be obtained 
to assess liver fat content once all other eligibility has been confirmed .  MRI results must be 
available prior to registration and administration of the first dose of study drug.  
Section 6.1.1 Screening/Qualification end of paragraph three  
Was:  
At the qualification visit TGs will be measured and MRI will be obtained to assess liver fat content.  
MRI results must be available prior to registration and administration of the first dose of study drug. 
Update: 
At the qualification visit TGs will be measured. MRI and DEXA scan will be obtained during 
screening once all other eligibility criteria are met to assess liver fat content.  MRI results must be 
available prior to registration and administration of the first dose of study drug.  
Section 6.2.6 MRI 
Was:  
An MRI to determine liver fat fraction will be done at Qualification , Week 13 and Week 27.  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
11  Update: 
An MRI to determine liver fat fraction will be done during Screening after all other eligibility 
criteria are met , and again at  Week 13 and Week 27.  
Appendix A Footnote d 
Was:  
d     MRI and DEXA scan will only be performed after subjects have met initial screening eligibility . 
MRI and  DEXA scan should be performed as close to anticipated Day 1 date as possible and to 
allow time for result reporting and analysis. 
Update: 
d     MR I and DEXA scan will only be performed during Screening after all other eligibility 
criteria are met .  MRI should be performed 10 days (+/ - 2 days) prior to anticipated Day 1 
date to allow time for result reporting and analysis .  DEXA scan should be perfor med as close 
to anticipated Day 1 date as possible.  
Rationale:  
The MRI and DEXA scan should be performed after all other eligibility criteria are met and as close 
to day [ADDRESS_1233467]  Enrollment 
 
A. Was:  
 
Subjects must sign the consent form before any screening tests or assessments are performed.  At the 
time of consent, the subject will be considered enrolled  into the Study and will be assigned a unique 
subject identification number before any study procedures, including screening procedures, are 
performed.  
 
A. Update: 
 Subjects must sign the consent form before any screening tests or assessments are performed.  At the 
time of consent, the subject will be considered screened  into the Study and will be assigned a unique 
subject identification number before any study procedures, including screening procedures, are 
performed.  
 
B. Was:  
 Subjects will be registered after all screening assessments have been completed and after the 
Investigator has verified that they are eligible per criteria in  Sections  5.[ADDRESS_1233468] identification number.  
 
B. Update: 
 
Subjects will be registered after all screening assessments have been completed and after the 
Investiga tor has verified that they are eligible per criteria in  Sections  5.[ADDRESS_1233469] identification number nor confirmation of 
eligibility . 
 
Rationale: 
 
These changes are meant to clarify screening and enrollment into the st udy. 
 
4. Section 6.2 Study/Laboratory Assessments paragraph eight  
Was:  
All lab samples sent to the central laboratory are received on the next day  and processed.  Lab Alerts 
issued as per protocol safety monitoring requirements or stoppi[INVESTIGATOR_671558], the Sponsor  and the CRO Medical Monitors, the Sponsor Drug Safety Physician, and the 
Clinical Trial Manager (CTM), and should be received by [CONTACT_77314] 2 days from sample collection.  Hematology results from the site’s local laboratories are received by [CONTACT_882040] , and should be entered as soon as possible into the eCRF to inform the Sponsor 
and CRO study monitoring teams.  
Update: 
All lab samples are to be sent to the central laboratory by [CONTACT_882041].  Lab 
Alerts issued as per protocol safety monitoring requirements or stoppi[INVESTIGATOR_671558], the Sponsor and the CRO Medical Monitors, the Sponsor Drug Safety 
Physician, and the Clinical Trial Manager (CTM), and should be received by [CONTACT_77314] 2 days from 
sample collection.  Hematology results from the site’s local laboratories are received by [CONTACT_882042]’s standard reporting time, and should be entered as soon as 
possible into the eCRF to inform the Sponsor and CRO study monitoring teams.  
Rationale: 
There could be reasons why samples sent to the central lab are not rece ived the following day. The 
local laboratory will provide results on specimens tested within its standard timeframe.  
5. The following changes have been made to several sections with respect to renal function  
Section 8.5.2 Safety Monitoring for Renal Function paragraph three and six  
A. Was:  
While on treatment during the course of the study, urinary surveillance may include urinalysis to 
include urine albumin/creatinine ratio (UACR), urine protein/creatinine ratio (UPCR) and urinary red 
blood cells (RBCs), as wel l as serum creatinine and cystatin -C to estimate glomerular filtration rate 
(eGFR) which will be monitored every [ADDRESS_1233470] 3 -months of the study treatment 
period, and monthly thereafter.  In addition, other biomarkers of acute renal injury m ay also be 
measured if a safety signal is seen that warrants further testing.  (Appendix B ).  
A. Update: 
While on treatment during the course of the study, urinary surveillance may include urinalysis to include urine albumin/creatinine  ratio (UACR), urine protein/creatinine ratio (UPCR) and urinary red 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
13  blood cells (RBCs), as well as serum creatinine and cystatin -C which will be monitored every [ADDRESS_1233471] 3-months of the study treatment period, and monthly thereafter.  In a ddition, 
other biomarkers of acute renal injury may also be measured if a safety signal is seen that warrants 
further testing.  (Appendix B ).  
B. Was:  
Lab alerts for abnormal renal tests will be issued for:  Creatinine clearance (by [INVESTIGATOR_243843] D-EPI [INVESTIGATOR_14420]) 
decrease from Baseline > 25%, urine albumin/creatinine ratio (UACR) > 250 mg/g, urine 
protein/creatinine ratio (UPCR) >  0.5 mg/mg, or an increase in serum creatinine from Baseline > 0.3 
mg/dL).  
B. Update: 
Lab alerts for abnormal renal tests wil l be issued for: eGFR  (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) decrease from 
Baseline > 25%, urine albumin/creatinine ratio (UACR) > 250 mg/g, urine protein/creatinine ratio (UPCR) >  0.5 mg/mg, or an increase in serum creatinine from Baseline > 0.3 mg/dL).  
Section 8.6.[ADDRESS_1233472] Results/Temporary Stoppi[INVESTIGATOR_881998]:  
In the event of an estimated creatinine clearance (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) meeting any of the following 
criteria, or any change in renal biomarkers deemed by [CONTACT_882033], a 
serum creatinine and 24 -hour urine sample for creatinine clearance and protein should be obtained:  
1. CKD-EPI [CONTACT_57939] > 40% from Baseline  
2. CKD-EPI [CONTACT_10654] < 45 mL/min/1.73 m2 
Update: 
In the event of an eGFR  (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) meeting any of the following criteria, or any change 
in renal biomarkers deemed by [CONTACT_882033], a serum creatinine and 
24-hour urine sample for creatinine clearance and protein should be obtained: 
1. eGFR ( CKD -EPI) decrease of > 40% from Baseline  
2. eGFR ( CKD -EPI) value < 45 mL/min/1.73 m2 
Synopsis and Section 5.2 Exclusion Criteria  number 8 paragraph b 
Was:   
Estimated GFR ˂ 60 mL/min (as determined by [CONTACT_81105]-Epi[INVESTIGATOR_526913] (CKD -EPI) Equation for creatinine clearance 
Update:  
Estimated GFR ˂ 60 mL/min /1.73 m2 (as determined by [CONTACT_81105]-
Epi[INVESTIGATOR_368010] (CKD -EPI) Equation  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
14  Rationale:  
These changes are made to consistently identify estimated glomerular filtration rate as measured by 
[CONTACT_9289]- EPI [INVESTIGATOR_881999].  
6. The following changes have been made to several sections with respect to platelet monitoring  
Section 8.5.3 Safety Monitoring Rules for Platelet Count Results paragraph three and six 
A. Was:  
Any case of a platelet count reduction to levels below  50,000/mm3 (Grade 3 or Grade 4) is considered 
an adverse event of special interest and should be reported in an expedited  fashion to the Sponsor.  
A. Update: 
Any case of a platelet count reduction to levels below  50,000/mm3 (Grade 3 or Grade 4) is considered 
an adverse event of special interest and should be reported in an expedited fashion to the Sponsor. In 
this case, the Investigator should refer the subject to a hematologist to provide diagnostic and 
therapeutic management.  
B. Was:  
In the event of a platelet count ˂ 100,000/mm3 the laboratory tests outlined in  Table 3, should be 
performed as soon as possible.  Additional lab tests will be determined by [CONTACT_37878].  
B. Update: 
In the event of a  platelet count ˂ 100,000/mm3, the laboratory tests outlined in  Table 3 should be 
performed as soon as possible.  In addition to action taken as outlin ed in Table 3 , in the event of a 
platelet count <100,000/mm3, tests outlined in  Appendix F  should be performed as soon as 
possible. Additional lab tests, if warranted , will be determined by [CONTACT_37833].  
Section 8.6.3  Stoppi[INVESTIGATOR_882000] ( >) has been added to a couple of places in the fourth paragraph in 
order to align with updates in Table 3. In addition, paragraph six:  
Was:  
Once a subject commences weekly monitoring, this frequency of monitoring should continue irrespective of whether the platelet count rises into the normal range.   
Update: 
Once a subject commences weekly monitoring, this frequency of monitoring should continue until 
the platelet count returns to the normal range ( >140,000/mm3) for [ADDRESS_1233473] -Treatment Period 
Was:  
Footnote: Once a subject commences weekly monitoring this frequency of monitoring should 
continue irrespective of whether the platelet count rises into the normal range. 
Update: 
Footnote: Once a subject commences weekly monitoring this frequency of monitoring should 
continue until the platelet count returns to the normal range ( > 140,000/mm3) for 2 successive 
values.  
Rationale:  
Several changes have been made to Table [ADDRESS_1233474] and to clarify when to start and when to 
discontinue weekly platelet monitoring.  
Appendix F Addit ional testing for low platelet count 
Addition of a table outlining tests to be performed on patients that experience a single occurrence of platelets <100,000/mm
3.  
Rationale: 
Changes have been made in order to clarify normal ranges, to clarify the need to refer Grade [ADDRESS_1233475], and to clarify when to start and when to discontinue weekly 
platelet monitoring. These changes are expected to help better understand the reasons for platelet 
count reductions, were they to occur, and ensure close monitoring of subjects if a single platelet count reduction <100,000/mm
[ADDRESS_1233476] that monitoring of bleeding events has been taken 
out of Section 8.6.3 and added to Section 8.5.4.  
  The following has been deleted from Section 8.5.4 due to the redundancy resulting from the re-
arrangement above: 
 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant, non- major bleeding events (which are defined in  Section 8.6.3 ), for example, excess 
bruising, petechiae, or gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT), prothrombin time (PT), INR, hepatic 
enzymes, bilirubin and platelet count may be performed. 
 The following w as deleted from Section 8.5.4 to avoid protocol deviations:  
 
Patients will be instructed to promptly report any signs or symptoms of bleeding.  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
16   
In addition, Section 8.5.4 has an additional phrase and sentence:  
 
Was:  
Subjects will be evaluated for occurrence of bleeding events continuously after the start of Study Drug treatment (Day 1)   
Update: 
Subjects will be evaluated for occurrence of bleeding events continuously after the start of Study Drug treatment (Day 1) up to the end of the follow -up period fo r all cohorts.  All bleeding events 
are considered adverse events and reported on adverse event case report form.  
 
Rationale: 
Monitoring and the monitoring period have been clarified and clarification that bleeding events are to be considered adverse events has been added.  
 
8. Section 8.5.6 Safety Monitoring for Hypoglycemia  
Was:  
The alert value for hypoglycemia is ≤ 70 mg/dL (≤ 3.9 mmol/L) plasma concentration. 
Severe Hypoglycemia  
Requires assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event. Neurological 
recovery following plasma glucose levels returning to normal considered sufficient evidence that 
event was induced by [CONTACT_81816].  
Documented Symptomatic Hypoglycemia  
Typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 
mmol/L).  
Asymptomatic Hypoglycemia   
Not accompanied by [CONTACT_11017][INVESTIGATOR_81744]≤ 70 mg/dL 
(≤ 3.9 mmol/L) . 
Probable Symptomatic Hypoglycemia 
Typi[INVESTIGATOR_882001]  ≤ 70 mg/dL (≤ 3.9 mmol/L). 
A documented severe hypoglycemic event is defined as one in which the subject requires assistance 
of another person to obtain treatment for the event and has a plasma  glucose level ≤ 70 mg/dL 
(≤ 3.9 mmol/L).  The rescue treatmen t of hypoglycemia may include IV glucose or buccal or 
intramuscular glucagon.  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
17  Update:  
The alert value for hypoglycemia is ≤ 70 mg/dL (≤ 3.9 mmol/L) blood  glucose concentration.  
Severe Hypoglycemia  
Requires assistance of another person to actively administer carbohydrates, glucagon, or take other 
corrective actions. Glucose concentrations may not be available during an event. Neurological 
recovery following glucose levels returning to normal considered sufficient evidence that event was induced by l ow glucose concentration. 
Documented Symptomatic Hypoglycemia  
Typi[INVESTIGATOR_882002] ≤ 70 mg/dL (≤ 3.9 
mmol/L).  
Asymptomatic Hypoglycemia   
Not accompanied by [CONTACT_11017][INVESTIGATOR_671564] ≤ 70 mg/dL 
(≤ 3.9 mmol/L) . 
Probable Symptomatic Hypoglycemia 
Typi[INVESTIGATOR_882003] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
A documented severe hypoglycemic event is defined as one in which the subject requires assistance 
of another person to obtain treatment for the event and has a blood  glucose level ≤ 70 mg/dL 
(≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal or 
intramuscular gluc agon. 
Rationale:  
Determination of severe hypoglycemia can be measured by [CONTACT_398192]. Therefore, the language has 
been made more generic.  
9. Section 8.5.7 Safety Monitoring for Documented Hyperglycemia  
A. Was:  
From baseline visit to Week 13 (including value at Week 13) of Randomized Treatment period:  
• FPG > 270 mg/dL (15.0 mmol/L)  
From Week 13 to Week 25/27/ET (including value at Week 25/27/ET) of Randomized Treatment 
period : 
• FPG > 240 mg/dL (13.3 mmol/L) or  
• HbA1c > 9% (for subjects with Baseline HbA1c < 8%) and HbA1c increase of more than 1% 
from Baseline (for subjects with Baseline HbA1c ≥ 8%)  
ISIS [ADDRESS_1233477]/HbA1c above the threshold values, the Investigator should ensure that no reasonable 
explanation exists for insufficient glucose control and in particular th at: 
• Plasma glucose was actually measured in the fasting condition  
 
A. Update: 
From baseline visit to Week 13 (including value at Week 13) of Randomized Treatment period:  
• Blood glucose  > 270 mg/dL (15.0 mmol/L) 
From Week [ADDRESS_1233478]-treatment Follow -up (Week 4,  [ADDRESS_1233479] end of treatment period):  
• Blood glucose  > 240 mg/dL (13.3 mmol/L) or 
• HbA1c > 9% (for subjects with Baseline HbA1c < 8%) and HbA1c increase of more than 1% 
from Baseline (for subjects with Baseline HbA1c ≥ 8%)  
In case of blood glucose /HbA1c a bove the threshold values, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that:  
• Blood  glucose was actually measured in the fasting condition  
B. Was:  
If none from the above-mentioned reason can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, rescue  
B. Update: 
If none from the above-mentioned reason can be found, or if appropriate action fails to decrease 
blood glu cose/HbA1c under the threshold values, rescue 
Rationale:  
Monitoring for hyperglycemia did not include the post -treatment period. This change now 
incorporates that period. Fasting plasma glucose(FPG) has been updated to the more generic term 
“blood glucose ” for this section to allow for measurements made with a glucometer.  
10. Follow -up Period Post -Treatment  
Section 3.4.[ADDRESS_1233480]-Treatment   
Was:  
Subjects are to return to the Study Center for fol low-up visits.  These visits will take place at 4, [ADDRESS_1233481] dose. Refer to Schedule of Procedures in Appendix A . 
Update: 
Subjects are to return to the Study Center for fol low-up visits.  These visits will take p lace at 4, 8 and 
13 weeks after the Treatment Period (last dose through one dosing interval post last dose). Refer 
to Schedule of Procedures in  Appendix A . 
  
ISIS [ADDRESS_1233482]- Treatment Period  
Was:  
Each subject will be followed for safety assessments for [ADDRESS_1233483] dose of Study Drug.   
Update: 
Each subject will be followed for safety assessments for 13 weeks after the Treatment Period (last 
dose through one dosing interval post last dos e).   
Section 8.8.[ADDRESS_1233484] -Treatment 
Follow-up Period 
Was:  
Any subject who discontinues early from the treatment period or from post- treatment follow -up 
period should be followed as per the platelet monitoring rules shown in, Section 8.6.[ADDRESS_1233485] 6 
weeks after discont inuing Study Drug.  Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm3), the next platelet count should be taken within at least [ADDRESS_1233486] 13 weeks after discontinuing Study Drug.  
Update: 
Any subject who discontinues early from the treatment period or from post- treatment follow -up 
period should be followed as per the platelet monitoring rules shown in Section 8.6.[ADDRESS_1233487] end of treatment period 
(as per visit schedule).    
Appendix A Schedule of Procedures  and Appendix C PK Sampling Sche dule 
The follow -up period after treatment period has been clarified in both tables and a footnote has been 
added to both appendices.  
 
Rationale: 
 
The follow -up period is meant to start after the last dose through one dosing interval post last dose. 
The prior language could be interpreted to not include the dosing interval post last dose.  
 
11. Section 9.4.1 Serious Adverse Events  
Was:  
In the interest o f subject safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to Study Drug) should be reported to the Sponsor  or designee  within 24 hours of the 
Study Center’s first knowledge of the  event.  The collection o f SAEs will begin after the subject signs 
the informed consent form and stop at the end of the subject’s follow- up period .  When  the 
Investigator is reporting by [CONTACT_756], it is important to speak to someone in person versus leaving a 
message.   An Initial Serious Adverse Event Form should be completed and a copy should be faxed to 
the Sponsor  or designee.   
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
20  Update:  
In the interest of subject safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to Study Drug ) should be reported to the Sponsor  or designee  within 24 hours of the 
Study Center’s first knowledge of the  event.  The collection of SAEs will begin after the subject signs 
the informed consent form and stop at the end of the subject’s follow- up period .  An Initial Serious 
Adverse Event Form should be completed and a copy should be faxed to the Sponsor or designee.   
Rationale: 
To ensure that all pertinent information is reported, Akcea requires all clinical SAEs to be reported 
via two methods:  
1. Email: [EMAIL_16778]  (monitored 24/7)  
2. Fax: +[PHONE_18251]  
Reporting SAEs only by [CONTACT_882043] a valid and comprehensive case is received with proper documentation.  
12. Appendix E Mixed Meal Test  
A. Was:  
At Baseline, 3 months and end of study,… 
A. Update: 
At Qualification , 3 months and end of study,… 
B. Was:  
A cannula will be inserted into a forearm vein, and an overnight fasting venous blood sample will be taken… 
B. Update: 
A cannula will be inserted into a forearm vein, and an overnight fasting (minimum 10 hours)  venous 
blood sample will be  taken… 
Rationale: 
Procedure is to be done at Qualification and more detail is provided by [CONTACT_882044].  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
21  PROTOCOL SYNOPSIS  
Protocol Title  An O pen-label Phase 2 Study of ISIS 703802 (AKCEA -ANGPTL3-L Rx) 
Administered Subcutaneously to Subjects with Familial Partial Lipodystrophy  
Study Phase  2 
Indication  Familial Partial Lipodystrophy  (FPL) 
Primary Objective  To assess the effect of ISIS 703802 on reduction in fasting triglycerides (TG) . 
Secondary Objectives  To evaluate the safety and tolerability of ISIS [ADDRESS_1233488] of ISIS 703802 on changes from Baseline to end of 
treatment on: 
• Plasma glucose, serum insulin, serum C -peptide and free fatty acid 
(FFA) in responses to a mixed meal test (MMT)  
• L ipi[INVESTIGATOR_805], lipoproteins and lipid metabolism  
• Glycosylated hemoglobin (HbA1c)  
• L iver fat  and body fat distribution  
• Quality of life and pain score  
 
To evaluate pharmacokinetics (PK) of ISIS 703802  
Study Design  This is a single -center, open-l abel study.  
The study will comprise the following periods:  
Screening period: U p to 6 week s (including an up to  4 week run-in diet 
period)  
Treatment Period : [ADDRESS_1233489]-treatment Follow -up Period : [ADDRESS_1233490] give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]    
2. Age ≥ 18 years at the time of informed consent    
3. Clinical diagnosis of familial partial lipodystrophy plus diagnosis of type 
2 diabetes mellitus and hypertriglyceridemia.  
Diagnosis of lipodystrophy is based on deficiency of subcutaneous body fat in a partial fashion assessed by [CONTACT_882019]: men (≤ 10 
mm) and women (≤ 22 mm), and at least 1 of the following:  
- Genetic diagnosis of familial PL (e.g., mutations in LMNA, PPAR -γ, 
AKT2, CIDEC, PLIN1 genes)  
OR 
- Family history of FPL or family history of abnormal and similar fat 
distribution plus 1 Minor Criteria  
OR 
- 2 Minor Criteria (In the absence of  FPL-associated genetic variant or 
family history) and BMI< 35 kg/m
2  
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
22  MINOR Criteria  
a. Requirement for high doses of insulin, e.g., requiring ≥ 200 
U/day, ≥ 2 U/kg/day, or currently taking U -500 insulin  
b. Presence of acanthosis nigricans  on physical examination  
c. Evidence/history of polycystic ovary syndrome (PCOS) or PCOS -like symptoms (hirsutism, oligomenorrhea, and/or 
polycystic ovaries)  
d. History of pancreatitis associated with hypertriglyceridemia  
e. Evidence of non-alcoholic fatty liver  disease  
- Hepatomegaly and/or elevated transaminases in the 
absence of a known cause of liver disease or radiographic 
evidence of hepatic steatosis (e.g., on ultrasound or CT)   
4. A diagnosis of diabetes mellitus, made at least 6 months prior to the 
Screening, and:  
• A HbA1c ≥ 7% to ≤ 12% at Screening,  
• On anti -diabetic therapy consisting of:  
a. Metformin ≥ 1500 mg/day, or  
b. If the dose of metformin is <  1500 mg/day, or metformin is 
not tolerated, then the patient should be on other oral anti -
diabetic drugs (OAD) or an injectable glucagon-like peptide- 1 
(GLP -1) receptor agonist, or  
c. Insulin therapy alone or in combination with other anti -
diabetic drugs  
5. Hypertriglyceridemia as defined by [CONTACT_882020] ≥ 500 mg/dL (≥ 
5.7 mmol/L) at both Screening and Qualification visits. Patients with the 
clinical diagnosis of FPL and with Fasting TG levels ≥ 200 (≥ 2.26 mmol/L) to < 500 mg/dL (≥ 5.7 mmol/L) at both Scr eening and 
Qualification Visits who meet the genetic or family history criteria for study inclusion may be further screened and enrolled in the study  
 
6. Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI indicating a hepatic fat fract ion (HFF) ≥ 6.4%
 
 
7. Willing to maintain their customary physical activity level and to follow a 
diet moderate in carbohydrates and fats with a focus on complex carbohydrates and replacing saturated for unsaturated fats
 
 
8. Satisfy 1 of the following:  
a. Females:  Non-pregnant and non- lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in females  ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and follicle-stimulating 
hormone (FSH) levels in the postmenopausal range for the 
laboratory involved), abstinent*, or if engaged in sexual relations 
of child -bearing pot ential, patient is using an acceptable 
contraceptive method (refer to Section 6.3.1 ) from time of 
signing the informed consent form until at least [ADDRESS_1233491] dose of Study Drug administratio n. 
b. Males:  Surgically sterile, abstinent, or if engaged in sexual 
relations with a female of child -bearing potential, patient is 
utilizing an acceptable contraceptive method (refer to  Section 
6.3.1 ) from the time of signing the informed consent form until at 
least [ADDRESS_1233492] dose of Study Drug administration.   
*Abstinence is only acceptable as true abstinence, i.e., when this is in line 
with the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, post -ovulation methods), 
declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception).  
Exclusion Criteria  
1. A diagnosis of generalized lip odystrophy  
2. A diagnosis of acquired partial lipodystrophy (APL)  
3. Acute pancreatitis within 4 weeks of Screening  
4. History within 6 months of Screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new 
onset angina), stroke, transient ischemic attack, or unstable 
congestive heart failure requiring a change in medication  
5. Major surgery within 3 months of Screening  
6. History of heart failure with [LOCATION_001] Heart Association functional classification (NYHA) greater than Class I I  
7. Uncontrolled hypertension (blood pressure [BP] > 160 mm Hg systolic and/or 100 mm Hg diastolic)  
8. Clinically -significant abnormalities in screening laboratory values that 
would render a subject  unsuitable for inclusion, including the 
following:  
a. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg.  In the event 
of a UPCR above this threshold, eligibility may be confirmed by a 
quantitative total urine protein measurement of ˂ 1 g/24-hr  
b. Estimated GFR ˂ 60 mL/min/1.73 m2 (as determined by [CONTACT_490242]-Epi[INVESTIGATOR_368010] (CKD -EPI) 
Equation  
c. Alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) > 2x ULN  
d. Bilirubin > ULN, unless prior diagnosis and documentation of 
Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL  
e. Alkaline phosphatase (ALP) > 1.[ADDRESS_1233493] 
f. Platelet count ˂ LLN  
9. Uncontrolled hyper - or hypothyroidism .  Subjects on dose stable 
replacement therapy for at least [ADDRESS_1233494] for human immunodeficiency virus 
(HIV), hepatitis C or chronic hepatitis B  
14. Malignancy within 5 years, except for basal or squamous cell 
carcinoma of the skin or carcinoma in situ  of the cervix that has been 
successfully treated  
15. Treatmen t with another investigational drug, biological agent, or device 
within 1-month of Screening, or 5 half -lives of investigational agent, 
whichever is longer  
16. Unwilling to comply with lifestyle requirements (se e Section 6.3) 
17. Use of any of the following:  
a. Metreleptin within the last [ADDRESS_1233495] 3 months prior to Screening.  For lipid lowering medications (e.g., omega-3 fatty acids) dose, brand and regimen are expected to remain the same from Day 1 throughout Week 13.  Patients not receiving these drugs within 4 weeks prior to Screening are also eligible  
c. Insulin unless on a stable daily basal insulin dose regimen 
(± 20 %) for at least [ADDRESS_1233496] 4 weeks prior to dosing and regular clinical monitoring is performed  
j. Anti-obesity drugs [e.g., the combination of phentermine and 
extended-release topi[INVESTIGATOR_052] (Qsymia), orlistat (Xenical), and lorcaserin (Belviq), phentermine, amphetamines, herbal preparations] within 12 weeks prior to Screening (except 
liraglutide [rDNA origin] injection (Saxenda)  if on stable therapy 
for more than 6 weeks prior to Screening). 
k. Any other medication unless stable at least 4 weeks prior to 
dosing (occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
18. Blood donation of 50 to 499 mL within 30 days of Screening or of          
> [ADDRESS_1233497] any other conditions, which, in the opi[INVESTIGATOR_37593], or could 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
25  interfere with the patient participating in or completing the study  
Treatment Groups  Single Group, open-label treatment with 20 mg of ISIS 703802 SC weekly  
Study D rug Dosage and 
Administration  The Sponsor will provide ISIS 703802 in a single vial wi th a concentration of 
100 mg/mL 20 mg every week of ISIS 703802 (0.2 mL).  
The study dose of 20 mg (0.2 mL) of ISIS [ADDRESS_1233498] and/or caregiver.  
Rationale for Dose and S chedule 
Selection  A [ADDRESS_1233499] dose that provided 
maximum TG lowering of approximately 60%, based on the TG lowering 
effect of ISIS 703802 observed in healthy volunteers with elevated TGs.  
Adjustment of Dose or Treatment 
Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose and dose  
frequency may be allowed for safety or tolerability after consultation 
with the Sponsor Medical Monitor .   
Study Visit Schedule and 
Procedures  Detailed information regarding the study  procedures are outlined in Section [ADDRESS_1233500] of the following 
periods:  
• An up to 6-week Screening period, including a 4-week diet 
stabilization phase for subjects not already on a stable diet  
• A 26-week treatment period during which Study Drug will be 
administered weekly by [CONTACT_10530] 
• A 13-week post -treatment follow -up period  
During the Screening period, subject will be advised to maintain diet and 
exercise routines, and remain on a stable regimen of diabetes and lipid medications (if they are already taking any).  As part of the Screening period, 
subjects may have [ADDRESS_1233501] 6.4% liver fat assessed by [CONTACT_9268] -PDFF (via central 
reviewer) will return to the clinic on Day 1.   In addition, TG will be measured 
at qualification and results of TG and MRI must be available prior to 
registration and administration of  the first dose of study drug. 
Blood and urine samples will be collected regularly throughout the study for safety, efficacy, and PK analysis.  Appendix B  shows a list of analytes 
required for the study and Appendix C  details the PK sample schedules.  
The Mixed Meal Test (MMT) will be done at Baseline , at week [ADDRESS_1233502] , fasting plasma glucose, free fatty acids ( FFA), C-peptide, 
insulin, serum ghrelin, GIP, GLP -[ADDRESS_1233503] meal (such as 
Optifast®) and the same metabolic parameters are measured again over the 
course of 300 minutes  at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
26  minutes .  In addition, a validated visual analogue scale (VAS) will be used to 
measure the subject’s perception of hunger.  
Safety and Tolerability 
Evaluations  Safety and tolerability assessments include: AEs, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs,  use of c oncomitant 
medications .   
Efficacy Evaluations  Primary Endpoint:  
• The effect of ISIS  703802 on the percent change from Baseline  in 
fasting triglyceride levels  (TG) at week 27  
Secondary Endpoints:  
• Change from Baseline in AUC plasma glucose, serum insulin, serum 
C-peptide, free fatty acid, serum ghrelin, GIP, GLP -1, and PYY in 
response to a mixed meal test (MMT)  
• Change from Baseline in l ipi[INVESTIGATOR_882004]-
density lipoprotein cholesterol (HDL-C), low -density lipoprotein 
cholesterol (LDL-C),  total cholesterol (TC), very low -density 
lipoprotein cholesterol (VLDL- C), non-HDL -C, apolipoprotein B 
(apoB), apolipoprotein B -48 (apoB -48), apolipoprotein B -100 (apoB -
100), apolipoprotein A -1 (apoA -1), apolipoprotein C -III (apoC -III: 
total, chylomicron,  VLDL, LDL and HDL), Lipoprotein a [Lp(a)], free 
fatty acids (FFA), and glycerol levels , lipoprotein particle 
size/number  
• Change from Baseline in glycosylated hemoglobin (HbA1c)  
• Change from Baseline in homeostasis model assessment -estimated 
insulin resista nce (HOMA -IR) 
• Change from Baseline in adiponectin and leptin  
• Change from Baseline in hepatic fat fraction  (as assessed by 
[CONTACT_9252] [MRI])  
• Changes  from Baseline in body fat distribution for various areas in 
the body as measured by [CONTACT_882021]-energy X -ray 
absorptiometry (DEXA ); visceral adipose tissue ( VAT) and 
subcutaneous adipose tissue ( SAT) as measured by [CONTACT_9268]; body 
weight , waist circumference and waist/hip ratio  
• Change s from Baseline in quality of life and pain score  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of ISIS [ADDRESS_1233504] -
treatment Follow -up period.  Plasma sample collection time points are 
detailed in Appendix A  and Appendix C . 
Pharmacodynamic Evaluations  Plasma angiopoietin-like 3 (ANGPTL3), HDL -C, LDL -C, TC, VLDL -C, non -
HDL-C, apoB, apoB -48, apoB -100, apoA -1, apoC -III, Lp(a), FFA, glycerol 
levels, lipoprotein particle size/number  
Statistical Considerations  There is no statistical rationale for the selected sample size.   
Sponsor /Collaborator  Akcea Therapeutics , Inc./ Ionis Pharmaceuticals, Inc . 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
27  STUDY DESIGN AND TREATMENT SCHEMA  
 
 
TREATMENT PERIOD  
Weeks 1 to 26 
 
All Subjects will receive  20 mg of ISIS 
703802 administered weekly by [CONTACT_882045], routine safety assessments, PK and 
PD/efficacy assessment at specified  time 
points  
 
POST -TREATMENT 
EVALUATIONS                                 
Week 4, [ADDRESS_1233505] -treatment  
3 clinical visits for safety, PK and PD 
assessments  
END -OF-STUDY 
PROCEDURES  
Early termination or 13 
weeks after end of 
Treatment Period  
EARLY 
TERMINATION 
(ET) 
Follow ET visit in 
Schedule of 
Procedures  
Patient strongly 
encouraged to visit 
clinic for post -
treatment 
 
SCREEN PERIOD  Weeks -6 to 0  
Period may be reduced if the patient is following 
a stable low fat diet for a minimum of 4 weeks  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
28  STUDY GLOSSARY 
Abbreviation  Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase (SGPT)  
ANA  antinuclear antibody  
ANGPTL3  Angiopoietin -like [ADDRESS_1233506]  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time zero to 
time t  
Bb complement factor Bb (activated complement split product)  
βhCG  beta-subunit of human chorionic gonadotropin (pregnancy test)  
BP blood pressure  
BUN  blood urea nitroge n 
C centigrade  
C5a complement factor C5a (activated complement split product)  
Cmax maximum concentration  
CBC  complete blood count  
CKD -EPI [INVESTIGATOR_882005] -relevant Non -major Bleeding  
CRO  Clinical Research Organization  
CRP  C-reactive protein  
CS clinically significant  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTM  Clinical Trial Manager  
DEXA  dual-energy X -ray absorptiometry  
dL deciliter  
DLT  dose-limiting toxicity  
ISIS [ADDRESS_1233507]  
HIV human immunodeficiency virus  
HOMA -IR Homeostasis Model Assessment -estimated Insulin  Resistance  
HR heart rate  
hr, hrs  hour(s)  
hsCRP  CRP measured by [CONTACT_882046]-γ interferon -gamma  
IgM immunoglobulin M  
IL-1β interleukin -[ADDRESS_1233508]  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
30  ISIS 703802  antisense inhibitor of ANGPTL3  
IV Intravenous(ly)  
kg kilogram  
L liter 
LDL -C Low Density Lipoprotein Cholesterol  
LPL Lipoprotein Lipase  
m2 square meter  
MAD  multiple ascending dose  
MB Major Bleeding  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MedDRATM Medical Dictionary for Regulatory Activities  
mg milligram  
min minute  
mL milliliter  
mm millimeter  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid  
MMT  Mixed Meal Test  
MTD  maximum tolerated dose  
NAFLD  Nonalcoholic Fatty Liver Disease  
NEFA  Non-esterified Fatty Acids  
NOAEL  No Adverse Effect Level  
NCS  not clinically significant  
NSAID  non-steroidal anti -inflammatory drug  
NYHA  [LOCATION_001] Heart Association  
on study  The insert  [subject] or [patient] is ‘on study’ from signing of the 
informed consent until their last study visit  
OAD  Oral Antidiabetic Drugs  
OTC  Over the Counter  
PCOS  Polycystic OvarySyndrome  
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s)  
PLT Platelet  
pRBC  packed red blood cells  
PT prothrombin time  
PYY  Peptide Tyrosine Tyrosine  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
31  RBC  Red Blood Cells  
REMS  Risk Evaluation ad Mitigation Strategy  
RNase H1  an ubiquitous endonuclease that specifically hydrolyzes the RNA 
strand in RNA/DNA hybrids  
SAD  single ascending dose  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SAT  Subcutaneous Adipose Tissue  
siRNA  small interfering ribonucleic acid  
SC subcutaneous(ly)  
SMBG  Self Monitored Blood Glucose  
Study Day [ADDRESS_1233509]  upper limit of normal  
UACR  Urine albumin/creatinine ratio  
UPCR  Urine Protein Creatinine Ratio  
VAT  Visceral Adipose Tissue  
VLDL  Very Low Density Lipoprotein  
WBC  white blood cell  
WMA  World Medical Association  
 
  
ISIS [ADDRESS_1233510] of ISIS 703802 on reduction in fasting 
triglycerides (TG) . 
1.2 Secondary Objective (s) 
The secondary objectives are:  
• To evaluate the safety and tolerability of ISIS 703802  
• To evaluate the effect of ISIS 703802 on changes from Baseline to end of treatment on: 
o Plasma glucose, serum insulin, serum C -peptide and free fatty acid (FFA) in responses to a 
mixed meal test (MMT)  
o Lipi[INVESTIGATOR_805] , lipoproteins and lipid metabolism 
o Glycosylated hemoglobin (HbA1c) 
o Liver fat and body fat distribution 
o Quality of life and pain score 
• To evaluate pharmacokinetics (PK) of ISIS 703802. 
2. BACKGROUND AND RATIONALE  
2.1 Overview of D isease  
Lipodystrophy syndromes are a group of rare metabolic diseases characterized by [CONTACT_882047], diabetes, dyslipi[INVESTIGATOR_881979] (Garg 2004 ; Chan and Oral 2010; Garg et al. 
2011; Shulman et al. 2014).  
These syndromes are categorized according to the distribution of fat loss into generalized or partial and according to the underlying etiology as inherited or acquired ( Garg 2004; Chan and Oral 2010 ; Garg et al. 
2011).  
These syndromes constitute a significant medical unmet need as these patients are refractory to current therapi[INVESTIGATOR_014], mainly used to treat diabetes and elevated TG levels, in an attempt to reduce the risk of serious associated complications (coronary artery disease, diabetic nephropathy, c irrhosis and pancreatitis).  
As such, in February 2014, the FDA approved Myalept (metreleptin) as replacement therapy to treat the complications of leptin deficiency in addition to diet in patients with congenital or acquired generalized lipodystrophy.  The safety and effectiveness of Myalept was evaluated in 2  open -label studies conducted 
at the NIH, which included 72 patients (48 with generalized lipodystrophy and 24 with partial lipodystrophy [PL]) with diabetes, high TG, and elevated levels of fasting insulin.  The best results were achieved in patients with generalized lipodystrophy who had low leptin levels (mean [SD]: 1.3 [1.1] ng/mL), while patients with partial lipodystrophy who had a wider range of baseline leptin values (mean [SD]: 4.9 [3.1]  ng/mL)  had a more varied and attenuated response.  Because of the risks associated with 
the development of neutralizing antibodies and lymphoma, Myalept is available only through a risk 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
33  evaluation and mitigation strategy (REMS) program, which requires prescriber  and pharmacy certification 
and special documentation ( Chan et al. 2011;  Myalept  PI). 
At the present time, the Sponsor does not intend to study the generalized forms for which a specific 
therapy exists (metreleptin) nor the acqu ired forms of the partial lipodystrophy disorders because of the 
heterogeneity of etiologies, some iatrogenic, and the high incidence of associated immune disorders in these populations.  Therefore, this study will focus only on patients with the congenita l form of the partial 
lipodystrophy disorders and, among those, on the most severe subtype, patients with familial partial lipodystrophy, or FPL.  
Familial Partial Lipodystrophy (FPL) is an orphan disease for which no specific pharmacologic treatment 
currently exists.  FPL was described in the 1970s independently by Köbberling and Dunnigan (Dunnigan 
et al. 1974; Köbberling et al. 1975 ), and is the most common subtype of inherited PL ( National 
Organization for Rare Disorders [NORD] 2012 ).  It has been estimated that FPL affects approximately 
0.2 in 10,000 people in the European Union, which is equivalent to a total of around 10,000 people 
(Committee for Orphan Medicinal Products 2012 ).  FPL encompasses several subtypes differentiated by 
[CONTACT_882025] ([ADDRESS_1233511] been identified).  FPL 
type 1, Köbberling variety has been reported in a handful of individuals and its molecular basis is unknown.  FPL type 2, Dunnigan variety is the most common form and the most well characterized 
disor der and is due to missense mutations in the A and C LMNA gene.  FPL type [ADDRESS_1233512] mutations in any of these genes, suggesting that 
additional, as yet unidentified genes can cause the disorder (Hegele et al. 2007 ; Garg et al. 2011 ; National 
Organization for Rare Disorders [NORD] 2012 ). 
The diagnosis of FPL is mainly clinical and needs to be considered in patients presenting with the triad of 
insulin resistance (with or without overt diabetes), sig nificant dyslipi[INVESTIGATOR_81718], and fatty liver  (Huang-Doran et al. 2010) .  Patients often present with diabetes and 
severe insulin resistance requiring high doses of insulin.  Other evidence of severe insulin resistance is 
provided by [CONTACT_882026] (PCOS) (with symptoms 
like hyperandrogenism and oligomenorrhea).  Some patients develop severe hypertriglyceridemia 
resulting in epi[INVESTIGATOR_81719].  In many patients, the TG levels remain persistently elevated despi[INVESTIGATOR_81720].  Radiogra phic evidence of hepatic steatosis or 
steatohepatitis with hepatomegaly and/or elevated transaminases is common (Handelsman et al. 2013 ).  
Patients with the Dunnigan variety have a higher risk of coronary artery disease (Hegele 2001 ).  Although 
very rare, patients with a specific mutation in the LMNA gene are at an increased risk of cardiomyopathy  
and its associated complications, congestive heart failure and conduction defects.  
There is limite d natural history data, mostly cross-sectional and derived from publication of baseline 
characteristics of patients entering a clinical trial (Diker -Cohen CE et al. 2015 ; Ajluni N et al. 2016 ; 
Akinci B et al. 2017 ; Ahm ad Z et al. 2013; Bidault G. et al. 2013) .  The evidence that FPL progresses 
over time comes from a prospective, open-label NIH study with ongoing enrollment since 2000 (N = 87).  
Data analyzed in 2014 showed that metabolic manifestations of the cohort of 32 partial lipodystrophy patients (including [ADDRESS_1233513]) were as severe as those of the cohort of  generalized lipodystrophy (N = 55), 
which is recognized as a more severe form of lipodystrophy ( Diker -Cohen CE et al. 2015 ).  
ISIS [ADDRESS_1233514] been identified (Garg et 
al. 2011, Handelsman et al. 2013) .  Due to this severe dysfunction of adipose tissue FPL patients have 
much lower TG storage capacity than patients with hypertriglyceridemia without FPL, highlighting the importance of TGs in the pathophysiology of FPL.  Plasma TG levels in FPL patients varied across studies from mean (25 -75 percentile) 483 mg/dL (232, 856) (Diker -Cohen CE et al. 2015) , median (25-75 
percentile) 342 mg/dL (279, 801) (Akinci B et al. 2017 ), mean 383 mg/dL ( Bidault G et al. 2013 ), median 
389 mg/dL (155-3455) ( Ahm ad Z et al. 2013)  and mean 1058 mg/dL ( Ajluni N et al. 2016 ).  It is 
estimated that 1/4 to 1/[ADDRESS_1233515] TG levels >  500 mg/dL. 
Due to inability of adipose tissue to accommodate excess TGs, TGs are deposited in higher amounts in 
organs other than adipose tissue that are less well adapted to excess lipid storage (“ectopic fat”) (Garg et 
al. 2011, Handelsman et al. 2013; Robbins et al. 2015 ; Nolis 2014 ; Huang- Dora n et al. 2010 ). This 
ectopic fat accumulation has been found in and around many organs and is most clearly associated with 
metabolic abnormalities in the liver, pancreas and skeletal muscle contributing to severe insulin 
resistance, hepatic steatosis, diabetes and hypertriglyceridemia and increased risk of pancreatitis, non -
alcoholic steatohepatitis and cirrhosis (Robbins et al. 2015; Nolis 2014 ; Huang-Doran et al. 2010; Vatier 
et al. 2013; Sleigh A et al. 2012).  
Careful clinical assessment of fat distribution through visual and physical examination can confirm the diagnosis.  Patients with FPL have reduced subcutaneous fat in the limbs and truncal regions and may have excess subcutaneous fat deposition in neck, fa ce and intra-abdominal regions.  Patients with the 
Dunnigan variety have normal body fat distribution in childhood and gradually lose subcutaneous fat from the extremities and trunk around the time of puberty.  In women, the loss of fat may be most striking in the buttocks and hips.  At the same time these patients accumulate fat on the face (“double chin”), neck and upper back (“Cushingoid appearance with buffalo hump”).  The extent of adipose tissue loss usually 
determines the severity of the metabolic abnormalities.  Patients display prominent muscularity and 
phlebomegaly (enlarged veins) in the extremities and complain of disproportionate hyperphagia.  The condition in females is more easily recognized than in men, and so is reported more often.  Patient s may 
also have a family history of similar physical appearance and/or fat loss.  
Genetic testing, when available, is confirmatory. (Hegele et al. 2007 ; Huang -Dora n et al. 2010; Garg et al. 
2011).  
Current treatment includes lifestyle modification such as reducing caloric intake and increasing energy expenditure via exercise.  Conventional therapi[INVESTIGATOR_881981] (metf ormin, 
thiazolidinediones, Glucagon- like peptide 1s [GLP -1], insulin), and/or high TGs (dietary fat restriction, 
fibrates, fish oils) are not very efficacious in these patients (Chan and Oral 2010).  
Familial Partial Lipodystroph y is an ultra -orphan indication for which there is a significant unmet medical 
need.  Diabetes, hepatic steatosis, and hypertriglyceridemia associated with this condition can lead to 
serious complications (Handelsman et al. 2013 ) such as:  
• Acute pancreatitis, especially when triglyceride levels are > 1,000 mg/dL  
• Accelerated microvascular complications from uncontrolled diabetes  
• Accelerated cardiovascular disease from lipid abnormalities and insulin resistance  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
35  • Steatohepatitis that can progress to cirrhosis and an increased risk of hepatocellular carcinoma 
• Proteinuric nephropathies which can progress to end stage renal disease  
In patients with Generalized Lipodystrophy the metabolic complications are partially re lated to leptin 
deficiency, and can be ameliorated in part by [CONTACT_81777].  However, leptin deficiency alone 
cannot explain the severity of metabolic disease in patients with PL who have variable leptin levels.   
By [CONTACT_882027]3  and TG levels, I SIS [ADDRESS_1233516] and reduce their risk of acute pancreatitis.  In addition, reductions in TG could improve hepatic steatosis and reduce cirrhosis risk. Furthermore, this mechanism may also improve insulin se nsitivity in 
these patients and potentially lead to a reduction in the complications associated with diabetes.   
2.2 T herapeutic Rationale  
In humans, loss of function mutations within the ANGPTL3 gene give rise to familial combined 
hypolipi[INVESTIGATOR_035] (FHBL2), characterized by [CONTACT_671580], total cholesterol, LDL -C, 
and HDL -C (Minicocci et al. 2012 ).  Homozygous individuals with complete ANGPTL3 deficiency 
showed the full combined hypolipi[INVESTIGATOR_882006]3 
deficiency showed a more attenuated phenotype.  Of note, FHBL2 homozygous were not affected by 
[CONTACT_37110], showed lower plasma levels of insulin and lower degree of insulin resistance as estimated by [CONTACT_14785] -IR (Robciuc et al. 2013).   
ANGPTL3 protein is produced exclusively in liver, where its expression is downregulated by [CONTACT_525646] (Inukai et al. 2004 ).  Hepatic specific knock -down of ANGPTL3 mRNA is associated with 
reduction in plasma triglycerides due to increased lipoprotein lipase activity as well as decreased hepatic 
VLDL triglyceride secretion.  Because ANGPTL3 is produced by [CONTACT_882028], which does not express 
LPL, it is thought to function as an endocrine rather than paracrine factor with insulin sensitizing effects that go beyond the liver.  In fact, insulin sensitization has been shown in patients with ANGPTL3 gene mutations as well as in ANGPTL3 -deficient mice, in which increased uptake of fatty acids into o xidative 
tissues such as muscle and brown adipose tissue led to decreased uptake of fatty acids and increased uptake of glucose in white adipose tissue (Wang et al. 2015) .  Suppression of hepatic ANGPTL3 protein 
production in mi ce resulted in significant reductions in levels of triglycerides, LDL cholesterol, non -HDL 
cholesterol, and VLDL cholesterol and these favorable effects were associated with decreased liver 
triglyceride content, increases in insulin sensitivity, and a reduction in atherosclerosis progression  
(Graham et al. 2017 ).    
Treatment with ISIS 703802 would be expected to lower the hepatic expression of ANGPTL3 protein and result in lowering of the levels of triglyceride -rich lipoproteins and LDL- C, increased HDL -C, improved 
glycemic control and ameliorated insulin resistance in T2DM patients, leading to decreas ed liver fat 
content in NAFLD and ultimately, reduced overall risk of coronary artery disease.  
2.3 ISIS  703802 
2.3.1 Mechanism of Action  
ISIS 703802 is a second -generation ASO drug targeted to ANGPTL3 that has been covalently bonded to 
triantennary N -acetyl galactosamine (GalNAc), a high -affinity ligand for the hepatocyte -specific 
asialoglycoprotein receptor (ASGPR) to f orm an ASO- GalNAc conjugate.  This GalNAc-conjugate 
approach results in enhanced ASO delivery to hepatocytes versus non -parenchymal cells and has 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
36  increased ASO potency by [CONTACT_3450] 10- fold in mice (Prakash et al. 2014 ).  The ASO portion of ISIS 
703802 is complementary to a region within the ANGPTL3 messenger ribonucleic acid (RNA) (mRNA) 
coding sequence, and binds to the mRNA via Watson and Crick base pairing.  The hybridization (binding) 
of ISIS 703802 to the cognate mRNA  results in the Ribonuclease H1 (RNase H1) -mediated degradation 
of the ANGPTL3 mRNA, thus preventing production of the ANGPTL3 protein.  Maximal 
antisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37497] 90% of control levels in 
sensitive tissues ( Crooke and Bennett 1996; Zhang et al. 2010) .  Furthermore, reduction in target mRNA 
levels using this approach correlates directly with a subsequent reduction in target protein levels.  
2.3.2 Chemistry  
Chemically, ISIS 703802  is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are connected 
sequentially by [CONTACT_19966] (mixed backbone design).  The mixed 
backbone design reduces the total number of phosphorothioate linkages in the MOE -modified regions, 
which reduces non-specific interactions with proteins and further enhances potency of GalNAc 
conjugated ASOs.  The nucleotide sequence of ISIS 703802  (Figure 1 ) is complementary to a 20-
nucleotide stretch within Exon 6 of the ANGPTL3 mRNA coding sequence at position 1169-1188 bp. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 
nucleotides at the 3′ end, are composed of 2′- O-(2-methoxyethyl) (2′- MOE) -modified ribonucleotides.  
These MOE -modified nucleotides confer (1) increased affinity for the target mRNA (Altmann et al. 1996 ; 
McKay et al. 1999) , (2) increased resistance to exonucleases and endonucleases (thereby [CONTACT_368078]) (Geary et al. 2003) , and (3)  amelioration of some of the high do se toxicities thereby 
[CONTACT_368079] g eneration antisense drugs containing 
phosphorothioate modified oligodeoxynucleotides (DNA) ( Henry et al. 2000 ).  The third region, the 
central portion of the oligonucleotide, is composed of 10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and ISIS 703802 employs this chimeric structure to enable use of the RNase H1 
mechanism for antisense activity.  This is because while the 2 ′-MOE modification confers increased 
stability and affinity, it does not support RNase H1 catalyzed cleavage of RNA hybridized to 2′- MOE -
modified nucleotides ( McKay et al. 1999 ).  This is caused by [CONTACT_671583] 2′- alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H enzymes (Inoue et al. 1987; 
Monia et al. 1993 ).  By [CONTACT_37761] 2′-MOE modification to nucleotides flanking the phosphorothioate 
oligodeoxynucleotide core, the beneficial attributes of the 2′- MOE chemistry are preserved while also 
retaining RNase H1 recognition.  The fourth region is comprised of a triantennary cluster of N-acetyl 
galactosamine (GalNAc) sugars which  is linked to the 5ʹ end of ISIS 703802 via a phosphodiester 
linkage.  The GalNAc cluster is a high affinity ligand for the asialoglycoprotein receptor (ASGPR), a receptor expressed primarily on the surface of liver hepatocytes (Stockert 1995) .  The GalNAc cluster 
enhances delivery of ISIS 703802 to liver hepatocytes over other cell types and enhances potency.  After 
internalization into cells, the GalNAc cluster is metabolized to release ‘free ASO’ inside the cell (Prakash 
et al. 2014).  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
37   
Figure 1 Design of Chimeric 2ʹ- MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of ISIS 703802 is shown.  
2.3.3 Preclinical Experience  
Detailed information concerning the preclinical studies conducted with ANGPTL3 ASOs can be found in 
the Investigator’s Brochure.  A summary is included below. 
[IP_ADDRESS] Preclinical Pharmacology  
The pharmacology of ANGPTL3 ASOs has been examined in multiple in vitro  cell lines where specific 
and dose-dependent reduction of ANGPTL3 mRNA and protein was clearly demonstrated, resulting in 
reductions in apoB secreted protein.  The pharmacology of ISIS 563580, an unconjugated 2′- MOE 
modified ASO that has the same base sequence as ISIS 703802, at doses higher than planned for ISIS 
703802. 
ISIS 563580 has been explored in human ANGPTL3 transgenic mice, wherein liver mRNA and plasma 
ANGPTL3 protein levels were reduced upon treatment with ISIS 563580. 
Reductions in murine ANGPTL3 mRNA and protein were routinely observed in all mouse models treated 
with a murine-specific ANGPTL3 ASO.  Pharmacology studies were done with Ldlr-/- mice fed a 
hypercholesterolemic diet known to develop elevated LDL- C, TG, and atherosclerosis, as well as features 
of metabolic syndrome (hyper glycemia and hyperinsulinemia) (Huszar et al. 2000 ; Schreyer et al. 2002 ; 
Tsuchiya et al. 2012) .  Treatment of mice with a murine- specific ANGPTL3 ASO resulted in  
improvement in all of the aforementioned lipid and metabolic endpoints compared to controls.  In all 
mouse models tested, total plasma cholesterol, LDL -C, TG, and non- esterified fatty acids (NEFA) have 
been shown to be consistently reduced upon treatment with ANGPTL3 ASOs, while HDL -C is modestly 
decreased in wild type mice ( - 22%), and either stable or increased in others.  While a clear mechanistic 
understanding of HDL- C reductions has not been elucidated, results from in vitro  reverse cholesterol 
transport assays suggest that HDL function is maintained.  
Administration of ISIS 703802, a human specific, GalNAc conjugated, ANGPTL3 ASO, to human 
ANGPTL3  transgenic mice led to significant, dose-dependent reductions in hepatic ANGPTL3 mRNA.  In 
diet challenged mice, administration of ISIS 731875, a mouse- specific and GalNAc-modified ASO 
targeting ANGPTL3, led to dose-dependent reductions in both hepatic ANGPTL3 mRNA and plasma 
2′-MOE  
 2′-MOE  
 2′-Deoxy  
GalNAc = THA -GalNAc cluster  
2′-MOE = 2 ′-methoxylethyl RNA  
2′-Deoxy = DNA 
s = phosphorothioate linkage  
o = phosphodiester linkage  
(RNase H1 sensitive)  
GalNAc  
 GsGoAoCoAo 
 TsTsGsCsCsAsGsTsAsAs 
 ToCoGsCsA 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
38  ANGPTL3 with concomitant reductions in plasma TG and cholesterol.  Importantly, the potency and the 
lipid-lowering effects of the ANGPTL3 ASO were independent of diet.  
Finally, administration of a mouse- specific ANGPTL3 ASO to western diet fed Ldlr-/-, a mouse model of 
FH, also led to significant reductions in hepatic ANGPTL3 mRNA and plasma ANGPTL3 protein with concomitant reductions in plasma TG and LDL- C that were similar to what was observed in wild type 
western diet fed mice, indicating that the a bsence of Ldlr does not affect the ASOs potency or lipid -
lowering effects.  This suggests that administration of ANGPTL3 ASO administration is a promising target for clinical study in familial hypercholesterolemia patients.  
While formal pharmacology studies have not been conducted in the monkey with the human ANGPTL3 
ASO, hepatic mRNA expression has been shown to be reduced by [CONTACT_726] 60% in cynomolgus 
monkeys, the same model used to conduct the toxicology evaluation.  
[IP_ADDRESS] Preclinical Toxicology  
Genera l toxicology studies for ISIS 703802 consisted of sub- chronic (16-week) and chronic (26- or 39-
week) toxicity studies CD -1 in mice and cynomolgus monkeys.  Since ISIS 703802 is not fully 
complementary to the mouse ANGPTL3 transcript, treatment group receiving a mouse- specific inhibitor 
(ISIS  731875) was also included in the mouse study.  Please refer to the Investigator Brochure for a 
detailed description of the preclinical toxicology and pharmacokinetics with ISIS 703802. 
Pharmacokinetic data confirmed con tinuous and dose -dependent exposure to ISIS 703802.  An estimated 
liver and plasma terminal elimination half -life values of approximately 1 week  and 3 -4 weeks for 2  mg/kg 
and 35 mg/kg, respectively, were observed in monkeys.  The most noteworthy findings observed in mice 
and monkeys following ISIS [ADDRESS_1233517] noteworthy finding in the monkey was the kidney alteration (hypoalbuminemia and proteinuria) 
seen in one early -sacrifice animal from the 16 -week study at 35 mg/kg/week, a dose equivalent to at least 
~190-fold of the 40 mg weekly clinical doses by [CONTACT_671584].  Non -dose dependent increases in renal 
protein excretion (up to 2.2 -fold in quantitative urine protein, protein/creatinine ratio or urine albumin) 
were also observed  at 8 and/or 35 mg/kg/week (>  ~30 to 190-fold of the 40 mg weekly clinical doses by 
[CONTACT_671584] ) at the 16- week scheduled terminal necropsy .  However, Similar kidney alterations were not 
seen at the 6 -week interim at any doses or in the 39 -week chronic monkey study up to 12 mg/kg/week (> 
~200-fold of the 20 mg weekly clinical dose by [CONTACT_671584]).  
Additional findings related to ASO liver accumulation included increased alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) at ≥ 8 mg/kg/week in the 16- and 26- week mouse studies, and were correlated with  individual hepatocyte necrosis (minimal to mild) in 
mouse liver.  Those changes were most prominent in the high dose groups (50 and 24 mg/kg/week for the 
16- and 26- week studies, respectively).   Conversely, no changes in liver enzymes were observed in 
monkeys from the 39-week toxicity study up to 12 mg/kg/week.  In the 16- week monkeys study, increase 
in ALT was only evident in one early- sacrifice animal at 35 mg/kg/week, and non -statistically significant 
increases in ALT (<  2-fold of the prestudy baseline) were also observed in the interim - and terminal-
sacrifice animals at ≥ 8 mg/kg/week but showed no microscopic correlates or dose-dependency. 
ISIS [ADDRESS_1233518] article- related clinicopathologic alterations present in 
monkeys at do ses ≤ 12mg/kg/week (> ~100- fold of the 40 mg weekly clinical dose by [CONTACT_671584]) 
during the 39- week treatment phase, none would be regarded to represent an adverse effect (Dorato and 
Engelhardt 2005; Everds et al. 201 3).  Considering the monkey to be the most relevant species, these data 
have characterized the safety profile and established appropriate therapeutic margins for the clinical 
evaluation of ISIS 703802 in humans. 
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with ISIS 703802 can be found in the 
Investigator’s Brochure.  A summary is included below.  
The study drug, ISIS 703802, is being evaluated in Phase 1 in the clinical setting with single doses up to 
120 mg and multiple doses up to 60 mg (once per week for 6 weeks).  The parent drug ISIS  563580, an 
unconjugated 2′- MOE modified ASO that has the same base sequence as ISIS 703802, was also evaluated 
in a blinded, placebo-controlled Phase 1 study.  
An interim analysis of ISIS 703802 Phase 1 SAD/MAD Study (ISIS  703802-CS1) was performed in 44 
subjects administered single ascending (20, 40 and 80 mg) or multiple ascending doses (10, 20, 40 and 60 
mg/week for 6 weeks).   Twelve participants were randomly assigned to single-dose groups (9 to active-
agent dose groups and 3 to the placebo group) and 32 were randomly assigned to multiple-dose groups 
(24 to active-agent dose groups and 8 to the placebo group).  The main endpoints of the study were saf ety, 
tolerability, pharmacokinetics, pharmacodynamics and changes in lipi[INVESTIGATOR_6520].  After 6 weeks 
of treatment, persons in the multiple dose groups treated with ISIS 703802 had dose- dependent reductions 
in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from Baseline, P  < 0.01 for all doses vs. 
placebo 1.6%) and in levels of triglycerides (reductions of 33.2 to 63.1% vs placebo 11.4%), LDL cholesterol (1.3 to 32.9% vs placebo 13.6%), very-low-density lipoprotein cholesterol (27.9 to 60.0% vs placebo 4.0%), non– high-density lipoprotein cholesterol (10.0 to 36.6% vs placebo 9.1%), apolipoprotein 
B (3.4 to 25.7% vs placebo 11.0%), and apolipoprotein C-III (18.9 to 58.8% vs placebo 3.1%).  There 
were no serious adverse events documented during the trial.   No protocol- defined injection -site reactions 
were reported .  Of those participants who received the multiple -dose regimen, three reported headache 
(one who received placebo and two who received ISIS 703802) and three reported dizziness (two who received placebo and one who received ISIS 703802).  There was no clinical evidence of prothrombotic 
effects, bleeding epi[INVESTIGATOR_1841], significant decreases in platelet count or thrombocytopenia, or significant changes in renal function.  One subject in the [ADDRESS_1233519] had an ALT of 88 U/L on Day [ADDRESS_1233520] to follow-up after 5 doses.  There were no other 
discontinuations during the treatment period ( Graham et al. 2017 and data on file).   
The pharmacokinetics of ISIS 703802 evaluated in  Study ISIS  703802-CS1 showed rapid absorption 
following SC administration, with median time to maximum plasma concentrations (T
max) ranging from 1 
to 6 hours.  Similar T max values were observed at all dose levels.  After reaching C max, plasma 
concentratio ns of ISIS 703802 declined in a multi-phasic fashion with a rapid disposition phase, followed 
by a slower elimination phase with terminal elimination half -life of 3 to 5  weeks.  The peak (C max) and 
total exposure (AUC) after a single SC dose increased appr oximately dose proportionally from 20 to 
40 mg, and greater than dose proportionally from 40 to 80 mg, suggesting more efficient tissue uptake at 
lower doses.  After single and multiple SC doses in the range of 10 to 60 mg, the C max and AUC increased 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
40  approximately dose proportionally.  No accumulation based on C max or AUC was observed after 6 weekly 
doses.  
[IP_ADDRESS] ISIS  563580- CS1 Phase 1 SAD/MAD  
In a Phase 1 study, ISIS 563580-CS1, healthy volunteers received subcutaneous administration of 
ISIS 563580, an unconjugated 2′- MOE modified ASO that has the same base sequence as ISIS 703802, 
from 50 to 400 mg as a single dose, or 100 to 400 mg as multiple doses (8 doses in 36 days).  Overall, the safety findings from this study suggest that ISIS 563580 was not associated with any safety concerns.  
There were 383 adverse events (AE) reported in the ISIS  563580-treated subjects of which 363 (95%) 
were mild in severity.  For the multiple -dose subjects, the most common treatment- emergent adverse 
events were AEs at the injection site.  There was 1 serious adverse event (SAE) in the study of periorbital 
cellulitis which was considered a medically important event by [CONTACT_671585].  Together, the above suggest that ISIS 563580 was 
well-tolerated at the doses and regimen given, which exceed the dose levels and cumulative exposures to 
be tested in the current study.  There were no clinically -relevant changes in laboratory assessments and 
the heparin dose of 80 U/kg was well -tolerated in support of the post-heparin procedures.  ISIS 563580 
produced dose-dependent reductions in plasma ANGPTL3 (up to 93%; group means up to 84%), TG (up 
to 63%; group means up to 49%) and TC (up to 46%; group means up to 28%) at Day 36 (Brandt et al. 
2015).  
2.4 Rationale for Dose and S chedule of Administration  
The Phase 1 program evaluated ISIS 703802 doses of 10 mg, 20 mg, 40 mg and 60 mg given weekly for 6 weeks that were found to be generally well -tolerated and to induce clinically -relevant reductions in lipid 
biomarkers.  The dos e proposed for the present study will provide the equivalent drug exposure of 20 mg  
weekly  (80 mg monthly) and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) 
to result in mean reductions from Baseline in TGs of approximately 63% at steady -state.  
Safety data from the available chronic mouse (26 -week) and monkey (39-week) studies support 
once-weekly dosing for chronic administration.  The No Adverse Effect Level (NOAEL) for ISIS 703802 
in chronic monkey study was determined to be 12 mg/kg/wk.    
In healthy volunteers, 703802 achieved an equivalent reduction in ANGPTL3 plasma concentration to 
that of the unconjugated form, at approximately 1/10
th of the unconjugated ASO (ISIS 563580) dose 
(Brandt et al. 2015).   
2.[ADDRESS_1233521] be yond the end of the study.  
2.5.2 Risk Assessment  
The known potential risks to study participants associated with ISIS 703802 are elaborated on in the Guidance to Investigator section of the Investigator’s Brochure.  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
41  • In preclinical mouse studies, there were increases in ALT and AST and were correlated with 
increased incidence and/or severity of necrosis of individual hepatocytes (minimal to mild in 
severity).   Those changes were most prominent in the high dose groups and showed no clear 
progression over time.  No increases in liver enzymes were observed in monkeys from the 39 -
week toxicity study up to 12 mg/kg/week (~200-fold of the 20 mg /week  clinical dose by [CONTACT_882048]).  In the 16-week monkey study, increase in ALT was only evident in 1 early- sacrifice 
animal at 35 mg/kg/week, no meaningful increase in ALT was observed in the schedule sacrificed animals.  
• In the Phase 1 study, there was no elevations in ALT at single dose cohorts up to 120 mg.  In 
multiple dose cohorts, two out of six subjects in the 60 mg weekly dose cohort had a    > [ADDRESS_1233522] 
increase of ALT, without increase in bilirubin, which was considered a treatment related adverse event (AE) for one by [INVESTIGATOR_678] (PI).  There were no other observed clinically 
significant changes in ALT an d liver function in Phase 1 human study ( data on file ).  However, to 
evaluate and mitigate the potential for liver enzyme abnormalities, r egular liver chemistry 
monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6.  
• Injection site adverse events, while not considered safety issues, may affect the ability of the 
subject to tolerate dosing.  Injection site adverse events are the most common side effects 
observed following SC administration of unconjugated 2′ -MOE ASOs and are dose and 
concentration dependent.  Erythema is the most prevalent characteristic.  Generally, these events 
are mild and reversible, resolve spontaneously and do not worsen with time.  The histologic 
findings are consistent with a local inflammatory response.  Subjects should be informed of the 
possibility of occurrence of injection site adverse events.  Symptomatic interventions such as icing of the injection site or administration of NSAIDs prior to and/or after the SC dosing have been utilized. 
• 
Although no changes in platelet (PLT) counts have been observed in healthy volunteers, 
mouse or monkey in both sub-chronic and chronic studies with ISIS 703802, reductions in platelet counts to below the lower limit of normal have been observed after administration of other ASOs and some subjects have experienced severe thrombocytopenia following 
administration of unconjugated 2
′-MOE ASOs.  To evaluate and mitigate the potentia l for a 
reduction in PLT count, monitoring and stoppi[INVESTIGATOR_882007] 8.5 and 8.6 (Safety Mon itoring Rules and Stoppi[INVESTIGATOR_1869]) . 
• No significant changes in serum creatinine, electrolytes, BUN, or urinalysis were reported from 
the interim analysis of the ongoing Phase 1 study (data on file).  To evaluate and mitigate the 
potential for a reduction in renal function, since kidneys are an organ of high distribution for the studied ASO, monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6 (Safety Monitoring Rules and Stoppi[INVESTIGATOR_1869]) . 
While the long term effects of reducing ANGPTL3 as a target with the study drug are not known at this time, there is evidence in literature in humans in whom ANGPTL3 is absent from plasma, due to homozygous or compound heterozygous ANGPTL3 mutations, present a pan-hypobetalipoproteinemia phenotype, with generalized and marked decreases (~50% to 70%) in all apoB-100 containing 
lipoproteins, including VLDL and LDL, as well as HDL.   This clinical phenotype has been termed 
familial combined hypolipi[INVESTIGATOR_671554]2 ( Romeo et al. 2009 ; Musunuru et al. 2010; Martin -Campos 
et al. 2012; Minicocci et al. 2012 ; Noto et al. 2012; Pi[INVESTIGATOR_671555]. 2012 ; Wang et al. 2015).   Clinical 
studies in FHBL2 suggest a trend toward low er glucose and insulin levels and reported decrease in 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
42  VLDL.   Remarkably, diabetes and cardiovascular disease are reportedly absent from those with 
homozygous FHBL2 and no adverse clinical phenotype has been reported to date. 
2.5.3 Overall Assessment of Benefit: Risk  
ISIS 703802 has demonstrated the ability to reduce ANGPTL3, APOCIII, and TGs by [CONTACT_7809] 60% 
and LDL-C by [CONTACT_726] 30% in the Phase [ADDRESS_1233523] up 
to 6 weeks prior to Day 1 (the first day of Study Drug administration).  During the Screening period, 
subjects will be advised to maintain routine diet, and remain on a stable regimen of diabetes and lipid 
medications (if they are already taking any).  As part of the Screening period , following [ADDRESS_1233524] dose of 
ISIS 703802
 by [CONTACT_6567] (SC) injection.  During the treatment period subjects will receive ISIS 
703802 (20 mg) administered every week for 26 weeks.  
Subjects will return regularly for outpatient visits throughout the treatment period according to the 
Schedule of Procedures (Appendix A ).  The primary safety and efficacy analysis time point is at Week 
27.  
Subjects will then enter a [ADDRESS_1233525] -Treatment Follow -up Period and will return to the study center 
for outpatient evaluations according to the Schedule of Procedures ( Appendix A ). 
Blood and urine samples will be collected regularly throughout the study for safety, efficacy, and PK 
analysis.  Appendix B  shows a list of analytes required for the study and Appendix C  details the PK 
sample schedule.  
ISIS [ADDRESS_1233526] will be enro lled, but enrollment 
could be increased to 6 subjects, based on safety profile and efficacy observations. 
3.4 Overall Study Duration and Follow -up 
The length of subjects’ participation in the study may be up to 45 weeks.  This includes a n up to 6- week 
screening period, that includes a 4 -week diet stabilization / run -in period, a 2- week qualification period, a 
26-week treatment period, and a 13- week post -treatment evaluation period.   
Subjects may be required to attend additional visits for monitoring of adverse events or abnormal 
investigation results.  The frequency of additional monitoring will be determined by [CONTACT_882049]. 
3.4.1 Screening /Qualification  
Subject eligibility for the study will be determ ined within 42 days/ [ADDRESS_1233527] a 4 -week diet stabilization/run -in period followed by a up to 2- week 
qualification period.  Subjects on stable diet known to the investigator and followed at the site may go 
from Screening  to qualification without a [ADDRESS_1233528] at 4, 8 and 13 weeks after the Treatment Period (last dose through one dosing interval post last dose) . Refer to Schedule 
of Procedures in Appendix A . 
4. SUBJECT ENROL LMENT  
4.1 Screening  
Before subjects may be enrolled into the Study, the Sponsor or designee requires a copy of the Study Center’s written independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, informed consent form, and all other subject information and/or recruitment material.  
ISIS [ADDRESS_1233529] give written informed consent to participate in the study (signed and dated) and any authorizations required by [CONTACT_2371]   
2. Age ≥ 18 years at the time of informed consent   
3. Clinical dia gnosis of familial partial lipodystrophy plus diagnosis of type 2 diabetes mellitus and 
hypertriglyceridemia.  
Diagnosis of lipodystrophy is based on deficiency of subcutaneous body fat in a partial fashion 
assessed by [CONTACT_882050]: men (≤ 10 mm) and women (≤ 22 mm), and at least 1 of the following:  
- Genetic diagnosis of familial PL (e.g., mutations in LMNA, PPAR-γ, AKT2, CIDEC, PLIN1 genes)  
OR 
- Family history of FPL or family h istory of abnormal and similar fat distribution plus 1 Minor 
Criteria  
OR 
- 2 Minor Criteria (In the absence of FPL- associated genetic variant or family history) and 
BMI<  35 kg/m
2  
 
MINOR Criteria  
a. Requirement for high doses of insulin, e.g., requiring ≥ 200 U/day, ≥ 2 U/kg/day, or currently taking U -500 insulin  
b. Presence of acanthosis nigricans on physical examination  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
45  c. Evidence/history of polycystic ovary syndrome (PCOS) or PCOS-like symptoms (hirsutism, 
oligomenorrhea, and/or polycystic ovaries)  
d. History of pancreatitis associated with hypertriglyceridemia  
e. Evidence of non- alcoholic fatty liver disease  
- Hepatomegaly and/or elevated transaminases in the absence of a known cause of liver 
disease or radiographic evidence of hepatic steatosis (e.g., on ultrasound or CT)  
4. A diagnosis of diabetes mellitus, made at least 6 months prior to the Screening, and:  
• A HbA1c ≥ 7% to ≤ 12% at Screening,  
• On anti-diabetic therapy consisting of:  
a. Metformin ≥ 1500 mg/day, or  
b. If the dose of metformin is <  1500 mg/day, or metformin is not tolerated, then the patient 
should be on other oral anti- diabetic drugs (OAD) or an injectable glucagon -like peptide-1 
(GLP -1) receptor agonist, or  
c. Insulin therapy alone or in combination with other anti- diabetic drugs  
5. Hypertriglyceridemia as defined by [CONTACT_882020] ≥ 500 mg/dL (≥ 5.7 mmol/L) at both 
Screening and Qualification visits. Patients with the clinical diagnosis of FPL and with Fasting TG 
levels ≥ 200 (≥ 2.26 mmol/L) to < 500 mg/dL (≥ 5.7 mmol/L) at both Screening and Qualification 
Visits who meet the genetic or family history criteria for study inclusion may be further screened and enrolled in the study  
 
6. Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI indicating a hepatic fat fraction (HFF) ≥ 6.4% 
 
7. Willing to maintain their customary physical activity level and to follow a diet moderate in carbohydrates and fats with a focus on complex carbohydrates and replacing saturated for unsaturated fats 
 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
46  8. Satisfy 1 of the following:  
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal (defined as 
12 months of spontaneous amenorrhea in females > 55 years of age or, in fema les ≤ 55 years, 
12 months of spontaneous amenorrhea without an alternative medical cause and follicle-
stimulating hormone (FSH) levels in the postmenopausal range for the laboratory involved), 
abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to  Section 6.3.1)  from time of signing the informed 
consent form until at least [ADDRESS_1233530] dose of Study Drug administration.  
b. Males:  Surgically sterile, abstinent, or if engaged in sexual relations with a female of child -
bearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 
6.3.1)  from the time of signing the informed consent form until at least [ADDRESS_1233531] 
dose of Study Drug administration.  
*Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual 
lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception). 
 5.2 Exclusion Criteria  
1. A diagnosis of generali zed lipodystrophy  
2. A diagnosis of acquired partial lipodystrophy (APL) 
3. Acute pancreatitis within 4 weeks of Screening  
4. History within 6 months of Screening of acute or unstable cardiac ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack, or unstable 
congestive heart failure requiring a change in medication  
5. Major surgery within 3 months of Screening  
6. History of heart failure with [LOCATION_001] Heart Association functional classification (NYHA) greater 
than Class II  
7. Uncontrolled hypertension (blood pressure [BP] > 160 mm Hg systolic and/or 100 mm Hg diastolic)  
8. Clinically -significant abnormalities in screening laboratory values that would render a subject 
unsuitable for inclusion, including the following:  
a. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg.  In the event of a UPCR above this 
threshold, eligibility may be confirmed by a quantitative total urine protein measurement of 
˂ 1 g/24 -hr 
b. Estimated GFR ˂ 60 mL/min /1.73 m
2 (as determined by [CONTACT_81105] -
Epi[INVESTIGATOR_368010] (CKD-EPI) Equation  
c. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x ULN  
d. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
47  e. Alkaline phosphatase (ALP) > 1.[ADDRESS_1233532]  
f. Platelet count ˂ LLN 
9. Uncontrolled hyper - or hypothyroidism.  Subjects on dose stable replacement therapy for at least 
[ADDRESS_1233533] for human immunodeficiency virus (HIV), hepatitis C or chronic 
hepatitis B  
14. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in 
situ of the cervix that has been successfully treated  
15. Treatment with another investigational drug, biological agent, or device within 1 -month of 
Screening, or 5 half- lives of investigational a gent, whichever is longer  
16. Unwilling to comply with lifestyle requirements (se e Section 6.3 ) 
17. Use of any of the following: 
a. Metreleptin within the last [ADDRESS_1233534] 3 months prior to Screening.  For lipid lowering medications (e.g., omega -3 fatty acids) 
dose, brand and regimen are expected to remain the same from Day 1 throughout Week 13.  Patients not receiving these drugs within 4 weeks prior to Screening are also eligible  
c. Insulin unless on a stable daily basal insulin dose regimen (± 20 %) for at least [ADDRESS_1233535] 4 weeks prior to dosing and regular 
clinical monitoring is performed 
j. Anti-obesity drugs [e.g., the combination of phentermine and extended- release topi[INVESTIGATOR_052] 
(Qsymia), orlistat (Xenical), and lorcaserin (Belviq), phentermine, amphe tamines, herbal 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
48  preparations] within 12  weeks prior to Screening (except liraglutide [rDNA origin] injection 
(Saxenda) if on stable therapy for more than 6 weeks prior to Screening).  
k. Any other medication unless stable at least 4 weeks prior to dosing (occa sional or intermittent 
use of over -the-counter medications will be allowed at Investigator’s discretion)  
18. Blood donation of 50 to 499 mL within 30 days of Screening or of > [ADDRESS_1233536] -treatment Follow -up period.  
These periods are described below.  
All required study procedures are outlined in Appendix A . 
6.1.1 Screening /Qualification  
Written informed consent for the study will be obtained prior to the performance of any study- related 
procedures including screening procedures.  A 6-week period is provided for completing screening assessments and determining subject eligibility for the study.  During the screening period, subject will be advised to maintain diet and exercise routines, and remain on a stable regimen of diabetes and lipid 
medications (if they are already taking any).      
Subjects will undergo a medical history and physical examination including vital signs, 12-lead ECG, and have blood and urine samples taken for clinical laboratory testing.  Subjects will be screened for HIV, 
hepatitis B, and hepatitis C.  Safety labs may be re- tested for determination of subject eligibility after 
consultation with the Sponsor Medical Monitor. 
As part of the screening period, subjects not already on a stable diet will have [ADDRESS_1233537] dose of study drug. 
6.1.2 Treatment Period  
Subjects will be managed on an outpatient basis.  Safety and clinical laboratory evaluations as well as 
blood sampling for PK analysis will be performed periodically throughout the treatment period.  Any AEs 
and concomitant medications will be recorded.  
Collection and measurement of vital signs, physical examination results, ECGs, clinical laboratory 
parameters (Appendix B ), ISIS 703802 plasma concentrations, immunogenicity, MRI, AEs and 
concomitant medication/procedure information will be performed according to the Schedule of 
Procedures in  Appendix A . 
ISIS [ADDRESS_1233538] will be followed for safety assessments for 13 weeks after the Treatment Period (last dose 
through one dosing interval post last dose).  During the post-treatment evaluation period, subjects will 
return to the Study Center for outpatient visits for  safety and clinical laboratory evaluations.  A ± 3- day 
excursion from the scheduled visit date is per mitted for this time period.  
6.2 Study/Laboratory Assessments  
Laboratory analyte samples will be collected throughout the Study.  A list of these analytes is contained in Appendix B .   
Blood chemistry and urine samples (excluding 24-hour urine collection) should be taken after fasting for 
at least 10 hours.  During this time subjects can drink water and should ensure that they consume 
sufficient water to not become dehydrated.  
If tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) or missing, a 
repeat blood or urine specimen should be re-drawn as soon as possible (ideally within 1 week).  
While on treatment hematology samples will be collected every 14  days.  Each time a hematology lab is 
drawn and sent to the central laboratory for analysis, an additional sample should be collected in parallel and analyzed locally.  In the event that both the central and local samples are unreportable (e.g., due to 
hemolyzed or clumped blood samples), subject dosing cannot continue until another sample is repeated and determined not to have met a platelet stoppi[INVESTIGATOR_1877].  
If there is no reportable platelet count within [ADDRESS_1233539] 3 months of the study treatment, and 
monthly thereafter during the Treatment Period per  Section 8.5.2 .   
All lab samples are to be sent to the centr al laboratory by [CONTACT_474275].  Lab Alerts 
issued as per protocol safety monitoring requirements or stoppi[INVESTIGATOR_882008], the Sponsor and the CRO Medical Monitors, the Sponsor Drug Safety Physician, and the 
Clinical Trial Manager (CTM), and should be received by [CONTACT_77314] 2 days from sample collection.  
Hematology results from the site’s local laboratories are received by [CONTACT_882051]’s standard reporting time, and should be entered as soon as possible into the eCRF to inform the Sponsor and CRO study monitoring teams.  
All platelet coun t results must be reviewed promptly (within 48 hours of receipt) by [CONTACT_737], or 
designee, to ensure that the count has not met the stoppi[INVESTIGATOR_882009] d ose interruption rule of 75,000/mm
3 as 
specified in  Section 8.6.3.  Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or 
Grade 4) is considered an adverse event of special interest and must b e reported in an expedited fashion to 
the Sponsor as per  Section 9.4.1.  
ISIS [ADDRESS_1233540] also be reviewed promptly (within 48 hours of receipt) by [CONTACT_3786], or designee, to ensure th at the result has not met the stoppi[INVESTIGATOR_1877].  Any event meeting renal 
stoppi[INVESTIGATOR_368022] 8.6.[ADDRESS_1233541] be reported in an expedited fashion to the Sponsor as per  Section 9.4.1.  
All lab alerts received, including those related to platelet, liver, or renal function monitoring/stoppi[INVESTIGATOR_37626], are also reviewed promptly by [CONTACT_882052].  Within 24 hours of receiving an actionable lab alert the CRO Medical Monitor will 
communicate instructions to the Investigator and the study personnel by [CONTACT_368131]/study personnel and promptly returned to the Sponsor and CRO Medical Monitor.  In urgent cases, such as platelets results below  50,000/mm
3, or 
liver or renal test results reaching a critical stoppi[INVESTIGATOR_882010].  
Further information on safety monitoring and actions to be taken by [CONTACT_882053] 8.5.3 and 8.6.3.  
6.2.1 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures (Appendix 
A).  Vital signs should include weight, blood pressure (BP), pulse rate, respi[INVESTIGATOR_37499].  BP and pulse rate will be recorded after the subject has been in a sitting position for at least 
5 minutes.  BP should always be measured on the same arm (preferentially on the left arm).  Height will 
be measured at Screening . 
6.2.2 DEXA Scan  
Dual -energy X -ray Absorptiometry ( DEXA) scans will be conducted prior to administration of the first 
dose of Study Drug and repeated at Week 13 and 27 using standardized procedures and settings.  
6.2.3 Electrocardiography  
Electrocardiography (ECG) will be conducted as indicated in the Schedule of Procedures ( Appendix A ) at 
Screening, Day 1 (prior to the first dose of Study Drug), and during the treatment period.  
ECGs will be conducted during the post- treatment follow -up period at scheduled visits.  
ECGs will be recorded after the subject has been resting in a supi[INVESTIGATOR_21683] [ADDRESS_1233542] (MMT)  (Appendix E ) will be done at baseline, at week [ADDRESS_1233543] , fasting plasma glucose, free fatty acids ( FFA), C-
peptide, insulin, serum ghrelin, GIP, GLP-[ADDRESS_1233544] meal (such as Optifast®) and the same metabolic parameters are 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
51  measured again over the course of 300 minutes at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 minutes. 
In addition, a validated visual analogue scale (VAS) will be used to measure the subject’s perception of hunger. 
6.2.[ADDRESS_1233545] refrain from sperm/egg donation and either 
be abstinent
† or practice effective contraception from the time of signing the informed consent form until 
at least  a period of [ADDRESS_1233546]’s last dose of study treatment.  
For the purposes of this study, women of childbearing potential are defined as any female who has experienced menarche, and who does not meet one of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea withou t an alternative medical 
cause  and FSH levels in the postmenopausal range for the laboratory i nvolved  
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy  
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male subjects:  
• Effective male contraception includes a vasectomy with negative semen analysis at follow -up, or 
the use of condoms together with spermicidal foam/gel/film/ cream/suppository  
• Male subjects with partners that are pregnant must use condoms as contraception to ensure that 
the fetus is not exposed to the Study Drug 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
52  For female subjects and female partners of male subjects:  
• Using 2 of the following acceptable methods of contraception:  surgical sterilization (e.g., 
bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2 
barrier me thods (a combination of male or female condom* with diaphragm, sponge, or cervical 
cap) together with spermicidal foam/gel/film/cream/suppository  
†Note:  Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception.  
*Note: A female condom and a male condom should not be used together as friction between the 
two can result in either or both products failing.  
6.3.[ADDRESS_1233547] 10 hours before visits requiring fasted blood sampling.   
7. S TUDY DRUG  
7.1 ISIS 703802  
Study Drug (ISIS 703802) characteristics are listed in Table 1. 
Study Drug (ISIS 703802) will be provided as 0.[ADDRESS_1233548] 
be stored between 2 to 8 °Celsius and be protected from light. 
Table 1 Study Drug Characteristics  
Study Drug  
ISIS  703802  
Strength  100 mg/ mL  
Volume/Formulation 0.8 mL/vial 
Route of 
Administration  SC* 
* SC = subcutaneous 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug labeled in accordance with specific 
country regulatory requirements. 
7.3 Study Drug Accountability  
The study staff is required to document the receipt, dispensing, and return of Study Drug (ISIS 703802) 
supplies provided by [CONTACT_1034].  The subject must return all used and unused Study Drug to the Study 
Center for accountability. The Study Center must return all used and unused Study Drug to the Sponsor or 
designee.  All used syringes must be disposed of as per the site’s hazardous waste destruction policy.  
ISIS [ADDRESS_1233549] 
2 days apart.    
Every effort should be made to ensure the previous dose is given 7 days prior to a scheduled clinic visit.  
Volumes to be administered are shown in Table 2.  Please refer to the Study Drug Manual provided by [CONTACT_882054]/or administration.  
Table 2 Study Drug Dosing Information 
Volume to Administer*  Total Dose*  
0.20 mL  20 mg (open label)  
8.[ADDRESS_1233550]- treatment evaluation period.  
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol-required treatment procedures other than those outlined in the schedule of 
procedures. 
8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator” section of the Investigator’s Brochure.  
For the purposes of safety monitoring Baseline is defined as the average of the pre- dose test closest to 
Day [ADDRESS_1233551] results from 2 sources, safety -mandated action mus t be initiated 
based on the more critical (lower or higher, as relevant) of the 2 values.  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
54  Confirmation Guidance:  At any time during the Study (Treatment or Post- Treatment Periods), the initial 
clinical laboratory results meeting the safety monitoring criteria presented below must be confirmed by 
[CONTACT_10533] (ideally in the same laboratory that performed the initial measurement) on new 
specimens prior to administering the next dose of Study Drug.  All new specimen collections should take 
place as soon as possible (ideally within 3 days of the initial collection).   
Stoppi[INVESTIGATOR_86556]:  The Investigator may interrupt or permanently discontinue study treatment for 
any safety reason including clinically meaningful changes in clinical laboratory  results.  
In the event of an initial clinical laboratory result that meets a stoppi[INVESTIGATOR_107160], subjects must not be re-dosed until a confirmatory test result has been reviewed by [CONTACT_10542].  If any of the 
stoppi[INVESTIGATOR_881985], the subject will be permanently discontinued 
from further treatment with Study Drug (ISIS 703802), evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post-treatment evaluation portion of the study.  In general, subjects who do not meet the stoppi[INVESTIGATOR_395636].  However, the Investigator and the Study Medical Monitor (or appropriately qualified designee) shoul d confer as to whether additional close monitoring of the 
subject is appropriate.  
Additional Guidance:  If possible, a PK sample should be collected as soon as possible after a SAE has 
occurred (preferably within 2 weeks).  In addition, if a subject is asked to return to the clinic for additional evaluations due to an AE, then a PK sample should be taken at the time of the unscheduled 
visit.  
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug-Induced Liver Injury:  
Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S.  Department of Health and Human Services, Food 
and Drug Administration, July [ADDRESS_1233552] 3 -
months of the study treatment period, and monthly thereafter.  Upon completion of the study treatment period, liver chemistry tests should be monitored as per visit schedule in Appendix A .  
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever, rash, abnormal bleeding or bruising, or eosinophilia  > 
ULN) liver enzymes and bilirubin should be tested as soon as possible.  Testing at a lab that is local to the subject is permissible for this purpose.  
In the event of an ALT or AST measurement that is > [ADDRESS_1233553] (or the greater of [ADDRESS_1233554] if the baseline value was > ULN) at any time during the study (treatment or post-treatment period), the initial measurement(s) should be confirmed.  
Subjects with confirmed ALT or AST levels > [ADDRESS_1233555] their liver chemistry tests (ALT, AST, ALP, international normalized ratio [INR] and total bilirubin) retested at least once- weekly until 
ALT and AST levels become ≤ 1.[ADDRESS_1233556] be reviewed promptly (within 48  hours of  receipt) by [CONTACT_213328][INVESTIGATOR_004]. 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
55  Further Investigation into Liver Chemistry Elevations :  For subjects with confirmed ALT or AST levels > 
[ADDRESS_1233557],  the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, herbal 
and dietary supplement preparations), alcohol use, recreational drug use, an d special diets  
3. Obtain a history for exposure to environmental chemical agents and travel  
4. Serology for viral hepatitis (hepatitis A virus [HAV] immunoglobulin M [IgM], hepatitis B surface antigen [HBsAg], hepatitis C virus [HCV] antibody, Cytomegalovirus [ CMV] IgM, and 
EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a subject’s ALT and/or AST levels 
reach [ADDRESS_1233558] be promptly (within 48 hours of receipt) reviewed by 
[CONTACT_368094].  
Lab alerts for abnormal liver chemistry tests will be issued for:  1) ALT or AST > [ADDRESS_1233559]; 2 ) ALT or 
AST > 2 x baseline; 3) total bilirubin > ULN; 4) ALP > ULN.  These alert levels are set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the FDA Guidance.  
8.5.[ADDRESS_1233560] 3 
months of the study treatment period, and monthly thereafter.   Upon completion of the study treatment 
period, urine renal biomarkers should be monitored as per visit schedule in  Appendix A .  
In the event of appearance of symptoms or signs consistent with renal dysfunction such as hematuria, 
polyuria, anuria, flank pain, new-onset hypertension, nausea and/or anorexia, renal function should be tested as soon as possible.  Testing at a lab that is local to the subject is permissible for this purpose.  
While on treatment during the course of the study, urinary surveillance may include urinalysis to include urine albumin/creatinine ratio (UACR),  urine protein/creatinine ratio (UPCR) and urinary red blood cells 
(RBCs), as well as serum creatinine and cystatin -C which will be monitored every [ADDRESS_1233561] 3 -months of the study treatment period, and monthly thereafter.  In addition, other biomarkers of 
acute renal injury may also be measured if a safety signal is seen that warrants further testing.  (Appendix 
B).  
The assessment of serum creatinine, cystatin -C, and urinalysis more frequently than per the Schedule of 
Procedures in  Appendix A  will be guided by [CONTACT_671593].  Any decision taken 
by [CONTACT_882055].  In addition, the decision to discontinue Study Drug may also be based on lesser changes in 
these parameters observed in isolation or in association with other renal- related abnormalities.  Any 
ISIS [ADDRESS_1233562] be reviewed promptly (within  48 hours of receipt) by [CONTACT_213328][INVESTIGATOR_004]. 
Lab alerts for abnormal renal tests will be issued for:  eGFR (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) decrease from 
Baseline > 25%, urine albumin/creatinine ratio (UACR) > 250 mg/g, urine protein/creatinine ratio 
(UPCR) >  0.5 mg/mg, or an increase in serum creatinine from Baseline > 0.3 mg/dL). 
These alert levels are set to anticipate and prevent the risk of a medically significant change in renal function while receiving Study Drug.  
In the event of a confirmed laboratory result meeting one or more of the above criteria, the following 
supplemental renal tests should be immediately obtained:  
Serum creatinine, urine culture, 24-hour urine sample for creatinine clearance, urine albumin and 
urine protein, urine microscopy sample with inspection of sediment. 
The Investigator should also review the subject’s concomitant medications for potentially nephrotoxic agents, and, with the resul ts of these evaluations, review any decision to continue or discontinue the 
subject in consultation with the Study Medical Monitor. 
8.5.[ADDRESS_1233563] dose (as per visit schedule).  
All platelet count results must be reviewed promptly (within 48  hours of receipt) by [CONTACT_368105][INVESTIGATOR_882011] 75,000/mm
3.   
Any case of a platelet count reduction to levels below  50,000/mm3 (Grade 3 or Grade 4) is considered an 
adverse event of special interest  and should be reported in an expedited fashion to the Sponsor. In this 
case, the Investigator should refer the subject to a hematologist to provide diagnostic and therapeutic management.  
Lab alerts related to platelet monitoring/stoppi[INVESTIGATOR_368027]:  1) platelet counts are <  140,000 
mm
3; 2) when platelet count is ≥ 30% decreased from Baseline, or 3) when the hematology sample is 
unreportable.  All these lab alerts, are reviewed promptly by [CONTACT_474284] 24 hours of receiving an actionable lab 
alert.  
Actions to be taken in the event of reduced platelet count are shown in  Table 3. 
In the event of a platelet count ˂ 100,000/mm
3 the laboratory tests outlined in Table 3, should be 
performed as soon as possible.  In addition to action taken as outlined in Table 3, in the event of a platelet 
count <100,000/mm3, tests outlined in Appe ndix F  should be performed as soon as possible. Additional 
lab tests , if warranted, will be determined by [CONTACT_882056].  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
57  8.5.4 Safety Monitoring for Bleeding Events 
Subjects will be evaluated for occurrence of bleeding events continuously after the start of Study Drug 
treatment (Day 1 ) up to the end  of the follow -up period for all cohorts.  All  bleedin g events are considered 
adverse events and reported on adverse event case report form .   
Bleeding events that are either major or clinically -relevant non-major bleeding (as defined below) will 
need to be monitored and treated immediately. Subjects with a suspected bleeding event will undergo 
additional testing if deemed appropriate by [CONTACT_474285] (S)AE case report form will be 
completed. In addition, if bleeding is considered significant, hemoglobin (Hb), hematocrit (HCT), aPTT, PT, INR, and platelet count are to be obtained.  In addition, approximately [ADDRESS_1233564] be stored allowing for a centralized 
assessment of ISIS 703802
 concentrations.  
In addition, if a minor bleeding event occurs, the Investigator should notify the Sponsor Medical Monitor 
(or designee) and additional testing of coagulation parameters (aPTT, prothrombin time [PT], INR), 
platelet count, and platelet volume may be performed. 
Definitions :  
Major bleeding (MB) is defined as one of the following  (Büller et al. 2007 ):  
1. Fatal bleeding  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304] , intraocular, 
retroperitoneal, intraarticular if in a major joint, or pericardial, or intramuscular with 
compartment syndrome  
3. Clinically overt bleeding leading to transfusion of ≥ 2 units of packed red blood cells or whole 
blood or a fall in hemoglobin of 20 g/L (1.24 mmol/L) or more within 24 hours  
Clinically -relevant non- major bleeding (CRNMB) is defined as overt bleeding not meeting the criteria for 
major bleeding but that resulted, for example, in medical examination, intervention, or had clinical consequences for a subject (Büller et al. 2007).  
 Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -relevant, 
non-major bleeding events (defined above), for example excess bruisin g, petechiae, gingival bleeding on 
brushing teeth.  
8.5.[ADDRESS_1233565] Self Monitored Blood Glucose (SMBG) levels and report back alert values to the site.  Subjects will be instructed to promptly report symptoms of hypoglycemia: headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, 
ISIS [ADDRESS_1233566] ’s glucose level and treat the subject  accordingly.   Severe hypoglycemia will be 
qualified as a SAE only if it fulfills SAE criteria.  
Classification of Hypoglycemia  
The alert value for hypoglycemia is ≤ 70 mg/dL (≤ 3.9 mmol/L) blood glucose concentration. 
Severe Hypoglycemia  
Requires assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions.  Glucose concentrations may not be available during an event.  Neurological recovery  
following glucose levels returning to normal considered sufficient evidence that event was induced by 
[CONTACT_671596]. 
Documented Symptomatic Hypoglycemia  
Typi[INVESTIGATOR_882012] ≤ 70 mg/dL (≤ 3.9 mmol/L).  
Asymptomatic Hypoglycemia   
Not accompanied by [CONTACT_11017][INVESTIGATOR_671564]≤ 70 mg/dL (≤ 3.9 
mmol/L) . 
Probable Symptomatic Hypoglycemia 
Typi[INVESTIGATOR_882013] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
A documented severe hypoglycemic event is defined as one in which the subject requires assistance of 
another person to obtain treatment for the event and h as a blood glucose level ≤ 70 mg/dL 
(≤ 3.9 mmol/L).   The rescue treatment of hypoglycemia may include IV glucose or buccal or 
intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473] -treatment and which were thus thought to place  subjects at 
risk for injury to themselves or others. 
8.5.[ADDRESS_1233567] the Investigator and a central laboratory FPG measurement will 
be performed).  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
59  The threshold values are defined as follows, depending on study period: 
From baseline visit to Week 13 (including value at Week 13) of Randomized Treatment period: 
• Blood glucose > 270 mg/dL (15.0 mmol/L) 
From Week [ADDRESS_1233568] -treatment Follow -up (Week 4, [ADDRESS_1233569] end of treatment period): 
• Blood glucose > 240 mg/dL (13.3 mmol/L) or 
• HbA1c > 9% (for subjects with Baseline HbA1c < 8%) and HbA1c increase of more than 1% 
from Baseline (for subjects with Baseline HbA1c ≥ 8%) 
In case of blood glucose /HbA1c above the threshold values, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that: 
• Blood g lucose was actually measured in the fasting condition  
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency 
such as unplanned hospi[INVESTIGATOR_059] (e.g., surgery, infection), the Investigator can take appropriate 
measures for glycemic control.  If the measure does not exceed 7 days, then it will not be 
considered a rescue.  If the measure lasts beyond 7 days then it will be treated as a rescue  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate  
If any of the above can reasonably explain the insufficient glycemic control, the Investigator should undertake appropriate action, i.e.:  
• Investigation and treatment of intercurrent disease (to be reported in AE/concomitant medication parts of the eCRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or o ther qualified nutrition professional 
and stress on the absolute need to be compliant to diet and lifestyle recommendations 
• Schedule a FPG/ HbA1c assessment at the next visit  
If none from the above-mentioned reason can be found, or if appropriate action fails to decrease blood 
glucose/HbA1c under the threshold values, rescue medication may be introduced at the Investigator discretion and according to local guidelines.  
All assessments for primary and secondary efficacy and safety parameters planned in final primary 
endpoi nt assessment visit should be performed before adding the rescue medication if possible.  Then the 
subject continues the study treatment and stays in the study in order to collect safety information.  The planned visits and assessments should occur until the last scheduled visit.  (See more details in  Appendix 
A). 
Note: After Study Drug discontinuation any treatments are permitted, as deemed necessary by [CONTACT_737].  
ISIS [ADDRESS_1233570] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_368028], dosing of a patient with 
Study Drug will be stopped permanently: 
1. ALT or AST > [ADDRESS_1233571] > [ADDRESS_1233572], which is confirmed and persists for ≥ [ADDRESS_1233573] > [ADDRESS_1233574] (or the greater of [ADDRESS_1233575] if the baseline value was 
> ULN), which is confirmed and total bilirubin > [ADDRESS_1233576] or INR > 1.[ADDRESS_1233577] > [ADDRESS_1233578] (or the greater of [ADDRESS_1233579] if the b aseline value was 
> ULN), which is confirmed, and the new appearance (i.e., onset coincides wit h the changes in 
hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (> ULN) felt by [CONTACT_368096] . 
Dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency will be allowed for safety.  Any proposed adjustments to treatment schedule must be discussed with, and approved by, the Study Medical monitor prior to initiation.  
8.6.[ADDRESS_1233580] Results / Temporary Stoppi[INVESTIGATOR_882014] (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) meeting any of the following criteria, or any change in 
renal biomarkers deemed by [CONTACT_882033], a serum creatinine and 24 -hour 
urine sample for creatinine clearance and protein should be obtained: 
1. eGFR  (CKD- EPI) decrease of > 40% from Baseline  
2. eGFR  (CKD- EPI) value < 45 mL/min/1.73 m
2 
Dosing of a patient with Study Drug (ISIS 703802) will be stopped permanently if 24- hour urine testing 
confirms any of the following values in the absence of an alternative explanation:  
1. Urine protein is > 1.0 g 
2. Creatinine clearance decrease of > 40% from  Baseline  
3. Creatinine clearance < 45 mL/min/1.[ADDRESS_1233581] who has been engaged by [CONTACT_368098].  
Dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency will be 
allowed for safety.  Any proposed adjustments to treatment schedule must be discussed with, and 
approved by, the Study Medical monitor prior to initiation.  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
61  8.6.3 Stoppi[INVESTIGATOR_213276] a low platelet count are summarized in  Table 3 below. 
In the event of any platelet count less than 50,000/mm3, or a platelet count less than 75,000/ mm3 that 
occurs while the subject is already on reduced dose, dosing of the subject with Study Drug will be 
stopped permanently ( Table 3).  Platelet count will be mon itored daily until 2 successive values show 
improvement then monitored every 2- 3 days until platelet count is stable.  
Administration of steroids is recommended for subjects whose platelet count is less than 25,000/mm3.  
Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010)  recommend Dexamethasone 40 mg daily 
for 4 days every 2 -4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or 
methylprednisolone 30 mg/kg/day for 7 days  (note:   may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count ˂ 75,000/mm3 and > 50,000/mm3, dosing of a subject with Study Drug 
should be suspended temporarily until the platelet count has recovered to > 100,000/mm3.  If dosing is 
continued, it must be at a reduced dose as shown in Table 3.  The suitability of the subject for continued 
dosing will be determined by [CONTACT_368139] r ate of decline in the subject’s platelet count, whether any bleeding 
events were experienced by [CONTACT_423], and the speed of recovery of platelet count after interruption of dosing. 
If, after reintroduction of Study Drug, the platelet count again falls below 75,000/mm
3, then dosing of the 
subject with Study Drug will be stopped permanently.  
Once a subject commences weekly monitoring, this frequency of monitoring should continue until the 
platelet count returns to the normal range (≥140,000/mm3) for [ADDRESS_1233582] met a stoppi[INVESTIGATOR_10450].  
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
62  Table 3 Actions in Subjects  with Low Platelet Count   
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, > 140K/mm3 No action  Monitor every 14 days (+/- 2 days)  
>100K  to <140K/mm3 No action  Closer observation  
Monitor every week  * 
>75K to <100K/mm3 Permanently reduce as follows:  
Reduce to 10 mg every week  Closer observation  
Monitor every week * 
>50K to <75K/mm3 Pause dosing  
When platelet count returns to 
≥ 100K/mm3 restart dosing as follows 
only if approved by [CONTACT_671599] : 
Reduce to 10 mg every week  
or 
Permanently discontinue Study Drug if 
it occurs while on already reduced 
dose  Closer observation  
Monitor every 2-3 days until 2 successive 
values show improvement  
Consider discontinuation of antiplatelet 
agents/non-steroidal anti -inflammatory 
drug (NSAIDS)/ anticoagulant medication  
>25K to <50K/mm3 Permanently discontinue Study Drug   Closer observation: 
Monitor daily until 2 successive values 
show improvement then monitor every 2-3 
days until platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication 
while platelet count ˂ 50K/mm3 if possible . 
Refer to hematologist to provide diagnostic and therapeutic management.  
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 2 successive values 
show improvement then monitor every 2-3 days until platelet count stable  
Steroids recommended**  
Consider need for hospi[INVESTIGATOR_059] t 
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication 
while platelet count ˂ 50K/mm
[ADDRESS_1233583] to provide 
diagnostic and therapeutic management.  
* Once a subject  commences weekly monitoring this frequency of monitoring should continue until the platelet 
count returns to the normal range (≥ 140,000/mm3) for 2 successive values.    
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010)  recommend Dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1- 4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require continuation with oral steroids after methylprednisolone) . 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
63  8.7 Adjustment of Dose and/or Treatment Schedule  
Dose frequency adjustments for platelet count reduction must be made in accordance with  Section 8.6.3 
and Table 3 (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for 
safety or tolerability in consultation with the S ponsor Medi cal Monitor.   
Subjects may have their dose interrupted in response to AEs in consultation with Study Medical Monitor . 
8.8 Discontinuation of Study Drug/ Treatment  
A subject must permanently discontinue study treatment for any of the following: 
• The subject becomes pregnant.  Report the pregnancy according to instructions in  Section  9.5.4  
• The subject withdraws consent 
• The subject experiences an adverse event (AE) that necessitates permanent discontinuatio n of 
Study Drug 
• The subject develops laboratory test abnormalities that meet any of the stoppi[INVESTIGATOR_882015] 8.6.1 to 8.6.3  
• When a platelet count of  less than 50,000/mm3, or a platelet count less than 75,000/mm3 while the 
patient  is on a reduced dose . 
The reason for discontinuation of Study Drug Treatment must be recorded in the electronic Case Report 
Form (eCRF) and source documentation.  
For subject s who discontinue treatment early every effort should be made to complete the early 
termination study procedures and observations at the time of withdrawal (see  Appendix A ).  Subjects 
should then be entered into the post- treatment e valuation period.   
If a subject discontinues treatment after only [ADDRESS_1233584] end of treatment period (as per visit schedule) .  
If the subject declines or is unable to participate in the above, the early termination visit procedures 
should be performed at the time of withdrawal, at a minimum, and ideally within [ADDRESS_1233585] is 
agreeable to: in person, by [CONTACT_648]/mail, through family/friends, in correspondence/communication with other physicians, and/or from review of the medical records.  Wherever possible these subjects should 
continue to be followed up via the agreed means to collect information on adverse events, concomitant medications and survival status.  At the very least, the patient’s status at the end of the protocol def ined 
study period should be ascertained and documented. 
ISIS [ADDRESS_1233586] be withdrawn from the Study for any of the following: 
• Withdrawal of consent  
• The subject is unwilling or unable to comply with the protocol 
• The subject  meets any of the Exclusion Criteria (see Section 5.2 ) after enrolling in the study that 
in the opi[INVESTIGATOR_213280] a safety ri sk to the subject 
Other reasons for withdrawal of subjects from the Study might include: 
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation 
All efforts will be made to com plete and report the observations as thoroughly as possible up to the date 
of withdrawal.  All information, including the reason for withdrawal from Study, must be recorded in the 
eCRF.  
Any subject who withdraws consent to participate in the Study will be removed from further treatment 
and study observation immediately upon the date of request.  These subjects should be encouraged to 
complete the early termination study procedures and observations at the time of withdrawal ( Appendix  
A). For subjects withdrawn for reasons other than withdrawal of consent every effort should be made to 
complete the early termination study procedures and observations at the time of withdrawal (see 
Appendix A ).  The I nvestigator should clarify what type of follow- up the subject is agreeable to: in 
person, by [CONTACT_648]/mail, through family/friends, in correspondence/communication with other physicians, and/or from review of the medical records.  Wherever possible these subjects should continue to be 
followed up via the agreed means to collect information on adverse events, concomitant medications and survival status.  At the very least, the patient’s status at the end of the protocol defined study period 
should be ascertained and documented. 
8.[ADDRESS_1233587]’s eCRF.  
Adverse events related to administration of these therapi[INVESTIGATOR_368032].  
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-counter 
medic ations, herbal medications and vitamin supplements) administered between Screening  and the end 
of the post-treatment evaluation period. All concomitant medications/treatments and significant non-drug 
therapi[INVESTIGATOR_014] (including supplements and assistive devices) received by a subject, including changes in the subject’s current medications, must be recorded in the subject’s source documents and CRF.  Subjects taking over the counter (OTC) omega- 3 fatty acids should make every effort to remain on the same brand 
throughout the study. 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
65  Allowed Concomitant Therapy  
Ibuprofen may be used for symptomatic pain relief.  Any other therapy for pain (including OTC 
medications such as acetaminophen) should be approved by [CONTACT_748929].  
Disallowed Concomitant Therapy  
The use of prescription and OTC medications including nonsteroidal anti-inflammatory drugs (with the 
exception of occasional ibuprofen) is prohibited during this study unless the occurrence of an AE requires a drug therapy.  In cases when there is no AE, the Investigator must consult the Sponsor Medical Monitor 
to decide on s ubject continuation or withdrawal from  the study.  
The medications and therapy identified in exclusion criteria,  Section 5.2 are also d isallowed concomitant 
medications and are prohibited during the course of s tudy, unless there is a safety concern.   In those cases 
the Medical Monitor needs to be notified and rationale provided by [CONTACT_737]. 
Concomitant therapy with oral corticosteroids used as replacement therapy for pi[INVESTIGATOR_882016] (e.g., Pulmicort®), or intra -articular, or topi[INVESTIGATOR_881992]; 
however, the subject must be on a stable regimen for at least [ADDRESS_1233588] should consult with the Site Investigator or designee prior to initiating any new medication, 
including non-prescription or herbal compounds or any other non-drug therapy. 
8.10.2 Concomitant Procedures  
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or 
diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between Screening  and 
the end of the post- treatment evaluation period . 
8.11 Treatment Compliance  
Compliance with treatment dosing is to be monitored and recorded by [CONTACT_37714].  The Study Center staff is required to document the receipt, dispensing, and return/destruction of study medication.  
Subjects that are self -admi nistering study medication at home must record treatment in a dosing diary that 
will be reviewed periodically by [CONTACT_37715].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING   
9.[ADDRESS_1233589] of the clinical trial.  
9.2 Regulatory Requirements  
The Sponsor or designee  is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) per 
the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific 
regulat ory requirements will be followed in accordance with local country regulations and guidelines.  
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any SAE 
according to applicable regulations.  In addition to the Investigator’s assessment of relatedness, the 
Sponsor or designee  will evaluate the available information and perform an independent assessment of 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
66  relatedness.  While the Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade 
the Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R.  For the purpose of regulatory reporting of S[LOCATION_003]Rs, there are no “expected” AEs in this study 
population. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically- significant abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the Study or use of 
investigational drug product, whether or not the AE is considered related to the investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any AE caused by [CONTACT_81807]. A suspected adverse reaction  is any AE for 
which there is a reasonable possibility that the drug ca used the adverse event.  A suspected adverse 
reaction implies a lesser degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event that in the view of either the Investigator or Sponsor, meets 
any of the following criteria: 
• Results in death  
• Is life threatening: that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the subject  at immediate risk of death.  It does not 
include an AE or suspected adverse reaction that, had it occur red in a more severe form, might 
have caused death  
• Requires inpatient hospi[INVESTIGATOR_881993] 24 hours to a medical facility and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
• Results in a congenital anomaly or birth defect in the offspring of the subject  (whether the subject  
is male or female)  
• Impor tant medical events that may not result in death, are not life- threatening, or do not require 
hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
67  [IP_ADDRESS] Adverse Events of Special Interest  
For the purpose of this study severe reductions in platelet count < 50,[ADDRESS_1233590] to expediting reporting to the Sponsor following the same 
requirements as for SAE reporting ( Section 9.4.1 ). 
9.4 Monitoring and Recording Adverse Events 
Any pre-existing conditions or signs and/or symptoms presen t in a subject prior to the start of the Study 
(i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the 
pre-existing condition worsened.  The Investigator should always group signs and symptoms into a s ingle 
term that constitutes a  single unifying diagnosis  if possible.  
9.4.[ADDRESS_1233591] safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to Study Drug) should be reported to the Sponsor  or designee  within 24 hours of the 
Study Center’s first knowledge of the  event.  The collection of SAEs will begin after the subject signs the 
informed consent form and stop at the end of the subject’s follow -up period. An  Initial Serious Adverse 
Event Form should be completed and a copy should be faxed to the Sponsor or designee.    
The contact [CONTACT_144613]:  
Attention: INC Research, LLC  
Email: [EMAIL_3091]  
Fax: [PHONE_3145] 
Detailed information should be actively sought and included on Follow- Up Serious Adverse Event Forms 
as soon as additional information be comes available.  All SAEs will be followed until resolution.  SAEs 
that remain ongoing past the subject’s last protocol- specified follow -up visit will be evaluated by [CONTACT_35299].  If the Investigator and Sponsor agree the subject’s condi tion is unlikely to 
resolve, the Investigator and Sponsor will determine the follow -up requirement. 
9.4.[ADDRESS_1233592]’s follow -up period.  The Investigator will monitor each subject closely and 
record all observed or volunteered AEs on the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_37481] : 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
68  [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to the Study Drug (ISIS 703802) is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug, e.g., 
confirmation by [CONTACT_38000]- challenge test  
• Possible:   The event cannot be explained by [CONTACT_423]’s medical condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event and 
Study Drug (ISIS 703802) administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to Study 
Drug ( ISIS 703802) administration and/or exposure suggests that a causal relationship  is unlikely 
(For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_3433] e subject’s underlying medical condition, 
concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug 
[IP_ADDRESS] Severity  
The severit y of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE not listed in 
Appendix D  will be graded as follows:  
 
• Mild:   The event is easily tolerated by [CONTACT_368101]’s usual daily 
activities  
• Moderate:   The event causes the subject more discomfort and interrupts the subject’s usual daily 
activities  
• Severe:  The event is incapacitating and causes considerable interference with the subject’s usual 
daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in Secti on 9.3.3).  
[IP_ADDRESS] Action Taken with Study Drug  
Action taken with Study Drug (ISIS 703802) due to the event is characterized by 1 of the following:  
• None:  No changes were made to Study Drug ( ISIS 703802) administration and dose  
• Permanently Discontinued:   Study drug was discontinued and not restarted 
• Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily interrupted or 
delayed due to the AE and restarted at the same dose  
• Temporarily Interrupted, Restarted Reduced Dose:   Dosing was tempora rily interrupted or 
delayed due to the AE and restarted at the next lower dose  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
69  [IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment (e.g., medications or procedures) given for the AE should be recorded  on the A dverse 
Event Case Report Form .  Treatment  should also be recorded on the concomitant treatment or ancillary 
procedures eCRF , as appropriate . 
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE, then the event’s outcome is characterized by 1 of the following: AE 
Persists:   Subject terminates from the trial and the AE continues : 
 
• Recovered:   Subject  recovered completely from the AE 
• Became Serious:   The event became serious (the date that the event became serious should be 
recorded as the Resolution Date of that AE and the Onset  Date of the corresponding SAE) 
• Change in Severity (if applicable):   AE severity changed  
If the event is an SAE , then the event’s outcome is characterized by 1 of the following: Ongoing:   SAE 
continuing: 
 
• Persists (as non -serious AE):   Subject has not  fully recovered but the event no longer meets 
serious criteria and should be captured as an AE on the non -serious AE eCRF  (the SAE resolution 
date should be entered as the date of onset of that AE)  
• Recovered:   Subject recovered completely from the SAE (the date of recovery should be entered 
as the SAE resolution date)  
• Fatal:   Subject  died (the date of death should be ente red as the SAE resolution date)  
9.[ADDRESS_1233593] results may, in the opi[INVESTIGATOR_689], constitute or 
be associated with an AE.  Examples of these include abnormal laboratory results that are associated with 
symptoms, or require treatment (e.g., bleeding due to thrombocytopenia, tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia).  Whenever possible, the underlying diagnosis should be listed in preference to abnormal laboratory values as AEs.  Clinically -significant abnormalities will be 
monitore d by [CONTACT_37722].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_37723].  Similarly, laboratory 
abnormalities reported as AEs by [CONTACT_37724]. The 
Investigator is responsible for reviewing and signing all laboratory reports.  The signed clinical laboratory 
reports will serve as source documents and should include the Investigator’s assessment of clinical 
significance of out of range/abnormal laboratory values. All platelet count results must be reviewed promptly (within 48 hours of receipt) by [CONTACT_882057][INVESTIGATOR_368049] 75,000/mm
3 as specified in Section 8.6.3.  Any case of a platelet 
count reduction to levels below  50,000/mm3 (Grade 3 or Grade 4) is considered an adverse event of 
ISIS [ADDRESS_1233594] and should be reported in an expedited fashion to the Sponsor as per  Sections [IP_ADDRESS] and 
9.4.1).  
All results of liver function tests must be reviewed promptly (within 48 hours of receipt) by [CONTACT_882058] e result has not met the stoppi[INVESTIGATOR_882017]  8.6.1.  
All results of renal function tests must be reviewed promptly (within 48 hours of receipt) by [CONTACT_882059][INVESTIGATOR_882017]  8.6.2.  
9.5.[ADDRESS_1233595]  is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was 
on a waiting list to be scheduled) prior to obtaining the sub ject’s consent to participate in the 
Study 
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_882018]’s consen t to participate in the Study and the timing of the procedure or 
treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors 
Study Drug (ISIS 703802) errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the subject  was symptomatic (list symptoms) or 
asymptomatic, and the event accidental or intentional.  Dosing details should be captured on the Dosing 
eCRF .  If the subject  takes a dose of Study  Drug that exceeds protocol specifications and the subject  is 
symptomatic, then the symptom(s) should be documented as an AE and be reported per  Section 9.4.  
Should an overdose occur , the Investigator or designee should refer to the Guidance to Investigator’s 
section of the Investigator’s Brochure and contact [CONTACT_10557] [ADDRESS_1233596] learning of the occurren ce of pregnancy.  Follow-up 
information including delivery or termination is reported by [CONTACT_10558] ‘Follow-up’ on the Pregnancy 
Forms and reported within [ADDRESS_1233597]’s responsibility.  Female subjects:  If a suspected pregnancy occurs while on the Study 
(including follow-up), a pregnancy test will be performed.  The subject with a confirmed pregnancy will be immediately withdrawn from treatment with Study Drug.  However, the subject will be encouraged to complete the post-treatment follow-up portion of the Study to the extent that study procedures do not interfere with the pregnancy.  Regardless of continued study participation, the study physician will assist 
the subject in getting obstetrical care and the progress of the pregnancy will be followed until the outcome 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
71  of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the 
pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  Follow-up will be performed to the 
extent permitted  by [CONTACT_10559].  Male subjects:  The progress 
of the pregnancy of a male subject’s partner should be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may request access to the mother and infant’s medical 
records for an additional 8 weeks after birth.   Follow -up will be performed to the extent permitted by 
[CONTACT_76542] e regulations and privacy considerations . 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints, Subsets, and Covariates  
10.1.1 Primary Endpoint 
• The effect of ISIS  703802 on the percent change from Baseline in fasting triglyceride levels (TG) 
at week 27  
10.1.2 Secondary E ndpoints  
• Chang e from Baseline in AUC plasma glucose, serum insulin, serum C -peptide, free fatty acid, 
serum ghrelin, GIP, GLP-1, and PYY and incretin hormones in response to a mixed meal test 
(MMT)  
• Change from Baseline in lipi[INVESTIGATOR_881977] -density lipoprotein cholesterol 
(HDL -C), low- density lipoprotein cholesterol (LDL -C), total cholesterol (TC), very low -density 
lipoprotein cholesterol (VLDL -C), non- HDL -C, apolipoprotein B (apoB), apolipoprotein B-48 
(apoB-48), apolipoprotein B -100 (apoB-100), apolipoprotein A-1 (apoA-1), apolipoprotein C- III 
(apoC- III :total,  chylomicron, VLDL, LDL and HDL), Lipoprotein a [Lp(a)], free fatty acids 
(FFA), and glycerol levels,  lipoprotein particle size/number  
• Change from Baseline in glycosylated hemoglobin (HbA1c)  
• Change from Baseline in homeostasis model assessment -estimated insulin resistance (HOMA -IR) 
• Change from Baseline in adiponectin and leptin  
• Change from Baseline in hepatic fat fraction (as assessed by [CONTACT_882060] [MRI])  
• Changes from Baseline in body fat distribution for various areas in the body as measured by [CONTACT_882036]; VAT and SAT as measured by [CONTACT_9268]; body weight , waist 
circumference and waist/hip ratio  
• Change from Baseline in quality of li fe and pain score 
10.2 Sample Size Considerations  
There is no statistical rationale for the selected sample size.  The sample size is selected based upon prior 
experience with ISIS 703802 to ensure that the safety, tolerability and efficacy of ISIS 703802 can be 
explored in an ultra- rare condition before enrolling subjects in a larger study.   
10.3 Populations 
Safety Set:  All subjects who are enrolled and receive at least 1  dose of Study Drug.   PK Set:  All subjects 
who receive at least [ADDRESS_1233598] error, interquartile range (25th 
percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and 
percentages for categorical variables will be used to summarize most data.   
10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by [CONTACT_6490].  All patients enrolled will be included in a summary of patient disposition.  
10.6.2 Safety Analysis  
Treatment duration and amount of Study Drug received will be summarized by [CONTACT_14459].  
Injection Site Reactions (ISRs) will be summarized by [CONTACT_1570], MedDRA preferred term and severity.  
[IP_ADDRESS] Adverse Events  
Treatment duration and amount of Study Drug received will be summarized.  Patient incidence rates of all AEs will be tabulate d by [CONTACT_11189], and by [CONTACT_6213].  Narratives of 
treatment -emergent deaths, serious and significant AEs, including early withdrawals due to AEs, will also 
be provided. 
All treatment- emergent AEs, all treatment- emergent AEs poten tially related to Study Drug, all treatment-
emergent serious AEs, and all treatment -emergent serious AEs potentially related to Study Drug will be 
summarized.  
[IP_ADDRESS] Clinical Laboratory Data 
Laboratory tests to ensure patient safety including chemistry p anel, complete blood count (CBC) with 
differential, coagulation panel, complement, etc., will be summarized by [CONTACT_15449].  These safety 
variables will also be presented as change and percent change from Baseline over time after Study Drug 
administration, as appropriate.  In addition, the number of subjects who experience abnormalities in clinical laboratory evaluations will be listed.  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
73  [IP_ADDRESS] Vital Signs and Examinations 
Vital signs, weight, and ECG measures will be summarized by [CONTACT_15449].  
10.6.3 Efficacy Analysis  
Change at week 27 relative to Baseline will be summarized for:  
• Fasting TG  
• MTT (plasma glucose, serum insulin, serum C -peptide, FFA , serum ghrelin, GIP, GLP-1 and 
PYY) 
• Glycosylated hemoglobin  
• HOMA -IR 
• 24-hr glucose 
• Adiponectin and leptin 
• HFF 
• Fat distribution  
10.6.4 Pharmacokinetic Analysis  
The plasma PK of ISIS 703802 (as total full length oligonucleotides, including, fully conjugated, partially 
conjugated, and unconjugated ISIS 703802) will be assessed following multiple -dose SC administration.  
The plasma trough levels of ISIS [ADDRESS_1233599] immunogenicity s tatus if 
applicable.  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, and when applicable, titer of anti - ISIS 703802 antibodies) before, during, and after treatment with ISIS 
[ADDRESS_1233600] ADA status (positive/negative or not evaluable) for all evaluable patients, 
along with the study day associated with the first positive IM status emerged (T
first, i.e., onset of ADA 
development), the last positive IM status observed (T last), the last ADA sample collection day, and subject 
- peak titer if applicable, will be listed and study day.  Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjec ts with antibody negative, positive, and 
unknown status by [CONTACT_1570].  Furthermore, onset and titer of the ADA response, if applicable, will 
be summarized as median, quartiles (25% and 75%), and range.  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
74  10.6.5 Pharmacodynamic Analysis  
The following parameters will be measured throughout the trial and  change at week 27 relative to 
Baseline will be summarized:  
• ANGPTL3  
• HDL -C  
• LDL -C 
• TC  
• VLDL -C   
• non-HDL -C  
• apoB  
• apoB-48  
• apoB-100 
• apoA-1  
• apoC- III 
• Lp(a)   
• FFA  
• Glycerol levels  
• Lipoprotein particle size/number  
10.6.6 Additional Analyses 
Additional analyses may be performed not specified in this open label study protocol from the data 
available.  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_16015]. 
Before a subject’s participation in the trial, the Investigator is responsible for obtaining written informed consent from the subject or legally acceptable representative after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol- specific 
screening procedures or any Study Drug ISIS [ADDRESS_1233601]’s agreement or refusal to notify his/her primary care 
physician should be documented in the subject’s medical records and the informed consent form should 
be signed and personally dated by [CONTACT_356967] a legally acceptable representative and by [CONTACT_37994] (not necessarily an Investigator ).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by 
[CONTACT_10569], and a copy of the signed consent form should be provided to the subject  or legally 
acceptable representative. 
If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
representative, the  Investigator must provide an impartial witness to read the informed consent form to the 
subject  and must allow for questions.  Thereafter, both the subject  or legally acceptable representative and 
ISIS [ADDRESS_1233602] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October 200 2 
the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands 
of national drug and data protection laws and other applicable regulatory requirem ents will be strictly 
followed.  
11.3 Independent  Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent form, other written subject information, and any 
proposed advertising material must be submitted to the IEC/IRB  for written approval.  A copy of the 
written approval of the protocol and informed consent form must be received by [CONTACT_882061].  A copy of the written approval 
of any other items/materials that must be approved by [CONTACT_84225]/IRB  must also be received 
by [CONTACT_882037].  The Investigator’s Brochure must be submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator 
should notify the IEC/IRB  of deviations from the protocol in accordance with ICH GCP Section 4.5.2.  
The Investigator should also notify the IEC/IRB  of SAEs occurring at the Study Center and other AE 
reports received from the Sponsor or designee, in accordance with local procedures. 
The Investigato r will be responsible for obtaining annual IEC/IRB  approval/renewal throughout the 
duration of the study.  Copi[INVESTIGATOR_5699]’s reports, all IEC/IRB  submissions and the IEC/IRB  
continuance of approval must be sent to the Sponsor or designee.  
11.[ADDRESS_1233603]’s confidentiality is maintained.  On the case report forms or 
other documents submitted to the Sponsor or designee , subjec ts should be identified by [CONTACT_10573] (if 
permitted by [CONTACT_1769]) and a subject  identification  number only.  Documents that are not for submission 
to the Sponsor or designee ( e.g., signed informed consent forms) should be kept in strict confidence by 
[CONTACT_737].  
In compliance with Federal and local r egulations/ICH GCP Guidelines , it is required that the Investigator 
and institution permit authorized representatives of the company, of the r egulatory agency(s), and the 
IEC/IRB direct access to review the subject’s original medical records for verification of study -related 
procedures and data.  Direct access includes examining, analyzing, verifying, and reproducing any 
records and reports that are important to the evaluation of the study.  The I nvestigator is obligated to 
inform and obtain the consent of the subject  to permit named representatives to have access to his/her 
study- related records without violating the confidentiality of the subject . 
ISIS [ADDRESS_1233604] be obtained for all protocol amendments and amendments to the informed 
consent document.  The regulatory authority and IEC/IRB m ust be informed of all amendments and give 
approval for any amendments likely to affect the safety of the subjects or the conduct of the trial.  The Investigator must  send a copy of the approval letter from the IEC/IRB to the Sponsor or designee . 
12.[ADDRESS_1233605].  The Investigator/Sponsor or designee should notify the IEC/IRB in writing of the trial’s completion or early 
termination and send a copy of the notification to the Sponsor or designee. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC ) application will be 
used for this study. 
The Investigator should ensure that all appropriately qualified persons to whom he/she has delegated trial 
duties are recorded on a Sponsor-approved Delegation of Site Responsibilities Form. 
Source documents are original documents, data, and records from which the subject’s case report form data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and pharmacy records, diaries, imaging, and correspondence .  Case report form entries may be 
considered source data if the case report form is the site of the original recording (i.e.,  there is no other 
written or electronic record of data).   
The Investigator and S tudy Center staff are responsible for maintaining a c omprehensive and centralized 
filing system of all study -related (essential) documentation  in accordance with Section 8  of the ICH 
Guidelines (E6) , suitable for inspection at any time by [CONTACT_882062]/or applicable r egulatory authorities.  Elements should include: 
• Subject files containing completed case report forms, informed consents, and supporting copi[INVESTIGATOR_10467] 
• Study files containing the protocol with all amendments, Investigator’s Brochure, copi[INVESTIGATOR_014] o f pre-
study documentation and all correspondence to and from the IEC/IRB and the Sponsor  or 
designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug Product Accountability Record, Return of Study Drug Product for Destruction, final Study Drug product 
reconciliation, and all drug-related correspondence 
In addition, all original source documents supporting entries in the case report forms must be maintained 
and be readily available.  
No study document should be destroyed witho ut prior written agreement between the Sponsor or designee  
and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify the Sponsor or designee. 
ISIS [ADDRESS_1233606], inspecting the various 
records of the trial (e.g., case report forms and other pertinent data) provided that subject  confidentiality is 
respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular intervals 
throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the 
data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to subject  medical records and other study-related records needed to verify the entries on the case 
report forms.  
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by 
[CONTACT_10576]’s Clinical Quality Assurance Department (or designees) .  Inspection of 
Study Center facilities (e.g., pharmacy, drug storage areas,  laboratories) and review of study- related 
records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on subject  data 
received by [CONTACT_221301].  During this review, subject  data will be checked for consistency, 
omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, 
data queries and/or Study Center  notifications will be sent to the Study Center for completion and return 
to Sponsor or design ee. 
The Principal Investigator [INVESTIGATOR_10469].  These 
signatures will indicate that the Principal Investigator [INVESTIGATOR_368037], the data queries, and the Study Center notifications, and agrees with the content.  
12.[ADDRESS_1233607] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow applicable local 
compensation laws.   Subjects will be treated and/or compensated for any study- related illness/injury in 
accordance with the in formation provided in the Compensation for Injury section of the Informed Consent 
document. 
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
78  13. REFERENCES  
Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams -Huet B, Garg A. . Cholic acid for hepatic steatosis in 
patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013 Apr 15;168(5):771- 8. doi: 
10.1530/EJE -12-0969. Print 2013 May.  
Akinci B, Onay H, Demir T , Savas -Erdeve S, Gen R , Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, 
Ozdemir NK, Atik T, Ozen S, Yurekli BS , Apa ydin T , Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA . 
Clinical presentations, metabolic abnormalities and end -organ complications in patients with familial partial 
lipodystrophy. Metabolism. 2017 Jul;72:109- 119. doi: 10.1016/j.metabol.2017.04.0 10. Epub 2017 Apr 27.  
Ajluni N , Dar M, Xu J, Neidert AH, Oral EA. Efficacy and Safety of Metreleptin in Patients with Partial 
Lipodystrophy: Lessons from an Expanded Access Program . J Diabetes Metab 2016; 7: 659  
Altmann KH, Dean NM, Fabbro  D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals. Chimia 1996; 50: 168 -176. 
Bidault G,  Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, Moritz S, Capeau J, Vigouroux 
C, Béréziat V. Lipodystrophy -linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro 
endothelial dysfunction. Arterioscler Thromb Vasc Biol 2013.  
Brandt TA, Lee RG, Digenio A, Graham MG, Crooke RM, Hughes SG, Singleton W, Witztum JL,  Tsimikas S.  
ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin -like 3, reduces plasma lipid levels in mouse models and 
in healthy human volunteers. Atherosclerosis 2015; 241: e30- e31.  
Büller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, P illion G, Pi[INVESTIGATOR_787784] F, Prins MH, Raskob GE . 
Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine 2007; 
357: 1094- 1104.  
Chan JL and Oral EA. Clinical classification and treatment of congenital and acquired li podystrophy. Endocr Pract 
2010; 16: 310- 323. Crooke ST and Bennett CF. Progress in antisense ol igonucleotide  therapeutics. Annual Review 
of Pharmacology and Toxicology 1996; 36: 107- 129. 
Cobelli C, Toffolo GM, Dalla MC, Campi[INVESTIGATOR_91919] M, Denti P, Caumo A, Butler  P, Rizza R. Assessment of beta- cell 
function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests.  Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E1- E5. Epub 2007 Mar 6.  
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan 
designation June 2012  
Diker -Cohen Cochran E, GordenT P, Brown RJ. Partial and generalized lipo dystrophy: Comparison of baseline 
characteristics and response to metreleptin. J Clin Endocrinol Metab 2015.  
Dorato MA and Engelhardt JA. The no -observed -adverse -effect -level in drug safety evaluations: use, issues, and 
definition(s) . Regul Toxicol Pharmacol. 2005; 42(3):  265-74. 
Dunnigan MG, Cochrane MA, Ke lly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new 
syndrome. Q J Med 1974; 43: 33- 48.  
Everds N, Li N, Bailey K, Fort M, Stevenson R, Jawando R, Salyers K, Jawa V, Narayanan P, Stevens E, He C, 
Nguyen MP, Tran S, Doyle N, Poi tout-Belissent F, Jolette J, Xu C, Sprugel K . Unexpected thrombocytopenia and 
anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody. Toxicol Pathol. 2013;  
41(7):951- 69. doi: 10.1177/0192623312474727. Epub 2013 Mar 7.  
FDA guidance for industry, “Drug- Induced Liver Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S. 
Department of Health and Human Services, Food and Drug Administration, July 2009  
https://www.fda.gov/downloads/Guidances/UCM174090.pdf   
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
79  Garg  A. Acquired and inherited lipodystrophies.  N Engl J Med . 2004 Mar 18; 350(12):1220- 34.  
Garg  A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.  J J Clin Endocrinol Metab. 
2011 Nov;96(11):3313- 25. doi: 10.1210/jc.2011- 1159. Epub 2011 Aug 24.  
Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. 
Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ -O-(2-methoxyethyl) modified antisense 
oligonucleotide: comparison  across species. Drug Metab Dispos 2003; 31: 1419- 1428.  
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham 
NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S . Cardiovascular and Metabolic Effects 
of ANGPTL3  Antisense Oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222- 232. doi: 
10.1056/NEJMoa1701329. Epub 2017 May 24.  
Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapi[INVESTIGATOR_881994], Weyer C; American Association of Clinical Endocrinologists . 
The clinical approach to the detection of lipodystrophy - An AACE Consensus Statement. Endocr Pract. 2013 Jan -
Feb;19(1):107- 16  
Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circ 2001; 103: 2225 -2229.  
Hegele RA, Joy TR, Al -Attar SA, Rutt BK. Thematic review series: Adipocyte Biology. Lipodystrophies: Windows 
on adipose biology and metabolism. J Lipid Res 2007; 48: 1433- 1444.  
Henry SP, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit 
decreased immune stimulation in mice. J Pharmacol Exp Ther. 2000 Feb;292(2):468- 79.  
Huang -Doran  I, Sleigh A, Rochford JJ, O'Ra hilly S, Savage DB. Lipodystrophy: metabolic insights from a rare 
disorder.  J Endocrinol . 2010 Dec;207(3):245- 55. doi: 10.1677/JOE -10-0272. Epub 2010  Sep 24  
Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild -Huntress V, Donovan MJ, Tall AR. Incr eased LDL 
cholesterol and atherosclerosis in LDL receptor -deficient mice with attenuated expression of scavenger receptor B1. 
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1068- 73. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E.  Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H. FEBS Letters 1987  May 11 ; 215(2) : 327 -30. 
Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, Oka Y, Katayama S.  ANGPTL3 is 
increased in both insulin -deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004 May 
14;317(4):1075- 9.  
Köbberling J, Willms B,  Kattermann R, Creutzfeldt W.  Lipodystrophy of the extremities. A dominantly inherited 
syndrome a ssociated with lipatrophic diabetes.  Humangenetik. 1975 Sep 10;29(2):111- 20.  
Luscombe -Marsh ND, Noakes M, Wittert GA, Keogh JB, Foster P, Clifton PM. Carbohydrate -restricted diets high 
in either monounsaturated fat or protein are equally effective at prom oting fat loss and improving blood lipi[INVESTIGATOR_805]. Am J 
Clin Nutr. 2005 Apr;81(4)762 -72. 
Martin -Campos JM, Roig R, Mayoral C, Martinez S, Martí G, Arroyo JA, Julve J, Blanco- Vaca F. Identification of 
a novel mutation in the ANGPTL3 gene in two families diagnosed of  familial hypobetalipoproteinemia without 
APOB mutation. Clin Chim Acta. 2012 Mar 22;413(5- 6):552- 5. doi: 10.1016/j.cca.2011.11.020. Epub 2011 Nov 29.  
McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM.  Characterization of a potent and specific 
class of antisense oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem. 1999 Jan 
15;274(3):1715- 22.  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
80  Minicocci I, Montali A, Robciuc MR, Quagliarini F, Censi V, Labbadia G, Gabiati C, Pi[INVESTIGATOR_119203] G, Sepe ML, Pannozzo 
F, Lütjohann D, Fazio S, Jauhiainen M, Ehnholm C, Arca M. Mutations in the ANGPTL3 gene and familial 
combined hypolipi[INVESTIGATOR_035]: A clinical and biochemical characterization. J Clin Endocrinol Metab. 2012 
Jul;97(7):E1266- 75. doi: 10.1210/jc.2012- 1298. Epub 2012 Jun 1.  
Mon ia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense inhibitors of gene expression. J  Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Moran LJ, Luscombe -Marsh ND, Noakes M, Wittert GA, Keogh JB, Clifton P M. The satiating effect of dietary 
protein is unrelated to postprandial ghrelin secretion.  J Clin Endocrinol Metab. 2005 Sep;90(9)5205- 11. Epub 2005 
Jul 12.  
Musunuru K, Pi[INVESTIGATOR_19961], Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry 
AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S. Exome sequencing, 
ANGPTL3 mut ations, and familial combined hypolipi[INVESTIGATOR_035]. N Engl J Med. 2010 Dec 2;363(23):2220- 7. doi: 
10.1056/NEJMoa1002926. Epub [ADDRESS_1233608] 13.  
Myalept, Package Insert . https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf (accessed 
February 5, 2 018).  
National Organization for Rare Disorders [NORD]. The Physician’s Guide to Lipodystrophy Disorders 2012.  
Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J of Human Gen 2014; 59:16- 23.  
Noto D, Cefalu AB, Valenti V, Fayer F, Pi[INVESTIGATOR_347294] E, Ditta M, Spi[INVESTIGATOR_28947] R, Vigna G, Yue P, Kathiresan S, Tarugi P, Averna MR.  Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipi[INVESTIGATOR_035]. 
Arterioscler Throm b Vasc Biol. 2012 Mar;32(3):805- 9. doi: 10.1161/ATVBAHA.111.238766. Epub 2012 Jan 12.  
Pi[INVESTIGATOR_20664] L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, Fancello T, Zavaroni I, Ardigò D, Bernini F, 
Calabresi L, [LOCATION_009]schini G, Tarugi P, Calandra S, Bertol ini S.  Characterization of three kindreds with familial 
combined hypolipi[INVESTIGATOR_881995] -of-function mutations of ANGPTL3. Circ Cardiovasc Genet. 2012 Feb 
1;5(1):42- 50. doi: 10.1161/CIRCGENETICS.111.960674. Epub 2011 Nov 7.  
Prakash TP, Graham MJ, Yu J , Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, 
Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP. Targeted delivery of 
antisense oligonucleotides to hepatocytes using triantennary N -acetyl  galactosamine improves potency 10- fold in 
mice. Nucleic Acids Res. 2014 Jul;42(13):8796- 807. doi: 10.1093/nar/gku531. Epub 2014 Jul 3.  
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton -Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer 
TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ.  International consensus report on the investigation and management of primary 
immune thrombocytopenia.  Blood. 2010 Jan 14;115(2):168- 86. doi: 10.1182/blood- 2009- 06-225565. Epub [ADDRESS_1233609] 21.  
Robbins AL and Savage DB. The genetics of lipid storage and human lipodystrophies. Trends Mol Med. 2015 Jul;21(7):433- 8. doi: 10.1016/j.molmed.2015.04.004. Epub [ADDRESS_1233610]. 2009 
Jan;119(1):70- 9. doi: 10.1172/JCI37118. Epub 2008 Dec 15.  
Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC. LDL re ceptor but not apolipoprotein E deficiency 
increase diet -induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E207- 14. 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
81  Shulman, GI.  Ectopic Fat in Insulin Resistance, Dyslipi[INVESTIGATOR_035], and Cardiometabolic Disease N Engl J Med 2 014; 
371:1131- 1141.  
Sleigh A, Stears A, Thackray K , Watson L, Gambineri A, Nag S, Campi [INVESTIGATOR_227302], Schoenmakers N, Brage S, Carpenter 
TA, Murgatroyd PR, O'Rahilly S, Kemp GJ, Savage DB.  Mitochondrail oxidative phosphorylation is impaired in 
patients with congenital lipodystrophy. J Clin Endocrinol Metab. 2012 Mar;97(3):E438- 42. doi: 10.1210/jc.2011-
2587. Epub 2012 Jan 11.  
Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 
1995; 75: 591- 609. 
Tsuchiy a H, Ikeda Y, Ebata Y, et al. Retinoids ameliorate insulin resistance in a leptin -dependent manner in mice. 
Hepatology 2012: 56(4): 1319 -1330.  
Vatier C, Bidault G, Briand N, et al. What the genetics of lipodystrophy can teach us about insulin resistance an d 
diabetes. Curr Diab Rep 2013; 13 Sep (online).  
Wang Y , McNutt MC , Banfi S , Levin MG , Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH . Hepatic 
ANGPTL3 regulates adipose tissue energy homeostasis.  Proc Natl Acad Sci  U S A. 2015 Sep 15;112(37):[ZIP_CODE]- 5. 
doi: 10.1073/pnas.[PHONE_18250]. Epub [ADDRESS_1233611] Factor XI by [CONTACT_81834]: a novel 
antithrombotic strategy with lowered bleeding risk. Blood. 2010 Nov 25;116(22):4684- 92. doi: 10.1182/blood- 2010-
04-277798. Epub 2010 Aug 31.   
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
82  14. APPENDICES  
  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
83   
 
  
 
 
 
Appendix A  Schedule of Procedures 
 
 
 
 
 
  
 
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
84  Appendix A  Schedule of Procedures  
 
   Screen ing 
Treatment Period  Follow -up Period  
Run-in# Qual† 
Study Week  -6 to -1 -1 to 0  1 5 9 13 17 21 25 27/ET  4* 8* 13* 
Study Day  -42 to -1 -7 to -1 1 29 57 85 113 141 169 183 *Weeks from the end of 
treatment periodo 
Visit and Testing Window +/ - Days  0 0 0 2 2 2 3 3 3 0 3 3 3 
Informed Consent  X             
Outpatient Visit  X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X X           
Medical History  X             
Genetic Testingp X             
Vital Signs  X  X X X X X X X X X X X 
Physical Examination a X  X X  X    X X  X 
Body Weight and Height  b X X X X X X X X X X X X X 
Waist and hip circumference  X         X    
DEXA Scan  Xd    X    X    
12- lead ECG (triplicate)  X  X X  X  X  X X X X 
Ultrasound  X             
Mixed Meal Test c  X    X    X    
MRI  Xd    X    X    
24-Hour Urine for Creatinine 
Clearance and Proteinq  X            
Extended Urinalysis  e X  EVERY 14 DAYS (+/- 2 days) e, f X X X X X X X 
Serum Creatinine and Cys -C i, j, k X  EVERY 14 DAYS (+/- 2 days) f, i X X X X X X X 
Chemistry Panel j , k X  EVERY 14 DAYS (+/- 2 days) f X X X X X X X 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
85  Appendix A  Schedule of Procedures Continued  
  Screening  
 Treatment Period   Follow -up Period  
 
 Run-in# Qual† 
Study Week  -6 to -1 -1 to 0  1 5 9 13 17 21 25 27/ET  4* 8* 13* 
Study Day  -42 to -1 -7 to -1 1 29 57 85 113 141 169 183 *Weeks from the end of 
treatment periodo 
Visit and Testing Window +/ - Days  0 0 0 2 2 2 3 3 3 0 3 3 3 
Hematology  X  EVERY 14 DAYS (+/- 2 days) f Xh Xh Xh 
Coagulation  X  X       X    
Hepatitis  B, C, HIV  X             
Thyroid Panel  X             
Inflammatory    X   X    X   X 
Liver Biomarkers    X   X    X   X 
Plasma PK - ISIS 703802 l   X1 X1 X1 X1 X1 X1 X1 X X X X 
Anti-ISIS 703802 Antibodies    X X X X  X  X  X X 
FSH (women only, if applicable)  j, m X             
Serum Pregnancy Test  m X  X X X X X X X X X X  
Archived Serum & Plasma Samples  
j, n   X  X  X   X   X 
PD Panel j X X X X X X X X X X X X X 
Extended Lipid Panel j X X X X X X X X X X X X X 
HbA1C j X  X   X    X   X 
Quality of Life Assessment   X    X    X    
Widespread Pain Diary   X TO BE DONE AT OUTPATIENT VISITS  X X X 
Study Drug:  SC Injection    WEEKLY SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 
through Week 26/Day 176)      
Adverse Events  TO BE COLLECTED FROM TIME OF INFORMED CONSENT TO END OF FOLLOW -UP PERIOD  
Concomitant Medication  TO BE COLLECTED FROM TIME OF INFORMED CONSENT TO END OF FOLLOW -UP PERIOD  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
86  Appendix A  Schedule of Procedures Continued  
# Subjects on stable diet known to the investigator and followed at the site may go from Screening to qualification without the diet run-in period.  
† Qual =Qualification  
All procedures and study samples are to be done pre-dose at respective visits, unless s pecified  
a Full physical exam will be performed at the screening visit and an abbreviated physical exam will be performed during treatment and follow -up period s. 
b     Height only required at Screening  
c     Mixed Meal Test -refer to Appendix E  for fur ther details  
d     MRI and DEXA scan will only be performed during Screening after all other  eligibility  criteria are met .  MRI should be performed 10 days (+/ - 2 days) prior to 
anticipated Day [ADDRESS_1233612] be no more than 
4 weeks apart during the treatment period. 
g U rine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values are taken every 14 days (+/ - 2 days)  for [ADDRESS_1233613] 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons.  
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) a repeat blood 
specimen should be re- drawn as soon as possible (ideally within 7 days).  All platelet count results will be reviewed promptly (within 48 hours of receipt) by [CONTACT_671609] 6.2.1 .  Any ca se of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor.  
l      Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically  sterile or post -menopausal.  
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.)  and will be retained until completion of the final 
study report.  
o     Treatment period is defined as the time from the first dose through one dosing interval post last dose.  
p     Genetic testing will only be performed for eligibility if there is no documented genetic testing in medical history.  
q     24-hour urine sample for creatinine clearance and protein should also be obtained in the event of an eGFR (CKD -EPI) value meeting criteria specified in 
Sections 8.5.2 and 8.6.2.  
Time (time is in reference to Study Drug administration):  
[ADDRESS_1233614] of Laboratory Analytes 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  
• Creatinine kinase 
• GGT  
• Cys-C 
 
PD Panel  
• ANGPTL3  
• Insulin  
• Proinsulin  
• C-peptide  
• Fructosamine  
• Glycated albumin  
• Delipi[INVESTIGATOR_671575]  
• Fasting Plasma Glucose  
 
Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR Screening Tests  
• Hepatitis B 
surface antigen  
• Hepatitis C 
antibody  
• HIV antibody  
• FSH (women 
only)  
• Serum βhCG  
• TSH  
• Free T4  
 
 
Extended Lipid  Panel  
• Total Cholesterol 
(TC)  
• LDL cholesterol 
(LDL -C) 
• HDL cholesterol (HDL -C) 
• Triglycerides (TG)  
• VLDL  cholesterol 
(VLDL -C) 
• Non-HDL 
cholesterol (Non -
HDL -C) 
• Lp(a)  
• FFA 
• ApoB  
• ApoB -48 
• ApoB -100 
• Apo A-1 
• ApoCIII  (total, 
chylomicron, 
LDL, HDL, VLDL)  
• Delipi[INVESTIGATOR_881996]  
• Ceramides  
• Sphingolipi[INVESTIGATOR_805]  
• Diacyglycerol  
• Lipoprotein 
particle analysis  Hematology  
• Red blood cells  
• Hemoglobin 
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 703802  levels in 
plasma  
 
Immunogenicity  
• Anti-ISIS 703802  
antibodies  
 
Liver Biomarkers ( Biomarkers 
of liver apoptosis and fibrosis ) 
• CK18  
• PI[INVESTIGATOR_671576]  
• hs-CRP  
• IL-6 
• IFN gamma  
• TNF alpha  
• Leptin  
• Adiponectin  
 
Genetic Testing  
• Genetic sequencing of FPL causing genes
3 
 Extended Urinalysis  
• Routine Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Blood  
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio (UPCR)  
• A/C Ratio (UACR)  
 
24-Hour Urine Test 
• Creatinine clearance  
• Protein  
• Albumin  
 
Mixed Meal Test  
• Plasma glucose  
• FFA 
• C-peptide  
• Insulin  
• Serum ghrelin  
• GIP 
• GLP-1 
• PYY 
• Incretin hormones  
[ADDRESS_1233615] (e.g., mutations in LMNA, PPAR -γ, AKT2, CIDEC, PLIN1 
genes ).  May not be collected if adequate genetic data are available in medical history or if patient does not consent to 
genetic testing  
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
89   
 
 
 
 
 
Appendix C PK Sampling Schedule  
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
90  Appendix C  PK Sampling Schedule  
 Treatment Period  Follow -up Period  
Study 
Week  1 5 9 13 17 21 25 27 4* 8* 13* 
Study 
Day D1 D29 D57 D85 D113 D141  D169  D183 * Weeks from the end of treatment 
period1 
 
 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  Anytime  
Note:  D, Day  
[ADDRESS_1233616] abnormalities are based 
upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. 
 
 
 

ISIS [ADDRESS_1233617] (MTT) 
as follows: subjects will consume a standardized meal the evening before the test (750 kcal; 20% of 
energy from protein, 30% from fat, and 50% from carbohydrate) and refrain from consuming alcohol for 
72 h.  
A cannula will be inserted into a forearm vein, and an overnight fasting (minimum 10 hours ) venous 
blood sample will be taken between 8:00 AM and 10:00 AM for measurement of plasma glucose, FFA,         
C-peptide and insulin concentrations and serum ghrelin, GIP, GLP-1, and PYY.  Incretin hormones will 
be measured using a multiplex assay (EMD Millipore, Billerica, MA).  The tubes for the incretin 
hormones will contain Pefabloc SC (Sigma-Aldrich, St. Louis, MO) and DPP- IV inhibitor (EMD 
Millipore, Billerica, MA) to inhibit DPP-IV and other proteases.  The change in ratings from Baseline 
will be quantified.  
Subjects will then consume a liquid load of Optifast (Optifast; [COMPANY_001], Minneapolis, MN; 474 ml, 320 
kcal, 50% carbohydrate, 35% protein, 15% fat) within a 15 -min period.  Additional blood samples will be 
taken at 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 min after meal consumption.  VAS will be completed at 180 minutes and 300 min.  To calculate the insulin sensitivity ind ex (S
I), the oral minimal 
model for glucose will be used; and to calculate the hepatic insulin extraction, oral minimal model for insulin and c -peptide will be used [Cobelli et al, 2007] . Subjects will complete a validated visual analogue 
scale (VAS)
 questionnaire to assess subjectiv e hunger at 0, 180 and 300 minutes [ Luscombe- Marsh et al, 
2005; Moran et al, 2005] . 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
97   
 
 
 
 
 
  
 
 
Appendix F  Laboratory Tests to Be Performed in the Event of a 
Platelet Count ˂ 100,000/ mm3  
  
 
 
 
  
 
 
 
  
 
 
 
 
 
ISIS 703802 -CS5 CONFIDENTIAL  Amendment 1  
Protocol   16 February  2018 
 
98  Appendix F Laboratory Tests to Be Performed in the Event of a Platelet Count ˂ 100,000/ mm3*  
*Labs only need to be performed once.  Labs may be collected over multiple visits, if blood requirements 
are a concern, as per Investigator discretion  
Note:  The following labs may change as additional data is assessed, and sites will be updated regarding any changes.  
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for rev iew) 
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 
  
 
 [ADDRESS_1233618] 
Cambridge, MA  [ZIP_CODE]   
www.akc eatx.com  
 
Page 1 of 2 
ISIS 703802- CS5: Administrative Clarification  Letter 1 to Protocol Amendment 1 
ISIS 703802- CS05:  Administrative Clarification Letter 1 to Protocol Amendment  1 
 
11 September  2018 
 RE: Protocol ISIS  703802- CS5: An open -label Phase 2 Study of ISIS 703802 (AKCEA- ANGPTL3 -LRx) 
Administered Subcutaneously to Subjects with Familial Partial Lipodystrophy , Protocol Amendment  1 
dated 16 February 2018  
Dear Investigators:  
The following administrative clarification s are being issued for P rotocol ISIS 703802- CS5 Amendment  1. 
 
Administrative Clarification  1 – Section 6.2.1 Physical Exams and Vital Signs 
Current Text : 
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures (Appendix A). 
Vital signs should include weight, blood pre ssure (BP), pulse rate, respi[INVESTIGATOR_12876]. BP 
and pulse rate will be recorded after the subject has been in a sitting position for at least 5 minutes. BP should always be measured on the same arm (preferentially on the left arm). Height  will be measured at Screening.  
Clarification : (new text indicated in bold) 
Physical exams, vital sign s, and skin fold measurements  will be performed as indicated in the Schedule of 
Procedures (Appendix A). Vital signs should include weight, blood pressure (BP), pulse rate, respi[INVESTIGATOR_12876]. BP and pulse rate will be recorded after the subject has been in a sitting position for at least 5 minutes. BP should always be measured on the same arm (preferentially on the left arm). Height will 
be measured at Screening.  Skinfold measurements will be recorded as per the Schedule of Procedures 
(Appendix A) starting at Day [ADDRESS_1233619]’s 
right mid anterior thigh and right tricep.  
Rationale: 
The secondary endpoints include “ Changes from Baseline in body fat distribution for various areas in the 
body as measured by [CONTACT_882036] .”  The purpose of this clarification it to provide omitted 
details regarding the collection of skinfold measurements that were missing from Section 6: Study 
Procedures. This measurement will occur at every visit in which a physical exam (full or abbreviated) occurs.  
 
Administrative Clarification 2 – Appendix A Schedule of Procedures – Skinfold Measurements  
Current Text : 
None. 
 [ADDRESS_1233620] 
Cambridge, MA  [ZIP_CODE]   
www.akc eatx.com  
 
Page 2 of 2 
ISIS 703802- CS5: Administrative Clarification  Letter 1 to Protocol Amendment 1 
Clarification:  (new text indicated in bold) 
Skinfold Measurements: Performed at Study Day 1 (Pre -dose) and at Weeks 5, 13 and 27/ET, and 
during the Follow Up Period at Weeks 4 and 13. 
Rationale: 
The secondary endpoints include “ Changes from Baseline in body fat distribution for various areas in the 
body as measured by [CONTACT_882036] .” It has come to o ur attention that the details of the 
collection and specific timepoints of collecting skinfold measurements w ere missing from Appendix A: 
Schedule of Procedures. Skin fold measurements will occur as part of the physical exam and therefore,  this 
measurement will occur at every visit in which a physical exam (full or abbreviated) occurs.  
 
Summary  
This Administrative Clarification  Letter serves to align  the planned secondary endpoints with Section 6: 
Study Procedures and Appendix A: Schedule of Procedures.   It is noted that no s afety assessments or 
procedures have been added or removed.  This clarification does not affect the rights, safety, or well-being of 
study participants.  
 
Sincerely,  
 
 
Akcea The
rapeutics, Inc.  
 
cc: ISIS 703802- CS5 Study Coordinators, ISIS 703802- CS5 TMF  

 [ADDRESS_1233621]  
Cambridge, MA  [ZIP_CODE]   
www.akc eatx.com  
 
Page 1 of 2 
ISIS 703802 -CS05: Administrative Clarification  Letter 2 to Protocol Amendment  1 
ISIS 703802 -CS5:  Administrative Clarification Letter 2 to Protocol Amendment  1 
02 October  2018  
RE: Protocol ISIS  703802 -CS5: An open -label Phase 2 Study of ISIS 703802 (AKCEA -ANGPTL3 -LRx) 
Administered Subcutaneously to Subjects with Familial Partial Lipodystrophy , Protocol Amendment  1 
dated 16 February 2018  
Dear Investigators:  
The following administrative clarification s are being issued for Protocol ISIS 703802 -CS5 Amendment  1. 
 
Administrative Clarification 1 – Appendix A Schedule of Procedures – Footnote H  
Current Text : 
During follow -up period, hematology sampling for platelet values are taken every 14 days (+/ - 2 days) for [ADDRESS_1233622] dose of Study Drug, the n at Week 8 and Week 13 Follow -up visits.  
Clarification:  (new text indicated in bold) 
During the treatment  period, hematology sampling for platelet values are taken every 14 days (+/ - 2 days) from 
first dose through  [ADDRESS_1233623] treatment period , then at Week 8, and Week 13 Follow -up visits.  
Rationale:  
Clarification to f ootnote H of the Schedule of Procedures in order to align with the timing for hematology 
sampling following the treatment period . 
 
Summary  
This Administrative Clarification  Letter serves to align  the timing for hematology sampling as outlined in the 
Schedule of Events Table in Appendix A.  It is noted that no s afety assessments or procedures have been added or 
removed.  This clarification does not affect the rights, safety, or well -being of study participants.  
 
Sincerely,  
 
 
Akcea Therapeutics, Inc.  
 
cc: ISIS 703802 -CS5 Study Coordinators, ISIS 703802 -CS5 TMF  
